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ABSTRACT 
 
 
Muscle-derived cells (MDCs) are a heterogeneous population consisting of cells that can 
undergo myogenic differentiation; however, it has emerged that not all MDCs are restricted 
to the myogenic lineage. This discovery may have many implications; for example, MDCs 
may be a suitable alternative source of osteogenic cells for bone repair. The currently 
accepted treatment for bone repair, bone grafting, is often associated with small amount of 
obtainable bone.  Much of the work published regarding the differential potential of MDCs 
has not, to date, focused on the osteogenic pathway and even fewer studies have been 
performed on human cells. In this thesis osteogenic MDCs were isolated by differential 
adhesion to fibronectin (Fn) i.e. MDCsFn and compared with mesenchymal stem cells 
(MSCs) in relation to their osteogenic potential. The osteogenic potential was assessed by 
measuring mineralization and relevant gene- and protein- expression. MSCs and MDCsFn 
had a similar pattern of ALP activity and expression. Furthermore, MSCs and MDCsFn 
both showed mineralization after 3 weeks measured by Alizarin Red S. A qPCR Array 
measuring the activity of 46 osteogenic genes also showed similarities in gene expression 
between the two cell types; however, the MSCs showed a more consistent pattern between 
patients, compared to MDCsFn. Titanium (Ti) has previously been used as a bone repair 
scaffold in humans due to its osteoconductivity. The interaction between Ti, of various 
roughness and hydrophilicity, and the two cell types, i.e. MSCs and MDCsFn, were 
assessed with relation to biocompatibility. Interestingly, the hydrophilic, rough surface, 
which has been described as superior in bone formation applications, showed higher levels 
of cell death, both apoptosis and necrosis, compared to the other tested surfaces for both 
cell types. In conclusion, due to the similarities between MDCsFn and MSCs there might 
be possibilities to use the osteogenic fraction in future bone regenerative applications. 
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1.1 TISSUE ENGINEERING 
 
Tissue engineering is a form of regenerative medicine where the focus is on using both 
living cells and biomaterial together to engineer new tissue to restore or improve lost or 
damaged biological function. Much focus has been on the use of stem cells to achieve 
this desired goal (Corsi et al, 2007). By using stem cells, tissues have been synthesized 
in vitro or in bioreactors where matrices, synthetic or natural, were used to produce 
precisely shaped constructs to replace diseased or damaged tissue (Schonmeyr et al, 
2010). There have been attempts to engineer a variety of tissues; for example, breast 
tissue has been engineered from human epithelial and pre-adipocyte cells derived from 
breast biopsies (Huss & Kratz, 2000).  
 
Scaffolds are considered to be important if not essential in tissue engineering, especially 
in orthopaedic applications (Corsi et al, 2007). For example, Alhadlaq and Mao (2005) 
used polyethylene glycol-based hydrogel to engineer an articular condyle of MSCs in 
the shape and dimensions of the adult human mandibular bone. To achieve the desired 
outcome they added 15 million pre-differentiated cells to the gel and left them for a 12-
week long incubation time in vivo. 
 
When stem cells are used in the tissue engineering process, it is generally accepted that 
before introducing the cells into patients they need to be differentiated into the desired 
lineage.  There are concerns that clinical use of undifferentiated stem cells may lead to a 
situation of uncontrolled proliferation i.e. cancer (Abdullah & Kassem, 2008).  The 
great advantage of using adult stem cells in tissue engineering applications is that it is 
easier to expand MSCs and other adult stem cells, than mature cell types e.g. osteoblasts 
(Alhadlaq & Mao, 2005)  
 
 
 CHAPTER 1: INTRODUCTION 
 26 
1.1.1 STEM CELLS 
 
In general stem cells are divided into two groups; embryonic and adult stem cells. 
Embryonic stem cells are reported to have unlimited self-renewal capacity, but there are 
ethical concerns regarding the sourcing and use of these cells. There are no ethical 
concerns regarding the usage of adult stem cells; however, they have limited differential 
potential and self-renewal in vitro, so the amount of stem cells that can be cultured 
sometimes limits their clinical usage especially in the repair of larger defects (Davis & 
zur Nieden, 2008).  
 
 
1.1.2 BONE ENGINEERING 
 
Scaffolds will most likely play a central role in the development of engineered 
orthopaedic applications. One promising biomaterial for the scaffold is Ti; Warnke et al 
(2004) used a Ti scaffold to engineer a new mandible for a patient who had his jaw 
removed due to a tumour. In this case they used the patient’s own body as a bioreactor 
and used his blood vessels to create a natural bone environment. After 7 weeks they 
detected active osteoblasts within the scaffold. 
 
It is considered that one of the major challenges facing the bone engineering field is to 
combine the knowledge in material science, tissue engineering and biology. Knowledge 
in these areas are important to design implant surfaces providing biological signals to 
cells that favour bone healing and osseointegration (Ellingsen et al, 2000).  In order to 
achieve this it is especially important to study the interaction of implant surfaces and 
precursor cells with bone forming capacity, such as MSCs since bone marrow-derived 
MSCs are believed to be the cells that migrate on implant in vivo, not committed 
osteoblasts (Schwartz et al, 1999).  
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1.1.3 ALLOGENEIC OR AUTOLOGOUS 
TRANSPLANTATION 
 
In autologous transplantation the donor and the recipient is the same person and in 
allogeneic transplantation the donor and the recipient are two separate people.  Both 
allogeneic and autologous bone marrow transplantations are performed on patients 
regularly (Chinen & Buckley, 2010); however, autografts are considered to be the safer 
option, since it has a minimised risk of rejection (Thibodeau & Patton, 2007). Another 
advantage of using autografts, it is that autografts, but not allografts, are considered 
osteoinductive i.e. are able to drive cells along the osteogenic lineage (Khan et al, 
2005). However, even if autografts are considered the preferable alternative in terms of 
efficiency and safety, there are problems associated with this technique. Harvest of the 
autograft can result in donor site pain and often the grafted amount is not sufficient for 
the desired clinical application (Korda et al, 2009).  
 
 
1.1.4 DEFINITION OF STEM CELL AND OSTEOGENIC 
TERMINOLOGY 
 
Various research groups are using slightly different stem cell terminology (Collins et al, 
2005; Sinanan et al, 2006). In this section following stem cell and osteogenic 
terminology has been defined (Table 1.1; Table 1.2).  
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Table 1.1 Stem cell terminology 
TERM DEFINITION 
Totipotent -Cells that can differentiate into any cell type. 
Pluripotent 
-Cells that can differentiate along lineages belonging to different 
germ layers. 
Multipotent 
-Cells that can differentiate along various lineages within the same 
germ layer. 
 
 
Table 1.2. Osteogenic terminology 
TERM DEFINITION 
Endochondral 
ossification 
-The formation of bone in which a bone matrix gradually replaces 
a cartilage template. This is the bone formation process of long 
bones e.g. arm or leg bones. 
Intramembraneous 
ossification  
-The formation of bone without using a cartilage template. This is 
the bone formation process of flat bones e.g. skull bones. 
Osseoconductivity  
-A passive process where a scaffold or a matrix facilitate bone 
growth. 
Osseoinductivity  -An active process where bone formation is induced. 
Osseointegration  
-Creation of a structural and functional connection between living 
bone and a loading surface. 
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1.2 BONE  
 
Bone tissue might be the most distinctive form of connective tissue in the body, since its 
extracellular matrix (ECM) is calcified and therefore hard (Thibodeau & Patton, 2007).  
The ECM of the bone is much more abundant than the cells and can be subdivided into 
inorganic salts and organic matrix (Thibodeau & Patton, 2007). The adult human 
skeleton is comprised of 213 bones (Dempster, 2006) and its principal role is to provide 
structural support for the body (Sommerfeldt & Rubin, 2001); nevertheless, it also 
serves as the mineral reservoir of the body. The mineral, often referred to as 
hydroxyapatite, Ca10(PO4)6(OH)2, is the basis of the skeleton; it resists loads caused by 
the body, protects internal organs and opposes muscle contraction that results in motion 
(Sommerfeldt & Rubin, 2001).    
 
Bone can, in general, be divided into two types; long bone, e.g. femur and tibia, or flat 
bone, e.g. skull and mandible (Dempster, 2006). Both bone types consist of both 
compact and spongy bone. Spongy bone is mainly located in the edges of the long bone 
but also in the wall surrounding the medullary cavity. In long bone the compact bone is 
located in the part between the spongy bones (Figure 1.1).  
 
 
 
Figure 1.1.  Long bone with medullary cavity. The 
bone marrow resides in the medullary cavity. Long bones 
have most of their spongy bone in the ends and compact 
bone in the middle surrounding the medullary cavity; 
however, the walls around the medullary cavity also 
consist of spongy bone. The epiphyseal line is the 
remaining of an area of growth in childhood where the 
bones lengthen. Adapted picture from www.nlm.nih.gov 
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Compact bone is built up by osteons or haversian system that contains nerves-, blood- 
and lymphatic- vessels (Thibodeau & Patton, 2007).  Terminally differentiated bone 
cells, i.e. osteocytes, are located in lacunae, which are arranged in concentric layers of 
bone matrix called lamellae. Each lacuna, with its osteocytes is supplied with nutrient 
by blood vessels or canaliculi from the haversian canal; the haversian canals are 
connected to each other by Volkmann’s canals. Around the bone tissue, apart from 
around the joints, there is a dense, white fibrous membrane called the periosteum 
(Figure 1.2; Thibodeau & Patton, 2007).  
 
 
Figure 1.2. Bone structure. Bone consists of compact and spongy bone. The compact bone is 
built up by osteons or haversian system that contains nerve-, blood- and lymphatic- vessels. The 
osteocytes are located in the lacunae, which forms the lamellae. Canaliculi supply each lacuna 
with nutrients via the blood vessels from haversian canal that are connected to each other by 
Volkmann’s canals. The periosteum is the white fibrous membrane that covers the bone 
(Thibodeau & Patton, 2007). Adapted picture from http://training.seer.cancer.gov/index.html 
 
There are three major bone cell types; osteoblast, osteocytes and osteoclasts that are all 
involved in the remodelling process of bone (Dempster, 2006; Thibodeau & Patton, 
2007). Osteoblasts, which build up bone and can be either active or inactive, are derived 
from MSCs. The inactive osteoblasts are called bone lining cells and these have a more 
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flattened morphology than (active) osteoblasts. Osteoblasts (active) have a cuboidal 
morphology, where their nucleus is towards the upper part of the cell and their protein 
synthetic apparatus towards the extra cellular matrix (Figure 1.3). They synthesise and 
secrete a specialised organic matrix, osteoid, where collagen fibrils line up in regular 
arrays. The osteoid serves as a framework for the deposition of calcium and phosphate 
i.e. mineralised bone (Thibodeau & Patton, 2007). Osteoblasts will eventually be 
trapped in their own mineralization, which will differentiate them into non-dividing 
terminally differentiated osteocytes (Schwartz et al, 1999; Thibodeau & Patton, 2007).  
Osteoclasts, which are the third type of bone cells, are derived from haematopoietic 
stem cells (HSCs); their main function is to direct the new bone formation by degrading 
the old mineral matrix (Schwartz et al, 1999). 
 
 
1.2.1 BONE MARROW 
 
Bone marrow is a specialized type of soft connective tissue also called myeloid tissue. It 
serves as the site for production of blood cells and is located in the medullary cavities or 
in the spongy part of certain long and flat bones (Figure 1.1; Thibodeau & Patton, 
2007). There are two types of bone marrow; red bone marrow, which produces red 
blood cells, and yellow bone marrow, where the cells have become saturated with fat 
and are inactive in blood cell production (Thibodeau & Patton, 2007).  Infants have only 
red bone marrow, but with age the red bone marrow transforms to yellow; however, 
there are several bones in an adult that still contain red marrow including ribs, pelvis, 
femur and thigh bone (Thibodeau & Patton, 2007) and it is from these bones the bone 
marrow is aspirated for bone marrow donations.  
 
Most types of blood cells in adult mammals are generated in the bone marrow 
(Thibodeau & Patton, 2007), but there are many other cell types that reside within the 
bone marrow, such as stromal cells (Alberts et al, 2002). Bone marrow stroma includes 
MSCs, endothelial cells, osteoblasts and adipocytes (Tokoyoda et al, 2010). The 
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different types of cells and their precursors are intermingled with one-another, which 
produce a supporting meshwork of ECM components (Thibodeau & Patton, 2007).  
At bone trauma, there is immediately vascular damage and subsequently hematoma due 
to the blood vessels located in the bone. The fracture hematoma develops a fibrin mesh 
and transforms into a soft mass of granulation tissue containing inflammatory cells, 
fibroblast, bone- and cartilage-forming cells, i.e. MSCs. Procallus, an early form of 
cartilage tissue, anchor the ends of the fractured bone together. Osteoblasts derived 
from MSCs continue the healing process with formation of calcified tissue. (Thibodeau 
& Patton, 2007). 
 
 
1.2.2 GENETIC COORDINATION OF OSTEOGENIC 
DIFFERENTIATION 
 
The osteogenic differentiation of MSCs is characterized by cell proliferation, 
differentiation and production of a specific ECM (Figure 1.3). The osteogenic ECM can 
be divided in two parts, an organic part, which is composed of mostly type 1 collagen 
and bone matrix proteins, and an inorganic part i.e. hydroxyapatite (Marie & Fromigue, 
2006). The osteogenic differentiation of human MSCs can be initiated by 
dexamethasone (dex), L-ascorbic acid and inorganic phosphate (Muraglia et al, 2000; 
Marie & Fromigue, 2006). During the osteogenic differentiation several genes are 
sequentially upregulated in vitro, such as Alkaline phosphatase (ALP), Collagen 11 
(Col1A1), Osteopontin (OP) and Bone sialoprotein (BSP; Marie & Fromigue, 2006). 
 
 
 
Figure 1.3. Osteogenic differentiation. Stem cells differentiate into osteogenic precursor cell 
that differentiate into osteoblasts expressing mineralised, osteogenic ECM.  
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Runt-related transcription factor 2 (Runx2) is the main known transcription factor 
required for osteoblastic differentiation and the most commonly used marker for 
osteogenic commitment (Jonason et al, 2009). It is an early marker and regulates cell 
proliferation; furthermore, it interacts with various signalling pathways to control the 
expression of many genes e.g. Vascular endothelial cell growth factor (VEGF) and 
Dentin matrix protein-1 (DMP1; Khosla et al, 2008; Table A9.3). However, it has been 
noted that in some human MSCs the activity but not the expression of Runx2 increases 
with osteogenic differentiation (Marom et al, 2005).  
 
Lately there have been studies suggesting that osteogenic differentiation is regulated by 
an interactive process between the two Twist proteins, Twist1 and Twist2, and Runx2 
(Bialek et al, 2004; Isenmann et al, 2009). Twist1 and Twist2 are expressed in Runx2 
expressing cells throughout the skeleton during early development and osteoblast 
specific differentiation only occurs after their expression decreases (Bialek et al, 2004).  
It is believed that the expression of Twist1 and Twist2 maintains cells in an osteo-
progenitor or preosteoblast-like state (Figure 1.4) in order to prevent premature or 
ectopic osteoblast differentiation (Lee et al, 2000; Bialek et al, 2004).  
 
 
Figure 1.4. Importance of TWIST 1 and 2 in osteogenic differentiation. Stem cells start to 
differentiate along the osteogenic lineage, but before they can become osteoblasts there is an 
interaction between Runx2 and Twist 1 and 2 to prevent premature osteogenic differentiation. 
When the cells are ready, the levels of Twist 1 and 2 decrease and Runx2 levels increase and the 
cells can differentiate into osteoblast and eventually osteocytes.  Adapted from Lee et al (2000). 
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As previously mentioned, Runx2 interacts with and controls the expression levels of 
several osteogenic genes, including the early osteogenic marker ALP (Weiss et al, 
1986) and the late marker OP. Runx2 deficient mice showed no expression or severely 
decreased levels of ALP and OP. These mice completely lacked mature osteoblast and 
could not mineralize their skeleton (Jonason et al, 2009). 
 
ALP is a commonly used osteogenic marker; mature ALP is glycosylated and anchored 
to the cells plasma membrane but its exact osteogenic role is not yet known. However, 
ALP is expressed in high levels within mineralized tissue (Gosike-Sone et al, 1998) and 
its importance for osteogenic differentiation is well established. For example, ALP is 
essential for expression of necessary genes to produce osteogenic ECM (van der Dolder 
& Jansen, 2007) and Khosla et al (2008) showed that the expression of ALP and type 1 
collagen are essential for mineralization. 
 
 Type 1 collagen is the major protein component in many tissues, including bone, skin, 
ligaments and tendons. As mentioned earlier, in bone it functions as the template for 
mineral deposit. Procollagen is its soluble precursor molecule and compromises two 
pro-1 and one pro-2 chains that are encoded by Col1A1 and Collagen 1A2 (Col1A2) 
genes. The formation of the heterotrimer starts in the rough endoplasmic reticulum, as a 
propeptide, and is thereafter transferred to the ECM where it forms mature collagen 
(Pace et al, 2001). 
 
Several Bone morphogenic proteins (BMPs), which all apart from BMP-1 belong to 
Transcription growth factor-beta (TGF-) superfamily, are capable of acting as potent 
bone inducing factors, including BMP-2, -4, -7  (Wang et al, 1990; Canalis et al, 2003; 
Ito & Miyazono, 2003; Cheng et al, 2003; Farhadieh et al, 2004). BMP-7 is considered 
to be a weaker bone inducer than BMP-2 and -4 (Cheng et al, 2003). The BMPs initiate 
their signalling pathway by binding to BMP receptors, such as BMPR-I and BMPR-II. 
The activated receptors phosphorylate Sma- and mad- related protein (Smad) 
transcription factors, e.g. Smad1 (Cheng et al, 2003; Ito & Miyazono, 2003). The 
phosphorylated Smads then form a complex with Smad4 in the nucleus and activate the 
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expression of target genes together with other co-activators (Cheng et al, 2003). Runx2 
is also involved in this signalling cascade mediating the osteogenic differentiation 
initiated by BMPs (Cheng et al, 2003). 
 
 Parathyroid hormone (PTH) is produced by the parathyroid glands in humans and is 
consider to be the most important regulator of calcium ion homeostasis in vivo 
(Mannstadt et al, 1999; Pioszak & Xu, 2008) together with its receptor PTH1R (Huang 
et al, 2001). Its synthesis and secretion are largely regulated by the extracellular 
concentration of calcium and phosphate, which is monitored by the Calcium sensing 
receptor (CASR) of the parathyroid glands (Mannstadt et al, 1999; Pioszak & Xu, 
2008). PTH mediates actions in both kidney and bone; in this study only its interaction 
with bone tissue will be discussed. In response to low blood calcium or high phosphate 
levels, PTH is secreted into the circulation and acts with PTH1R on osteoblasts 
(Mannstadt et al, 1999; Pioszak & Xu, 2008). PTH increases bone mass and has been 
used clinically to enhance bone formation and increase bone density in patients with 
osteoporosis (Pioszak & Xu, 2008). Interestingly, the expression of PTH1R is regulated 
by the osteoblast-specific Col1A1 promotor (Ono et al, 2007). 
 
Modulated vitamin D or 1,25-(OH)2D can both positively and negatively regulate the 
expression of osteoblastic phenotype markers. In early osteogenic cultures, 1,25-
(OH)2D treatment inhibit type 1 collagen and ALP mRNA levels; in contrast, the 
expression of both genes was stimulated by the hormone in late-stage cultures (St-
Arnaud, 2008). This can also explain the finding that BSP expression is suppressed by 
Vitamin D (Oldberg et al, 1990). 
 
Another protein group that regulates the osteoblastic differentiation is TGF-; TGF-1 
stimulates development and proliferation of osteogenic precursor cells, but it inhibits 
their maturation (Alliston et al, 2001; Tang et al, 2009). When TGF- activates, it binds 
to receptor TGF-BRII, which initiate the recruitment of receptor TGF-BRI. Subsequent 
phosphorylation of TGF-BRI by TGF-BRII enables activation of Smad 2 and 3, which 
propagate the TGF- signals (Hao et al, 2008). Although all isoforms of TGF- signal 
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through the same cell surface receptors and have similar cellular targets, they 
demonstrate different or opposing effects in vivo (Hao et al, 2008).  
 
 
1.2.3 BONE MARROW-DERIVED MSCs 
 
MSCs are a heterogeneous multipotent cell population of mesoderm origin that can 
differentiate along several lineages including chondrogenic, osteogenic and adipogenic 
(Marie & Fromigue, 2006). Researchers have also reported that MSCs can differentiate 
along the myogenic lineage by fusing with myoblasts (Lee et al, 2005).  There have 
been reports that they can also differentiate along non-mesoderm lineages, for example, 
neuronal cells and hepatocytes (Abdallah & Kassem, 2008); however, these findings are 
more controversial. MSCs are in general derived from the bone marrow, but researchers 
have also derived MSCs-like cells from other tissues, such as umbilical cord blood, 
adipogenic and connective tissue (Young et al, 1995; Lee et al, 2004; Romanov et al, 
2005). There is no single cell marker to define the MSC population; therefore, a whole 
range of the presence or absence of markers define the MSCs e.g. they are CD29+, 
CD73+, CD90+, CD105+, CD166+, CD44+, CD34-, CD45- and CD14- (Abdallah & 
Kassem, 2008). However, only approximately 30% of the cells in a MSCs population 
are truly multipotent i.e. can differentiate along at least three lineages (Abdallah & 
Kassem, 2008).  
 
Recently, Stro-1, an uncharacterized cell surface epitope expressed by human MSCs 
and erythrocytic cells (Gronthos et al, 1994), has been used as a marker for osteogenic 
progenitor cells (Marie & Fromigue, 2006). However, bone marrow cells expressing 
Stro-1 can also give rise to cells with the phenotype of fibroblasts, adipocytes and 
smooth muscle cells (Gronthos et al, 1994). Furthermore, MSCs can change their 
morphology and cell surface expression between different in vitro processes (Abdallah 
& Kassem, 2008). Cell surface expression could also be due to time in culture 
(Alhadlaq & Mao, 2004). 
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The mechanism by which MSCs regenerate tissues or organs in vivo is not very well 
understood but it has been suggested that it is a process by tissue-specific progenitor 
cells, which are renewed by MSCs from bone marrow (Sethe et al, 2006).  It appears 
that injured mature cells are able to secrete not only homing signals but also 
differentiation signals. Uninjured cells can also induce differentiation when direct 
contact is allowed (Kolf et al, 2007). MSCs are considered to be the reason why bone 
can repair itself without scaring (Sommerfeldt & Rubin, 2001).  
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1.3 MUSCLE 
 
Muscle can be divided into three groups; smooth muscle, cardiac muscle and skeletal 
muscle. In this study, craniofacial skeletal muscle from the masseter muscle has been 
used and from now on skeletal muscle will be referred as ‘muscle’ or ‘muscle tissue’.  
 
Muscles have a very particular structure (Figure 1.5) that distinguishes them from other 
cell types. Muscle tissue consists of bundles of multi-nuclei muscle fibres, i.e. fasicles, 
where individual fibres can vary considerably in diameter, 10-100 um, and length, 1- 4 
cm (Thibodeau & Patton, 2007). The muscle fibre is composed by myofibrils i.e. they 
have in their cytoskeleton bundles of fine fibrils, myofibrils. A muscle fibre may have 
1000 myofibrils tightly packed inside it (Thibodeau & Patton, 2007). 
 
 
Figure 1.5. Structure of skeletal muscle. Muscle fibres are organised by three layers of 
connective tissue. Endomysium surrounds the muscle fibre, and bundles of muscle fibres, 
fasicles, are surrounded by perimysium. Bundles of fasicles are surrounded by epimysium. 
Picture adapted from Sinanan et al     (2006). 
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The myofibrils are made up of even finer filaments called myofilaments. There are two 
types of myofilaments thin and thick filaments (Thibodeau & Patton, 2007). Four 
proteins make up these myofilaments. The thin myofilaments consist of three proteins 
actin, tropomyosin and troponin, and the thick myofilament consists of myosin. Within 
a myofibril the thick and thin myofilaments alternate (Stewart & Rittweger, 2006) and 
this particular structure makes it possible for muscle to contract and relax.  
 
Calcium ions also play an important role in muscle contraction. They are concentrated 
within the sarcoplasmic reticulum and when the calcium ions are released from 
sarcoplasmic reticulum into the sarcoplasm surrounding the myofilaments this activates 
the sliding filament mechanism resulting in muscle contraction (Thibodeau & Patton, 
2007). 
 
However, it is important to know that apart from muscle fibres, muscle tissue consists 
of a heterogeneous population of cells (Beauchamp et al, 2000). Hence, if you isolate 
cells from muscle tissue by the explant method (Chapter 2.1.2) the amount of myogenic 
cells are estimated to be 5-45% (Lewis et al, 2000). 
 
 
1.3.1 MYOGENIC DIFFERERNTIATION 
 
The myogenic differentiation pathway has been investigated to find a successful therapy 
for muscle diseases e.g. muscular dystrophy. The cells responsible for the muscle 
regeneration are named satellite cells. They are considered to be myogenic stem cells 
and are small, flattened, quiescent, mononucleated cells situated beneath the same basal 
lamina as the multinucleated muscle fibre (Sinanan et al, 2006). Satellite cells are 
defined by their location and their main known function is to act as reserve cells for 
muscle growth and repair (Seale & Rudnicki, 2000; Sinanan et al, 2006). Skeletal 
muscle fibres are unable to divide: the only way they can increase in number is by 
muscle precursor cells (MPCs) fusion (Cornelison & Wold, 1997). When satellite cells 
become activated, e.g. by injury, they start to proliferate and become MPCs that express 
 CHAPTER 1: INTRODUCTION 
 40 
specific muscle markers e.g. desmin (Seale & Rudnicki, 2000) before they fuse with 
damaged muscle fibres to restore the damage or with each other to create new muscle 
fibres (Ambrosio et al, 2009; Figure 1.6).  This process is helped in vivo by Insulin-like 
growth factor-1 (IGF-1; Table 1.3), which is synthesized and secreted by muscle cells to 
enhance the proliferation and myogenic differentiation (Stewart & Rittweger, 2006; 
Clemmons, 2009). 
 
 
 
Figure 1.6. Scheme over regeneration of muscle fibre by satellite cells. Signals released by 
muscle injury to activate satellite cells, which start to proliferate, and their progeny, MPCs, can 
either self-renew, restoring the satellite cell pool, or differentiate along the myogenic lineage 
and fuse to repair damaged muscle fibres or fuse to form new ones. Picture taken from Carlqvist 
et al (2010). 
 
 
This transition from mono-nuclear MPCs to multinucleic myotubes is regulated by 
various factors including a transcription factor family, the Myogenic factor (Myf) 
family, where Myogenic differentiation antigen 1 (MyoD) and Myogenic factor 5 
(Myf5) are required for the commitment of stem cells to the myogenic lineage, whereas 
myogenin and Muscle regulatory factor 4 (MRF4) regulate the transition of these 
committed cells to multinucleated myofibres (Table 1.3; Stewart & Rittweger, 2006). If 
the myogenic differentiation is disturbed the precursor cells can form myosacs, which 
are rounded multi-nuclei structures (Kang et al, 1995). 
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Stem cell     Satellite cell                 MPCs                  Myotube 
 
Figure 1.7. Adult muscle-derived stem cells are hypothesised to be precursor cells to 
satellite cells.  According to this theory the myogenic differentiation pathway would go from 
stem cells to satellite cells to MPCs that proliferate and fuse to myotubes. 
 
 
Furthermore, there have been several reports about adult stem cells (Figure 1.7) residing 
in the skeletal muscle i.e. cells that are not restricted to the myogenic lineage (Qu-
Petersen et al, 2002; Sinanan et al, 2004). Most researchers agree that the cell 
population that is able to differentiate along non-myogenic lineages is distinct from 
satellite cells (Jankowski et al, 2002); there have been suggestions that muscle-derived 
stem cells are precursors to satellite cells (Figure 1.7; Jankowski et al, 2002).  
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Table 1.3 Myogenic markers and growth factors used in this study. Markers and growth factors are listed in an alphabetical order. 
 
MARKER 
 
 
DESCRIPTION 
 
MYOGENIC FUNCTION 
 
-sarcomeric actin 
 
 
- Contractile protein 
 
-The most abundant actin in terminally differentiated myofibres (Lancioni et al, 2007) 
 
CD56 
 
 
- Cell surface receptor 
 
- Used as a satellite cell marker (Mackey et al, 2009) 
 
Desmin 
 
-Cytoplastic 
intermediate filament 
- Links the z-lines of adjacent myofibrils 
- Maintaining sarcomere adhesion and structure (Stewart & Rittweger, 2006).  
- Expressed by myoblasts and myotubes (Lewis et al, 2000). 
 
IGF-1 
 
 
-Growth factor 
 
-Stimulate MPCs to proliferate and differentiate (Clemmons, 2009) 
 
Myogenin 
 
 
-Transcription factor 
-Belong to Myf family 
 
- Regulates the fusion of myoblasts to myotubes (Stewart & Rittweger, 2006) 
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1.4 ISOLATION OF CELLS 
 
1.4.1 MDCs 
 
Muscle tissue contains several different cell types (Lewis et al, 2000), so in order to 
improve the regenerative capacity of the muscle researchers have tested various 
isolation methods to obtain different subpopulations for study. Most researchers have 
focused on the isolation of the more myogenic population to use in muscle regeneration 
applications to treat diseases, such as muscular dystrophy. However, when it was 
discovered that MDCs contain cells that are not restricted to the myogenic lineage, 
attempts to develop methods to isolate other MDC-derived subpopulations have been 
made. Qu-Petersen et al (2002) developed an isolation method for MDCs derived from 
mice where the muscle was first enzymatically digested before the cells were isolated 
by differential adhesion to collagen. The main aim for this method was to isolate the 
more myogenic cells, however, they also isolated one population they named to muscle-
derived stem cells (MDSCs), that showed increased expression of neuronal (ca 1-2%) 
and endothelial markers (ca 15-20 %) after they had been treated with either neuronal or 
endothelial stimuli (Qu-Petersen et al, 2002). 
 
This pre-plate technique has not been thoroughly studied nor employed successfully for 
isolating human muscle stem cells (Ozeki et al, 2006). Therefore, other strategies have 
used cell surface markers of human MDCs to isolate specific cell types. The two 
markers that have been used are CD56, which has been used as a satellite cell marker 
(Mackey et al, 2009) and 7 (Ozeki et al, 2006), which has been used as a myoblast 
marker (Blanco-Bose et al, 2001). It was concluded that the MDCsCD56+ population 
consisted of both cells committed to the myogenic lineage and cells that are not able to 
express osteogenic and adipogenic genes when stimulated accordingly (Sinanan et al, 
2004). However, it was suggested that the cells with highest differentiation potential 
were the ones with either low expression of CD56 or lacking CD56 (Sinanan et al, 
2004), since CD56 is a marker for satellite cells.  
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Support for the theory that the more stem cell-like cells could reside in both the 
MDCsCD56+ and MDCsCD56- population was given by Andriamanalijaona et al (2008) 
who managed to induce chondrogenic differentiation in both subpopulations.  
 
Recently, Mitchell et al (2010) identified a novel cell population resident within the 
muscle interstitium by selecting the CD34+/Sca1+ population. When this cell population 
was freshly isolated, the cells expressed PW1, a stress mediator marker, but not Paired 
box transcription factor 7 (Pax7), which is expressed in satellite cells. Thus, the cell 
population was named PW1+/Pax7- interstitial cells (PICs). It was shown that PICs 
could differentiate into both smooth and skeletal muscle; however, PICs started to 
express Pax7, which is required for postnatal myogenic differentiation, before they 
formed skeletal muscle in vitro (Mitchell et al 2010).  
 
 
1.4.2 BONE MARROW-DERIVED MSCs 
 
The common approach to isolate MSCs from bone marrow is to let the cells adhere to 
tissue culture plastic (TCP). Bone marrow derived-cells adherent to TCP are considered 
more MSC-like, than other cells from the bone marrow, such as adipocytes, 
macrophages HSC and plasma cells (Alhadlaq & Mao, 2004). To confirm that the 
isolated population are MSCs, they are analysed by flow cytometry for a range of cell 
surface markers (Chapter 1.2.3; Alhadlaq & Mao, 2004). But it should be kept in mind 
that also in vivo MSCs express a heterogeneous set of cell surface markers and secreted 
matrix molecules (Tokoyoda et al, 2010). 
 
 
1.4.3 OTHER STEM CELL-LIKE POPULATIONS 
 
Researchers have also isolated stem cell-like populations from other tissues than muscle 
and bone marrow, for example from neonatal foreskin (Jones & Watt, 1993), cartilage 
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(Dowthwaite et al, 2004) and oral mucosa (Davies et al, 2010).  All these researchers 
have used the cells adhesion properties to fibronectin (Fn). For all these cell types the 
early adherent cells have been shown to belong to the more stem cell-like population 
(Jones & Watt, 1993; Dowthwaite et al, 2004; Davies et al, 2010). 
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1.5 DEVELOPMENTAL ORIGIN OF BONE AND 
MUSCLE 
 
Development of an organism starts with the fertilized egg cell divides to form the germ 
layers. Firstly, a layer facing the external medium is formed. A large part of this layer 
remains external, forming the ectoderm i.e. the precursor of epidermis and the nervous 
system. The interior part of the layer forms the endoderm i.e. the precursor of gut and its 
appendages, such as lung and liver. These are the primary germ layers (Hall, 2009). 
Thereafter, another group of cells move into the space between the ectoderm and the 
endoderm, and form the mesoderm i.e. the precursors of muscle and connective tissue 
(Alberts et al, 2002). The mesoderm arises by activation of genes following interactions 
between ectoderm and endoderm germ layer (Hall, 2009). According to the classical 
germ layer theory the ectoderm, endoderm and mesoderm, all belong to the primary 
germ layers; however, according to a modification of the theory, the mesoderm belongs 
to the secondary germ layer together with the neural crest (Hall, 2009). As mesoderm, 
neural crest arises early in the development and gives rise to divergent cell and tissue 
types and is formed by induction of primary germ layer (Hall, 2009).  
 
 
Figure 1.8. Classical view of the three germ layers; endoderm, ectoderm and mesoderm. 
The primary germ layers are the ectoderm, the outer layer, and the endoderm, the inner layer; 
the secondary germ layer is mesoderm, the middle layer.  Picture adapted from 
http://www.ncbi.nlm.nih.gov/About/primer/genetics_cell.html 
 CHAPTER 1: INTRODUCTION 
 
 
 
 
47 
The developmental origin of skeleton is dependant on its anatomical location. The 
craniofacial bone and connective tissue originate from the neural crest, while the 
associated muscles derive from cranial mesoderm (Dupin et al, 2007; Grenier et al, 
2009).  In the rest of the human body, the muscles and the skeleton, including the iliac 
crest, have the same developmental origin i.e. mesoderm (Alberts et al, 2002). 
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1.6 TI SCAFFOLDS 
 
Metal implants have the structure and the mechanical strength necessary to function in 
heavily loaded positions, such as jaws and joints (Ellingsen et al, 2000) and especially 
Ti and Ti alloys are commonly used in dental and orthopaedic implants (Brett et al, 
2004). Ti has apart from its mechanical strength and high degree of biocompatibility 
(Brett et al, 2004), also capacity to osseointegrate i.e. to create ‘a direct structural and 
functional connection between living bone and the surface of load’ (Granström, 2007).  
 
The osseointegration properties of Ti was originally used to anchor dental prostheses or 
bridges in the jaws to replace lost teeth (Granström, 2007) but Ti has also been used in 
various applications e.g. attachment of bone hearing aid, rehabilitation of patients with 
defects from cancer therapy and traumatic amputations (Granström, 2007). When a Ti 
implant is anchored, areas of bone are interspersed with regions of thicker fibroblastic 
tissue and regions of bone marrow (Schwartz et al, 2008).  In fact, bone marrow-derived 
MSCs are believed to be the cells that migrate on an implant in vivo, not committed 
osteoblasts (Schwartz et al, 1999). Hence, it is important that the surface coating gives 
the wanted signals to cells for successful osseointegration (Ellingsen et al, 2000). The 
aim for bone implant researchers is to manipulate the surface to make it more 
acceptable to bone cells for a rapid integration (Ellingsen et al, 2000).   
 
Ellingsen et al (2000) stated that successful osseointegration of an implant was 
dependent on both the physiology of the bone and the implant e.g. surface structure and 
chemistry. For example, the microstructure of the implant is known to affect 
osseointegration; a very smooth surface will result in poor integration, but with minor 
contraction. A very rough surface will result in rapid integration, but can cause 
secondary inflammation and contraction that can jeopardize integration later on 
(Ellingsen et al, 2000). However, there is a consensus in the dental world that rough 
surfaces have enhanced bone-to-implant shear strength and also osseous contact area 
compared with their smooth counterparts (Brett et al, 2004).  A fibrous capsule of 
poorly vascularised collagen is developed around most of smooth surfaces (Ellingsen et 
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al, 2000). Implants with rough surface have shown a reduction of fibrous encapsulation 
and an increment of the biomechanical properties of the implant-bone interface 
(Ellingsen et al, 2000).   
 
Polishing and blasting techniques are in general used to modify the topography of the Ti 
surface. During the process of polishing the surface is polished by a hard abrasive 
medium while using a lubricant. Sandblasting and acid etching are often used to 
increase the surface roughness (Ellingsen et al, 2000). Cells on Ti surfaces treated by 
sandblasting and acid etching have shown enhanced osteogenic properties compared to 
cells on polished Ti surfaces (Rupp et al, 2006). 
 
Lately, there have been suggestions that hydrophilic rough surfaces increase the rate and 
extent of bone formation compared to hydrophobic rough surfaces (Table 1.4; Zhao et 
al, 2005; Rupp et al, 2006). Straumann AG, has developed a hydrophilic rough surface 
for their dental Ti implant screws called SLActive, which Schwartz et al (2008) showed 
enhanced the amount of formed bone around its site compared to its hydrophobic 
counterpart, SLA. Used in clinic, Ti screws with SLActive surface significantly reduces 
the healing time; for standard screws the healing time recommended before loading is 
12 weeks, for screws with SLActive surface this time is reduced to between immediate 
or early loading i.e. 4 weeks (Zöller et al, 2008; Morton et al, 2010). There are several 
benefits of reducing the healing time of implants, such as simplifying the clinical 
procedure, lowering the cost and improved appearance for the patients (Morton et al, 
2010). 
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Table 1.4. Definition of hydrophilicity/hydrophobicity depending on the water contact 
angle. The water contact angel is the angle which a droplet of water meets the solid surface. 
WATER 
CONTACT ANGLE  
 (°) 
 
 HYDROPHILIC OR HYDROPHOBIC 
0 Very strongly hydrophilic 
0-30 Strongly hydrophilic 
30-90 Less hydrophilic 
> 90 Hydrophobic 
Ca 120 Strongly hydrophobic 
> 150 Superhydrophobic 
 
 
1.6.1 SURFACE ROUGHNESS (Ra) 
 
The surface roughness or the Ra value of the material is defined as the peak-to-valley 
measurement of a surface. However, it is important to remember that differences in the 
topography of a surface could also affect how the cells perceive its surface. In addition, 
the cells different differential stages and morphology could influence how they interact 
with the surface (Schwarts et al, 1999).  
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1.7 CELL DEATH 
 
In general, researchers divide cell death into two groups: apoptosis and necrosis. In 
healthy cells, phospholipids are asymmetrically distributed, with the anionic 
phospholipids e.g. phosphatidylserine situated on the cytoplasmic side of the plasma 
membrane. This asymmetrically distribution is disturbed by apoptosis; thus, AnnexinV, 
a natural human phosphatidylserine-binding protein can, and is often, used as a marker 
for apoptosis (Tait, 2008). 
 
 In necrosis, the cell and its organelles start to swell, whilst in apoptosis the cell shrinks 
together with its nucleus. This distinction is due to the plasma membranes different 
roles in the two processes. In necrosis, the plasma membrane looses its coherence, 
which allows an influx of extracellular ions and fluid. Thus, the cell and its organelles 
start to swell. In apoptosis on the other hand, plasma-membrane coherence persists until 
later in the process (Hotchkiss et al, 2009).  
 
It has long been known that apoptosis is genetically controlled i.e. programmed cell 
death (Hotchkiss et al, 2009). However, there is now evidence that necrosis, which was 
considered as being an accidental form of cell death, can be initiated or modulated by 
programmed mechanisms. It has also been shown that there can be cross-talk between 
the two forms of cell death pathways (Goldspink et al, 2004; Hotchkiss et al, 2009). 
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1.8 APPLICATION OF RESEARCH 
 
This thesis has compared the osteogenic differentiation potential between bone marrow-
derived MSCs and MDCs, or an osteogenic subpopulation of MDCs, and their 
interaction with Ti. 
 
The idea of using MDCs in bone regenerative applications originate in the discovery 
that muscle tissue contained cells that could differentiate along the osteogenic lineage 
(Bosch et al, 2000). There could be various advantages of using osteogenic MDCs 
instead of bone marrow-derived MSCs in bone regeneration applications. One could be 
that using osteogenic MDCs would lower the risks associated with bone marrow 
transplantation; the bone marrow containing MSCs also contains white blood cells and 
by removing white blood cells the patient’s immune system is decreased. Taking muscle 
biopsies is not associated with a decreased immune system and muscle tissue, especially 
masseter muscle, is considered to be easy accessible.  
 
If a patient is in need of bone material for repair and regeration as a result of a bone 
related disease, such as osteoporosis, it might be possible to use an expanded culture of 
their own osteogenic MDCs for transplantation into the affected sites. This would 
possibly have the advantage over the use of MSCs in a patient with osteoporosis who 
might suffer extra morbidity from the cell harvesting procedures. The possibility of 
using osteogenic MDCs in autologous transplantations is important since there is 
always a risk in allogenic transplantations that the patient will reject the donor’s bone 
marrow or contract an infection (Thibodeau & Patton, 2007).  
 
Osteogenic cells seeded onto Ti could be used as enhancers of osseointegration for 
implants used throughout the body. Using the osseointegrational properties of Ti is very 
common in dental industry, but has also been used in bone conducting hearing aids, 
implants after defects from cancer therapy and traumatic amputations (Granström, 
2007).  
 CHAPTER 1: INTRODUCTION 
 
 
 
 
53 
 
MSCs have already shown promising results to improve the bone regeneration around 
Ti knee implants in sheep (Frosch et al, 2006). Frosch et al (2006) coated Ti knee 
implants with autologous MSCs and inserted the implants back in vivo (Frosch et al, 
2006). Defects treated with MSC-coated implants demonstrated a complete regeneration 
of the subchondral bone in 50% of the cases. When uncoated implants were inserted, it 
resulted in incomplete healing in 50% of the cases. In 50% of the cases both uncoated 
and MSC-coated implants failed to osseointegrate (Frosch et al, 2006).  
 
Another application could be the use of osteogenic cells to regenerate new bone; in this 
case, Ti would function as a permanent scaffold that will be integrated in the newly 
formed or old bone structure. Promising results have already been shown in humans 
where autologous MSCs have been used. Warnke et al (2004) constructed a Ti scaffold 
to regenerate a new mandibular. They filled the scaffold with bone mineral blocks and 
bone marrow, including MSCs, and after 7 weeks found new osteoblast activity 
(Warnke et al, 2004).  
 
In both of these applications, it is considered necessary to culture the cells in vitro prior 
to transplantation in order to increase the cell number and differentiate the cells along 
the osteogenic pathway (Sikavitsas et al, 2001). A way to enhance the osteogenic 
differentiation of the cells in vivo could be to incorporate BMP-2 into the Ti coating 
(Liu et al, 2004). Implant failure in the clinic could have several causes, such as 
infections, impaired healing or overloading. If the rate of osseointegration between the 
implant and bone could increase by coating the implants with osteogenic cells the 
success rate could increase.  
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1.9 AIM OF RESEARCH 
 
The main aim for this research is to investigate the potential to use MDCs in bone 
engineering applications, where Ti is used as the scaffold. To achieve the aim of this 
project the research had to be divided into three parts with their own objectives: 
 
a) Develop an isolation method for the more osteogenic fraction of MDCs. 
 
b)  Study the osteogenic differentiation of the more osteogenic fraction of MDCs 
and compare it with MSCs 
 
c) Comparison of the interaction of the more osteogenic fraction of MDCs with Ti 
and compare it with MSCs 
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2.1 ISOLATION 
 
2.1.1 MSCs DERIVED FROM BONE MARROW* 
*Performed by Tulane Center for Gene Therapy, US, thanks to grant from NCRR 
of the NIH # P40RR017447 
 
The MSCs were isolated from iliac crest bone marrow from 5 male patients in the age 
range of 22-28 years old.  In order to separate the mononuclear cells from erythrocytes 
density centrifugation was performed. Thereafter, the cells were plated on TCP so the 
MSCs could adhere and cultured in -MEM based culture media. The MSCs were 
harvested when they reached 60%-80% confluency and named passage 0 cells. 
 
The isolated MSCs were expanded and tested for a range of cell surface markers at 
passage 2. The MSCs were positive for markers known to be expressed on MSCs i.e. > 
90% of the cells expressed, for CD29, CD49c, CD59, CD73a, CD90, CD105, CD147, 
CD166 and HLA-I. The cells were also negative for blood cell markers i.e. < 1 % of the 
cells expressed, for CD11b, CD19, CD34, CD36, and CD45.  
 
The MSCs were aliquoted in vials, 1x106 cells/vial, and delivered to UCL Eastman 
Dental Institute (EDI) in liquid nitrogen, where they were transferred directly to their 
permanent liquid nitrogen storage. 
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Table 2.1. Cell surface markers for which the MSCs were tested positive or negative. 
The table is an adapted version of the information sheet from Tulane Center for Gene Therapy 
CELL 
SURFACE 
MARKER 
 
DESCRIPTION 
 
CD11b 
 
Mediates adhesion to substrates 
 
 
CD19 
 
 
Early B-cell antigen in fetal tissue and regulates cell 
development 
 
CD29 
 
 
Fn receptor 
 
CD34 
 
 
Cell-cell adhesion and molecule and cell surface 
glycoprotein 
 
CD45 
 
 
Leukocyte antigen 
 
CD49c  
 
 
Receptor for laminin, collagen, Fn, thrombospondin 
 
CD59 
 
 
Regulates mediated cell lysis 
 
CD73a 
 
Catalyzes dephosphorylation 
 
 
CD90 
 
 
Marker for HSCs, neurons and connective tissue 
 
CD105 
 
 
Mediates cellular response to TGF-β1 
 
CD147 
 
Induces MMPs 
 
 
CD166 
 
Is an activated leukocyte cell adhesion molecule 
 
 
HLA-I 
 
 
Is associated with β-2 microglobulin 
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2.1.2 MDCs DERIVED FROM MASSETER MUSCLE 
TISSUE 
 
The MDCs were derived from masseter muscle biopsies from 3 healthy, adult, informed 
and consenting patients undergoing wisdom tooth removal at EDI. The procedure was 
approved by the ethical committee. Biopsies from three patients were used in this study; 
the sexes and ages of the donors were kept unknown. 
 
The biopsies were washed with 1% antibiotic (penicillin/streptomycin)-supplemented 
Dulbecco’s modified eagle’s essential medium (DMEM) and minced with sterile 
scalpels. The tissue fragments were plated onto 0.2%-gelatin-coated T25 cm2 flasks 
with culture media i.e. DMEM, low glucose, in the presence of 20 % Fetal bovine 
serum (FBS) and antibiotics, and incubated at 37 °C in 5 % CO2. 
 
The culture media was changed every 4 days and after 2-4 weeks cells started to migrate 
from the biopsies. The first wave of migration of mononuclear cells from the explant 
was named ‘α-wave’, and this population was used throughout this study. The harvested 
‘α-wave’ cells were named MDCs passage 1 cells. This isolation protocol has 
previously been developed and used in laboratories at EDI (Sinanan et al, 2004). 
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2.2 CELL CULTURE  
 
2.2.1 MDCs  
 
The MDCs were cultured on 0.2% gelatin (Gel)-coated TCP in DMEM, low glucose, 
supplemented with 20% FBS and 1% P/S if not otherwise stated. Before the MDCs 
reached confluency they were enzymatically harvested using Trypsin/EDTA (Trypsin), 
unless otherwise stated. All experiments were performed using cells in passage range  
3-7.  
 
2.2.2 MSCs 
 
The MSCs were cultured on TCP in alpha-minimal essential medium (-MEM), 
supplemented with 20% FBS and 1 % P/S unless otherwise stated. Before the MSCs 
reached confluency they were enzymatically harvested using Trypsin unless otherwise 
stated. All experiments were performed using cells in passage range 2-5.   
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2.3 DIFFERENTIATION 
 
At differentiation experiments, the cells were seeded at 5000 cells/cm2, and left in 
culture media until they became confluent approximately at 10000 cells/cm2. 
Confluency is a subjective term and Figure 2.1 demonstrates the degree of confluency 
that is defined confluence in this thesis. This degree of confluency was chosen since it is 
important for cells to have cell contact for differentiation purposes; however, the 
differentiation should be directed by the differentiation media and not by cell-to-cell 
contact. 
 
Figure 2.1. Level of confluency for when differentiation medium is added to the cells. 
These photographs by Phase contrast microscopy (PCM) show MSCs of a) x4 and b) x10 
magnification.  
 
 
a) b) 
Cell-to-cell contact 
Space in between cells Space in between cells 
Cell-to-cell contact 
500um 300um 
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2.3.1 OSTEOGENIC MEDIA  
 
The osteogenic media was titrated to find the optimal concentration of dex and β-
glycerophosphate (β-GP) in chapter 3, Result section 1. If nothing else is stated 
‘osteogenic media’ consisted of DMEM (low glucose), 20 % FBS, 100nM dex, 50ug/ml 
L-ascorbic acid, 2 mM β-GP and 1 % P/S (Table 2.2). The osteogenic media in the 
literature has had various concentrations of dex (Ahdjoudi et al, 2001; van den Dolder 
& Jansen, 2007) and β-GP (Aslan et al, 2006; Ozeki et al, 2006).  
 
 
2.3.2 MYOGENIC MEDIA  
 
The optimal myogenic media has been determined earlier by Allen & Boxhorn (1989) 
and consisted of 10 ng/ml IGF-1(E3R), DMEM (high glucose), 2 % FBS, and 1 % P/S 
(Table 2.2). 
 
 
2.3.3 ADIPOGENIC MEDIA 
 
The adipogenic media consisted of DMEM (low glucose), 20 % FBS, 0.5uM dex, 0.5 
uM isobutylmethylxanthine, 50 uM indomethacin and 1 % P/S (protocol taken from 
information sheet from Tulane Center for Gene Therapy; Table 2.2). 
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Table 2.2. Summary of types of cell media used in this project. All media were 
supplemented with 20% FBS apart from myogenic media that was supplemented with 2 % FBS. 
All media were supplemented with 1 % P/S. Media presented in alphabetical order. 
MEDIA BASAL MEDIA SUPPLEMENT 
Adipogenic media DMEM, low glucose 
0.5uM dex 
0.5 uM iso-butylmethylxanthine 
50 uM indomethacin  
Control media  DMEM, low glucose - 
Culture media for 
MSCs -MEM, low glucose - 
Culture media for 
MDCs DMEM, low glucose - 
Myogenic media DMEM, high glucose 2% FBS 10 ng/ml IGF-1 (E3R)  
Osteogenic media DMEM, low glucose 
100nM dex 
50ug/ml L-ascorbic acid 
2 mM β-GP 
Tulane’s osteogenic 
media -MEM, low glucose 
1 nM dex 
50 uM L-ascorbic acid 
20 mM β-GP 
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2.4 METABOLIC ACTIVITY 
 
In this thesis two methods have been used to assess metabolic activity of the cells: 
Alamar Blue and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT). 
 
 
2.4.1 ALAMAR BLUE 
 
Alamar Blue is a dye that assesses the metabolic activity of cells by functioning as an 
oxidation-reduction indicator.  Blue coloured non-fluorescent Alamar Blue dye is 
reduced to pink coloured fluorescence by live cells. The oxidation-reduction process is 
based on the detection of metabolic activity or on the level of oxidation during 
respiration.  The level of fluorescence is monitored at 530 nm excitation wavelength 
and 590 nm emission wavelength. The fluorescence is proportional with cell number 
(Figure 2.2), but the results are in general presented as percentage reduction of Alamar 
blue dye compared to maximal reduction (see equation below).  
 
Following formula gives reduction of Alamar Blue in percentage: 
 
 
Re ductionAlamarBlue(%) 
(FlSample  FlBlank)
(Fl100% Re dAB  FlBlank)
x100  
 
 
 where; FlSample = Fluorescence in sample 
  FlBlank  =  Fluorescence in an acellular sample 
  Fl100%   =  Fluorescence in an autoclaved sample 
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2.4.1.1 PROTOCOL  
 
The cell media were first removed and exactly 900 ul of fresh culture media was 
pipetted into each well, in a 24-well plate, with cells plus an acellular well, which was 
used as a blank control. Thereafter, 100 ul of Alamar Blue was added to each well and 
incubated for exactly 4 h in incubator at 37 C. In order to assess the maximal 
reduction, an acellular sample with Alamar Blue/culture media mixture was autoclaved.  
 
After 4 h incubation, 2x100 ul was taken from each well, the acellular and the 
autoclaved control and pipetted to a black 96-well plate. The fluorescence was 
measured immediately in a fluoroscan (Ascent, Labsystems) at 530 nm excitation 
wavelength and 590 nm emission wavelength using software Ascent version 2.4. One 
important feature of Almar Blue is that is not cytotoxic, so the cell cultures can be used 
over many time periods. In order to control that the incubation time, 4 h, gave a linear 
relationship between fluorescent intensity and number of cells control standard curves 
were performed (Figure 2.2).  
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Figure 2.2. Standard curve of fluorescence v.s. number of cells after 4 h incuabtion with 
Alamar Blue. Graph shows the result of different seeding densities of MSCs incubated with 
Alamar Blue. Result presented as mean± 1sd. 
 
 
2.4.2 MTT ASSAY 
 
MTT assay is a colorimetric method for measuring cell metabolic activity. Yellow MTT 
is reduced to form purple formazan in the mitochondria of live cells. The reduction from 
yellow MTT to purple formazan takes place when mitochondrial reductase enzymes are 
active, and is directly related to the number of viable cells. 
 
 
2.4.2.1 GENERAL PROTOCOL 
 
The 250 ul/ml culture media of the MTT dye, stock concentration 5mg/ml, was added to 
the cells in culture media before the cells are incubated 4 h in 37 ºC. After 4 h, the 
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medium was removed and an 1 ml/well, in a 24 well plate, extraction buffer, 0.5 M 
DMF in 20-% Sodium dodecyl sulfate (SDS) solution (w/v, SDS/dd-H2O) was added to 
dissolve the formed formazan over night in 37 ºC. 
 
When the formazan was extracted, 2x 100 ul aliquotes per sample were transferred to a 
96 well plate. The absorbance was measured using a plate reader at 590 nm where 
extraction buffer was used as a blank control. 
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Figure 2.3. Standard curve of absorbance at 590 nm v.s. number of cells after MTT Assay. 
Graph shows the result of different seeding densities of MDCs incubated with MTT. Result 
presented as mean± 1sd. 
 
 
2.4.2.1.1 PROTOCOL TO DETERMINE POPULATION DOUBLING (PD) 
 
Cells were seeded at a density of 100cells/cm2 in 6-well plates in triplicates. A reference 
plate was analysed, to measure the absorbance at time point 0. A theoretical standard 
curve was calculated with PD as a function of absorbance. This standard curve gave a 
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logarithmic equation (see equation below), which was used to calculate the PD values 
from the assessed absorbance.  
 
mxky  )ln(  
 
where; y = PD 
 k = slope constant 
     x = absorbance  
     m = constant 
2.4.2.1.2 PROTOCOL FOR ATTACHMENT 
 
In order to assess the level of attachment in different cell subpopulations the MTT assay 
was used (Chapter 4.3.2). Immediately after the wanted cell population was isolated 
MTT was added to the cells in culture media. This was done to minimise the bias of 
proliferation that might occur differently in different cell subpopulations. The MTT 
assay was performed as described in Chapter 2.4.2.1. 
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2.5 SIZE ASSESSMENT 
 
2.5.1 MEASURING BY IMAGE ANALYSIS 
 
In order to assess the average size of MDCsFn and MDCsPP the cells were isolated in 
triplicates and the area of the two populations were assessed by image analysis. The 
images were captured using Leica FW4000 on an inverted light microscope Leica 
DMIRB, 48 hours after isolation. Photographs of 30 cells of each triplicate were taken. 
First the photographs were calibrated by a micrometer graticule; thereafter, by using 
calibrated photographs of the cells and software Image-pro the cell size could be 
assessed. 
 
 
2.5.2 MEASURING BY FLOW CYTOMETRY 
 
In order to confirm the differences in size of the two cell populations, MDCsFn and 
MDCsPP, they were also studied by flow cytometry. Light scattering detects cells in 
flow cytometery where Forward scattering measures size and Side scattering measures 
granularity. The Forward scattering was used to compare the size of the cells in the two 
populations. 
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2.6 STAINING  
 
2.6.1 HISTOLOGICAL 
 
2.6.1.1 ALP  
 
ALP expression was analysed as it is known to initiate one of the earliest phases of 
osteogenesis (Weiss et al, 1986) as well as being involved in bone mineralization 
(Miyake et al, 1997).  
 
Cells were placed in osteogenic media or culture media, as a control, for various time 
points. For ALP expression analysis, the cells were fixed by 4% paraformaldehyde 
(PFA) for 10 min before they were washed by phosphate buffered saline (PBS). 
Thereafter, the freshly prepared ALP staining mixture (Figure 2.4), 0.5 ml/cm2, was 
added onto the cells. After 45 min incubation the ALP staining mixture was removed 
and the cells were washed three times with PBS. The cells were left in PBS and images 
were captured immediately. 
 
 
 
   
 
 
Figure 2.4. Protocol of ALP staining. The ALP solution was prepared fresh and added straight 
onto the cells and incubated for 45 min in room temperature.  
 
 
ALP staining:  
1. Add ALP solution (45 min) 
  -2mg Naphthanol AS MX 
-10 ml deionised H2O 
-10 ml Tris-HCl (0.2 M, pH8.3) 
- 80ul N,N-Dimethylformamide 
+ 12 mg Fast Red Violet LB Salt (added last) 
2. Wash 3 times 
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2.6.1.2 SIRIUS RED 
 
Collagen expression was analysed by Sirius Red S staining. Collagen is the major 
component in the specialised organic matrix of bone tissue (Thibodeau & Patton, 2007). 
 
The cells were incubated in osteogenic media for 3 weeks before they were fixed in 4% 
PFA for 15 min. After fixation the cells were washed with PBS and air dried. The Sirius 
Red dye, 100mg/ml, was freshly prepared in saturated picric acid. The cells were 
stained for 1 h under mild shaking on a microplate shaker. Thereafter, the dye solution 
was removed and the stained layer was washed by 0.01 M hydrogen chloride (HCl) to 
remove excess dye. The stained material was extracted by 0.1 M sodium hydroxide 
(NaOH) in 1 ml/well (in a 24-well plate) on a microplate shaker for 30 min at room 
temperature. The extracted dye solution was measured using a spectrophotometer to 
detect absorbance at 550 nm where 0.1 M NaOH was used as reference. The protocol 
was adapted from Tullbert-Reinert & Jundt (1999). 
 
2.6.1.3 ALIZARIN RED S 
 
In order to measure mineralization by cells, Alizarin Red S staining and quantification 
was performed. Alizarin Red S forms a complex with the Ca2+ in the hydroxyapatite 
(see Chapter 1.2).  
 
 The cells were washed in Ca2+ free PBS before being fixed for 10 min in 4% PFA. 
After a rinse with deionised water, Alizarin Red S solution 1 ml/well, in 24-well plate, 
(2 w/v-% in deionised water, pH 4.1-4.2) was added to the cells. After 10 min, the 
Alizarin Red S solution was removed and the cells were washed four times with 
deionised water to remove any excess dye. The dye was dried before images were 
captured of the cells using CoolSnap-Pro camera through an Olympus BX50 
microscope using Image-Pro Plus 4.5 software. 
 
CHAPTER 2: METHODS 
 71 
2.6.1.3.1 PROTOCOL QUANTIFICATION 
 
The Alizarin Red S-calcium complexes were extracted by 10 % cetylpyridium chloride 
in 10 mM sodium phosphate (w/v, pH 7.0) for 2 h. The result was analysed with 
spectrophotometer at 562 nm (Stanford et al, 1995). Extraction buffer was used as 
reference.  
 
 
2.6.2 IMMUNOCYTOCHEMICAL 
 
Desmin is an early myogenic marker (Lewis et al, 2000) and α-sarcomeric actin a 
myotube marker (Lancioni et al, 2007).  In order to visualise terminal myogenic 
differentiation, cells were stained for the presence of these two markers (Table 1.1). The 
cells were stained using primary antibodies, specific for desmin or α-sarcomeric actin 
and thereafter specific secondary antibodies (see Table A9.4). The cells were imaged by 
either inverted flourescent microscopy or confocal microscopy.  
 
The cells were seeded onto glass cover slips and cultured to confluency; thereafter, 
myogenic media or control media was added onto the cells for 4 days. After 4 days the 
cells were lightly fixed for 5 min with 2 % PFA and, after 2 washes with PBS, with ice-
cold Metanol (MeOH) for 10 min. If the staining was not performed directly, the cells 
were stored in PBS with 0.0625 % Sodium azide (NaN3) in 4 ºC until stained. 
 
Before the start of the staining the cells on the cover slips were washed five times in 
freshly prepared PBS before they were placed on home-made stands (Figure 2.5). The 
cells were permeabilised by a solution containing 0.25 % Triton-X (v/v) and 0.0625 % 
NaN3 in PBS for 15 min. Meanwhile the primary antibodies were diluted in antibody 
diluent i.e. PBS, 10 % heat-inactivated FBS, 0.0625 % (w/v) NaN3 and 0.1 M lysine; 
the desmin specific antibody was diluted 1:200 and the α-sarcomeric actin 1:500. The 
primary antibody was added onto the cells and incubated for 1h. Thereafter the cells 
CHAPTER 2: METHODS 
 72 
were washed 5 times in freshly prepared PBS, before the specific secondary antibodies 
and 4, 6-diamidino-2-phenylindole (DAPI), diluted in antibody diluent, were added and 
incubated with the cells for 30 min. The secondary antibody for desmin staining was 
diluted 1:200, and for α-sarcomeric actin diluted 1:800 (see Table A9.4 for antibody 
details). 
 
After the incubation with the secondary antibodies the cells were mounted onto glass 
slides with Citiflour and sealed with nail varnish. Example of the staining can be seen in 
Figure 2.6. 
 
 
 
Figure 2.5. Staining procedure. The cover slips with the cells were first washed five times in 
PBS before placed on stands made of Petri dishes and eppendorf lids. First the cells were 
permeabilised by 0.25 Triton-X for 15 min before they were washed five times in PBS. 
Therafter the primary antibodies in antibody diluent were added to the cover slips for 1 h. After 
the 1h incubation the cover slips were washed again five times, before the secondary antibodies 
in antibody diluent were added for 30 min. Finally, the cover slips were washed five times 
before being mounted onto glass slides.  
 
 
Petri dish 
Lid of Eppendorf tube 
Cover slips Incubated with  primary antibodies 
 for 1 h 
Incubated with  
secondary antibodies 
for 30 min 
5 washes 
5 washes 
 
5 washes 
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Figure 2.6. Example staining of MDCs in myogenic media. MDCs in a) bright field, b) nuclei 
stained by DAPI, c) desmin stained by FITC, d) α-sarcomeric actin stained by Cy3, e) merged 
photograph of a and b, f) merged photograph of b, c, and d.  
 
Bright field and DAPI staining 
 
Desmin, α-sarcomeric actin 
and DAPI staining 
100um 100um 
DAPI 
Desmin-FITC staining α-sarcomeric actin-Cy3 staining 
α-sarcomeric actin Desmin 
Bright field 
c) d) 
100um 100um 
100um 100um 
 
Nuclei-DAPI staining 
f) e) 
a) b) 
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2.7 ENZYME IMMUNOASSAY-ALP ACTIVITY 
 
The ALP activity was measured by p-nitrophenyl phosphate (p-NPP) kit according to 
the manufacturer’s guidelines. The cells in the 24-well plate were first washed by PBS 
then 200ul of 1%Triton-X/PBS (v/v) was added to each well (24-well plate) while they 
were shaken for 20 min on a microplate shaker (Biometra WY16). An aliquot of 50 ul 
of the Triton-X/ALP/PBS mixture was transferred in duplicates to a 96-well plate for 
exactly 30 min of incubation in the dark at room temperature with p-NPP solution, 
consisting of 1.0 mg/ml pNPP, and 0.2 M tris(hydroxymethyl)aminomethane (Tris) 
buffer.  During the incubation following reaction took place. 
 
 
 
Figure 2.7. ALP catalyzes the reaction to transform p-NPP to p-nitrophenol. The final 
product of p-nitrophenol has a yellow colour which absorbance can be measured using 
spectrophotometer at 405 nm.  
 
 
The reaction was stopped by 150 ul /well 1M NaOH and the ALP activity absorbance 
was read at 405 nm in a plate reader (MRX-TC, Dynex Technologies) using software 
Revelation version 4.25. To assess the ALP activity per cell density the ALP activity 
was normalised to the cell number calculated using the MTT assay (Chapter 2.4.2.1). 
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2.8 FLOW CYTOMETRY 
 
2.8.1 STRO-1 AND CD56 
 
Flow cytometry was used to study the expression of Stro-1 and CD56 on the cells. The 
Stro-1 antibody was reconstituted in PBS to 500ug/ml and stored accordingly to 
manufacturer’s recommendation; CD56 was delivered pre-reconstituted to 200 ug/ml 
(Table A9.4). 
 
 Subconfluent cells were washed then detached by 5-10 min incubation in accutase. The 
effect of accutase was inactivated by culture media and the cell suspension was 
transferred to flow tubes. The samples were washed twice in PBS by centrifugation for 
5 min at 1300 rpm and then resuspended in 200 ul/sample Flow buffer i.e. 2% FBS in 
PBS. To each tube 2ul of Stro-1 or 10 ul of CD56 antibody was added.  The cells were 
incubated with the antibody on ice for 1h before being washed twice in PBS by 
centrifugation for 5 min at 1300 rpm. The stainings were performed as single-stainings. 
 
For cells incubated with Stro-1, 10 ul of R-Phycoerythrin (R-PE)-conjugated IgM 
specific, 1 mg/ml, secondary antibody was added together with 190 ul Flow buffer to 
each sample (see Table A9.4). For cells incubated with antibodies for CD56, 5ul of 
Alexa Fluor 488-conjugated IgG1, 2 mg/ml, specific secondary antibody (see Table 
A9.4) together with 190 ul Flow buffer was added to the cells. For both cells incubated 
with antibodies Stro-1 or anti-CD56 the incubation period was 30 min on ice. After 
incubation the cells were washed three times in PBS by centrifugation for 5 min at 1300 
rpm and resuspended in Flow buffer. 
 
The cells were analysed in terms of size, granularity and fluorescence using the 
software CellQuest and FACScanTM (Becton Dickinson). Light scatter identified cells 
and 10000 cells/sample were counted and gated. Immunopositivity was determined by 
comparison with cells incubated with only the secondary antibody.  
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2.8.2 APOPTOSIS AND NECROSIS  
 
The levels of apoptosis and necrosis of cells were analysed by staining with Annexin V-
FITC and Propidium iodide (PI). Annexin V-FITC is a fluorescent probe which binds to 
phosphatidylserine in the presence of calcium. Phosphatidylserine is normally found on 
the internal part of the plasma membrane. The affinity between Annexin V and 
phosphatidylserine can be used in apoptosis measurements since the cell membrane, 
including the phospholipids, start to loose its asymmetry at an early stage of apoptosis 
(Chapter 1.7). PI is a nucleus stain, for which the cells stain positive when their 
membrane have been completely compromised as in necrosis. 
 
2.8.2.1 PROTOCOL 
 
The cells were detached by accutase that was later inactivated by culture media before 
the cells were washed twice in PBS by centrifugation at 1300 rpm. Thereafter, the cells 
were resuspended in 500 ul binding solution/sample i.e. 10X binding buffer in 450 ul 
deionised water. Finally, 5 ul of Annexin V-FITC and 10 ul of PI were added to each 
sample. The samples were incubated 10 min in darkness before being analysed by flow 
cytometry. 
 
In order to avoid superimposition between FITC and PI, the settings on the flow 
cytometer were adjusted (Figure 2.8).  
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Figure 2.8. Graphs of MSCs stained with either Annexin V-FITC or PI or both or left 
unlabelled.  MSCs a) unlabelled b) labelled with only Annexin V-FITC, c) labelled only with 
PI and d) labelled with both PI and Annexin V-FITC.  
 
 
a) b) 
c) d) 
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2.9 REAL-TIME/Q-POLYMERASE CHAIN 
REACTION (PCR) 
 
2.9.1 ISOLATION OF RNA 
 
Isolation of RNA was performed by the TRIzol method according to manufacturer’s 
protocol (Table A9.6). At the desired time point, the samples were lysed in TRIzol, 
0.125 ml/cm2; the samples were first homogenised by pipetting before they were 
transferred to 1.5 ml eppendorf tubes where they were vortexed to homogenise the 
sample further. If isolation was not performed immediately, the samples were stored at -
80 C. 
 
Before isolation, the samples were thawed and incubated for 5 min at room temperature; 
chloroform, 0.2 ml/ml TRIzol, was then added to the samples. The samples were shaken 
for 15 sec and incubated in room temperature for 2-3 min before centrifuged (Sorvall 
Legend RT) at 11999 x g for 15 min at 4 ºC.  This caused a phase separation with an 
upper aqueous colourless phase, where the RNA remained and a red phenol based lower 
base. 
 
The aqueous RNA phase was transferred to a fresh 1.5 ml-eppendorf tube and RNAse 
free glycogen, final concentration of 0.3ug/ul, was added to the samples as a RNA 
carrier. The RNA was precipitated by iso-propyl alcohol, 0.5 ml/ml TRIzol and 
incubated for 10 min before the samples were centrifuged for 10 min at   11999 x g at 4 
ºC. 
 
The supernatant was removed and the RNA was washed by 1ml ethanol (EtOH)/ml 
TRIzol and mixed by vortexing; thereafter, the samples were centrifuged by 5 min at 
7499 x g at 4 ºC.  After centrifugation, the supernatant was removed and the samples 
were air dried for 5 min before resuspended in nuclease-free water and dissolved by 10 
min at 55 ºC.  The quantity and the quality of the RNA sample was assessed by 
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spectrophotometer. All the RNA samples were diluted by nuclease-free water to 25 
ng/ul; the quality, which ranged between 1.6 and 2.0, was measured by the ratio of 
260/280 with corrections of absorbance at 320 nm, since dirty cuvettes and dust 
particles cause light scatter at 320 nm. 
 
2.9.2 RNA TO cDNA CONVERSION 
 
The RNA was converted to cDNA by using the High Capacity cDNA Reverse 
Transcription kit accordingly the manufacturer’s protocol (Table A9.5). The number of 
desired qPCR reactions was calculated first. Each reaction consisted of equal parts, 1:1, 
Master Mix (10X RT buffer/ 25X dNTP Mix/ 10X Random Primers/Multiscribe 
Reverse Transcriptase/ nuclease-free water, 2:0.8:2:1;4.2, v/v/v/v/v) and RNA, 10 
ng/reaction, diluted in nuclease-free water. The diluted RNA and Master Mix were 
added to a tube and mixed well. Before placing the tubes in the thermal cycler (PTC-
100, Genetic Research Instrumentation, Ltd), the samples were lightly centrifuged 
(MSE, Microcentaur, Scotlab) for 5 sec at 1000rpm. 
 
Table 2.3. The program used to convert the Master Mix and RNA mixture to cDNA. 
  
STEP 1 
 
STEP 2 
 
STEP 3 
 
STEP 4 
 
Temperature 
(ºC) 
 
25 
 
37 
 
85 
 
4 
 
Time 
 
 
10 min 
 
120 min 
 
5 sec 
 
∞ 
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2.9.3 Q-PCR  
 
RT-or q-PCR is a method to quantitative analyse the gene expression i.e. mRNA in 
cells. First the mRNA has to be converted to cDNA (Chapter 2.9.2) and thereafter the 
cDNA is replicated by q-PCR. Sequence-specific DNA oligonucleotide probes, with a 
fluorescent reporter dye and a quencher, hybridize with the complementary strand of 
cDNA (Figure 2.9). The fluorescence quenching depends on the proximity of the 
reporter dye and the quencher. When Taq polymerase adds nucleotides from each 
primer it also removes the probe from the template DNA (Figure 2.9). This separates 
the quencher from the reporter dye resulting in fluorescence. The fluorescence is 
measured continuously over the run of 40 cycles and the gene expression can therefore 
be quantified. 
 
 
Figure 2.9. Description of q-PCR. Gene specific probes, with a fluorescent reporter dye and a 
quencher, hybridize with the complementary strand of cDNA. Taq polymerase adds nucleotides 
from each primer so it removes the probe from the template DNA; this separates the quencher 
from the reporter dye resulting in fluorescence. 
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The calculation of the quantification was performed by the Ct method, where Ct is the 
number of cycles before the fluorescence reached the base line. The house keeping and 
the gene of interest were amplified in separate wells; the average Ct value of the gene of 
interested was subtracted from the average value of Ct for the house keeping gene 
generating a Ct value. The Ct value was normalised to the control i.e. creating a 
Ct value and the result was presented as 2-Ct. This equation takes into account the 
exponential nature of PCR reaction. 
 
2.9.3.1 PROTOCOL 
 
The RT-PCR reaction was set up by adding 1.25ul of gene assay, 2.5 ul of cDNA, 8.75 
ul of nuclease-free water and 12.5 ul of TaqMan Universal Master Mix to each well in a 
special designed qPCR 96-well plate. The gene assays were designed and supplied by 
Applied Biosystems (see Table A9.2 for more details). The fluorescence was measured 
after each cycle (Table 2.4) and 40 cycles were performed. GapdH was used as the 
house keeping gene if not otherwise stated. Ct levels ≥ 37 were considered to be 
negative. 
 
Table 2.4. The qPCR machine measured the fluorescence continuously during the PCR. 
Step 1 and 2 are only performed during the first cycle. Total numbers of cycles were 40. 
  
STEP 1 
-only cycle 1 
 
STEP 2 
-only cycle 1 
 
STEP 3 
 
STEP 4 
 
Temperature 
(ºC) 
 
50.0 
 
95.0 
 
95.0 
 
60.0 
 
Time 
(min) 
 
2.00 
 
10.00 
 
0.15 
 
1.00 
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2.10 STATISTICAL ANALYSIS 
 
The following section will go through the statistics and the terminology that have been 
used. The experiments were performed on n number of patients in triplicates, if not 
otherwise were stated. In a few cases the experiment has only been performed on one 
patient (n=1), then the results have been presented as mean  1standard deviation (sd). 
In these cases an up-or-down regulation is defined as an increase/decrease > 1sd. Sd is a 
measurement of the average spread of data around the mean and is defined by following 
equation:  
 
Sd  1
n
(x i  x )
2
i1
n
  
where;  n = number of replicates 
ix data of tested sample 
x mean of all tested samples  
       
  
The majority of experiments were performed on more than 1 patient and then the results 
were presented as meansem. Sem gives a measure of precision of the estimated mean, 
i.e. sem gives an interval within the true mean is expected to lie within. Sem is derived 
from sd accordingly following equation: 
 
Sem  1sd
n  
 
where; n= number of samples 
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Due to lack of consenting volunteers only three samples of MDCs were used in this 
thesis. It was considered not sensible to perform any kind of statistical analysis, such as 
ANOVA or t-test, due to the risk or impact of outliners within the samples. Therefore, 
in cases n>1 the trends of the data are reported and sample size estimation has been 
performed. The trends were reported in following form: 
 
SamplesPositive SamplesTotal   
 
where the number of samples following the trend (samplesPositive) are compared with the 
total number of analysed samples (samplesTotal). 
 
The sample size estimations have calculated the minimum sample size required to 
accept the outcome of a statistical test at a significance level of 0.05 and power of 80%. 
Using a significance level of 0.05 is generally accepted as a cut-off point and a power 
effect of 80% is generally considered to be the lowest power to accept the sample 
number for statistical analysis. In order to perform sample size estimations software 
G*Power version 3.1 has been used and the statistical analysis has been performed 
accordingly a statistician recommendation. Another important parameter, for sample 
size estimations, is variability i.e. sd of the data.  
 
Pearson correlation coefficient, r, is used to measure linear correlation of a set of 
samples; r has a value between -1 and 1. R2 gives the proportion of variation of one 
variable, y, explained by variable, x. 
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3.1 INTRODUCTION SPECIFIC FOR RESULT 
SECTION 1 
 
In this chapter the cell populations, both MSCs and MDCs, were analysed in terms of 
their differentiation potential i.e. their potential to differentiation along the osteogenic, 
adipogenic and myogenic lineage. This was done to verify the cells differentiation 
potential. The importance of CD56 for the myogenic differentiation will also be 
discussed. 
 
The CD56+ fraction of MDCs, i.e. MDCsCD56+, has previously been analysed in the 
laboratories of EDI in terms of their cell surface expression and differentiation potential 
(see Sinanan et al, 2004 for more details). In this thesis the CD56- fraction, i.e. 
MDCsCD56-, was analysed in terms of their differentiation potential along the 
adipogenic, osteogenic and myogenic lineage. This was performed to investigate if the 
MDCsCD56- contained osteogenic cells and also compare this fraction in terms of their 
differentiation potential of the already analysed MDCsCD56+ (Sinanan et al, 2004).  
Throughout this chapter MDCs will refer to the unsorted parental population of MDCs 
and MDCsCD56- to the sorted CD56- fraction of MDCs. 
 
 Osteogenic differentiation protocols with various concentrations of the osteogenic 
components have been reported in the literature; thus, the osteogenic media was titrated 
for both MSCs and MDCs (the unsorted parental population of MDCs) in terms of 
metabolic activity, ALP activity and mineralization. Furthermore, also the two cell types 
maximal PD numbers were determined 
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3.2 METHODS SPECIFIC FOR RESULT  
SECTION 1  
 
3.2.1 MAGNETIC-ACTIVATED CELL SORTING (MACS) 
 
MACS is an isolation method of cells depending on their surface markers. The cells 
were incubated for 30 min at 4 C with magnetic beads that were coated with antibodies 
to CD56.  They were then placed in a column and exposed to a magnetic field. The 
CD56+ cells where the magnetic beads attached were held within the column due to the 
magnetic field; the CD56- cells were washed through by MACS buffer (Figure 3.1). The 
cells of the negative fraction used in this study had been previously isolated by 
colleagues at EDI and had been cryopreserved in liquid nitrogen. This fraction was 
named MDCsCD56- and the parental population i.e. the unsorted population of MDCs 
was named MDCs. 
 
 
 
 
 
 
Figure 3.1. Cell isolation by MACS. The cells were incubated 
with magnetic beads coated with CD56 specific antibodies. The 
mixture was placed in a column and exposed to a magnetic field 
so the CD56+ cells (turquoise) i.e. MDCsCD56+ stayed in the 
column and the CD56- cells (purple) i.e. MDCsCD56- were 
washed through by MACS buffer.   
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3.3 RESULTS FOR RESULT SECTION 1 
 
3.3.1 VERIFICATION OF DIFFERENTIATION 
POTENTIAL 
 
3.3.1.1 MSCs MULTIPOTENCY  
 
It has been known for many years that MSCs have the potential to differentiate along 
the osteogenic, adipogenic and chondrogenic lineages (Pittenger et al, 1999). 
Researchers have tried to explore where the limits of MSCs multipotency lay, for 
example, there have been some reports that MSCs can differentiate along the myogenic 
lineage (Lee et al, 2005). In this section, Chapter 3.3.1.1, MSCs myogenic and 
adipogenic differentiation potential will be studied, the osteogenic will be discussed in 
Chapter 3.3.2.2. 
 
 
3.3.1.1.1 MYOGENIC DIFFERENTIATION 
 
In order to investigate whether the MSCs could differentiate along the myogenic 
lineage, cells were placed in a well-established in vitro myogenic media (Allen & 
Boxhorn, 1989) for six weeks and their gene expression of desmin and myogenin was 
studied. Desmin’s role in vivo is linked to the adjacent myofibrils to maintain sarcomere 
adhesion and structure (Stewart & Rittweger, 2006) and has been used as early marker 
for myogenic commitment (Sinanan et al, 2004). Myogenin is a transcription factor that 
is expressed during the terminal myogenic differentiation (Charge & Rudnicki, 2004; 
Stewart & Rittweger, 2006; Chapter 1.3.1). The cells morphology was also studied by 
PCM to see if the cells formed myotubes. Desmin expression of a low level was found 
in the MSCs, but no upregulation of gene expression, defined as an increase  1sd, 
could be detected by qPCR (Figure 3.2). Myogenin (data not shown) was neither 
expressed nor could any myotubes be detected by PCM (Figure 3.3). These results are 
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consistent, since MPCs start to express myogenin when myoblasts fuse to myotubes 
(Charge & Rudnicki, 2004; Stewart & Rittweger, 2006). These results clearly show that 
human MSCs are not able to differentiate along the myogenic lineage, at least, not by 
using the published protocol. It was concluded that even though researchers have stated 
that MSCs are able to differentiate along the myogenic lineage, this is still very 
uncertain with inconsistent results; for example, Lee et al (2005), managed to fuse 
human MSCs with mouse myoblasts but no group has managed to differentiate a pure 
monoculture of human MSC cultures along the myogenic lineage.  
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Figure 3.2. MSCs did not upregulate desmin in myogenic media.  The MSCs in myogenic 
media did not upregulate, defined as an increase  1sd, their gene expression of desmin during 
six weeks compared to MSCs in culture media. The result (n=1) is presented as mean + 1sd of 
triplicates. 
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(a) 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
Figure 3.3. MSCs did not fuse into myotubes in vitro. No myotubes were detected throughout 
the test period of six weeks in myogenic media. The experiments (n=3) were performed in 
triplicates. Photographs taken through PCM at week 3 have the magnification a) x4 and b) x10.  
b) 
1mm 
500 um 
No myotubes 
No myotubes 
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3.3.1.1.2 ADIPOGENIC DIFFERENTIATION  
 
It is known that MSCs can differentiate along the adipogenic lineage, when placed in 
adipogenic media (Pittenger et al, 1999). In this study, the MSCs upregulated, defined 
as an increase  1sd, the adipogenic transcription factor PPAR-2 after 3 days (Figure 
3.4) and this increased until day 28. The first lipid droplets could be detected by PCM 
after 2 weeks and the amount of lipid droplets continued to increase throughout the test 
period of six weeks (Figure 3.5). These experiments (Figure 3.4-3.5) show that MSCs 
have the potential to differentiate along the adipogenic lineage. 
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Figure 3.4. MSCs upregulated PPAR-2 in adipogenic media. The upregulation, defined as 
an increase  1sd, of the adipogenic transcription factor PPAR-2 was detected after 3 days and 
increased to day 28. This showed that MSCs can differentiate along the adipogenic lineage. The 
experiment was performed in triplicates and the result (n=1) is presented as mean + 1sd of 
triplicates.  
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Figure 3.5. MSCs formed lipid droplets in adipogenic media.  MSCs could form lipid 
droplets. Photograph was taken by PCM after 6 weeks in adipogenic media. The experiments 
were performed on three patients (n=3) in triplicates. Magnification x20. 
 
 
3.3.1.2 MDCs MULTIPOTENCY  
 
3.3.1.2.1 MYOGENIC DIFFERENTIATION 
 
The MDCs placed in myogenic media could easily differentiate along the myogenic 
lineage and some of the desmin-expressing myoblasts had fused and formed 
multinucleated myotubes after 4 days (Figure 3.6). 
Lipid droplets 
100 um 
CHAPTER 3: RESULT SECTION 1 
- CULTURE AND DIFFERENTIATION CONDITIONS 
 92 
 
(a)  
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
Figure 3.6. Myogenicity of MDCs. The cells a) were stained for desmin (green) and α-
sarcomeric actin (red) and nuclei were stained with DAPI (blue) b) in bright field. All 
experiments were performed on three patients (n=3) in triplicates. Photographs taken by an 
inverted fluorescence and bright field microscope. Magnification x40. 
Nuclei 
Desmin 
α-sarcomeric actin 
100 um 
100 um 
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3.3.1.2.2 THE IMPORTANCE OF CD56 FOR MYOGENIC 
DIFFERENTIATION 
 
CD56 has been identified as a satellite cell marker (Mackey et al, 2009; see Chapter 
1.3.1). In order to study its importance for myogenic differentiation, MDCsCD56+ were 
depleted from the population by MACS. When the MDCsCD56- were placed in myogenic 
media they could not form myotubes; instead they formed multinucleated, dysmorphic 
myosacs (Figure 3.7). No myotubes could be detected by PCM in the MDCsCD56- 
population, and after 2 weeks the cells started to become rounded. When the cells were 
stained and analysed by confocal microscopy for desmin and -sarcomeric actin, it 
became clear that the cells had fused to desmin-expressing myosacs. No -sarcomeric 
actin was detected. 
 
 
Figure 3.7. MDCsCD56- formed myosacs in myogenic media. MDCsCD56- formed myosacs after 
2 weeks in myogenic media. The experiments were performed on two patients (n=2) in 
triplicates. Magnification x63. 
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Figure 3.8. MDCsCD56- upregulated desmin in myogenic media. MDCsCD56- upregulated, 
defined as an increase  1sd, desmin during six weeks in myogenic media, but did not express 
myogenin (data not shown). The experiment was performed in triplicates. Results (n=1) 
presented as mean + 1 sd of the triplicates.   
 
 
The cells’ gene expression was analysed by qPCR for desmin and myogenin and the 
MDCsCD56- cells did upregulate, defined as an increase  1sd, desmin expression over 
the test period of six weeks (Figure 3.8) but did not express myogenin (data not shown). 
It is known from previous studies that myosacs express desmin (Hill et al, 1986). 
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3.3.1.2.3 ADIPOGENIC DIFFERENTIATION 
 
In order to test if the MDCsCD56- could differentiate along the adipogenic lineage, they 
were placed in adipogenic media for six weeks. In this study it was clearly shown that 
MDCsCD56- could upregulate, defined as an increase  1sd, PPAR-2 (Figure 3.9) and 
form lipid droplets (Figure 3.10) under adipogenic conditions. They started to form lipid 
droplets after 2.5 weeks and the formation continued during the whole test period 
(Figure 3.10). Previously, it has been demonstrated by Sinanan et al (2004) that the 
MDCsCD56+ could also form lipid droplets. Also Ozeki et al (2006) have previously 
shown that a human derived subpopulation of MDCs, MDCsα7+, could differentiate 
along the adipogenic lineage. 
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Figure 3.9. Expression of PPAR-γ2 in MDCsCD56- in adipogenic media.  The MDCsCD56- 
showed upregulation, defined as an increase  1sd, of PPAR-γ2 at day 28 and 42, which 
demonstrated that they could differentiate along the adipogenic lineage. The experiment was 
performed in triplicates. Results (n=1) presented as mean +1sd of the triplicates.  
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Figure 3.10. MDCsCD56- formed lipid droplets. Picture taken of lipid droplets after six weeks 
in adipogenic media. The experiments were performed on two patients (n=2) in triplicates. 
Magnification x20.  
 
 
3.3.1.2.4 OSTEOGENIC DIFFERENTIATION 
 
In order to analyse if the MDCsCD56- could differentiate along the osteogenic lineage, the 
cells were placed in osteogenic condition and stained for ALP. However, the results 
were inconsistent. One out of two patients expressed ALP (Figure 3.11), but the other 
patient did not (data not shown). The inconsistency in osteogenic response in 
MDCsCD56- led to the need for the development of a reliable isolation method for 
osteogenic MDCs described in Chapter 4, result section 2. 
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Figure 3.11. The ALP expression in MDCsCD56- was inconsistent. MDCsCD56- from one 
patient expressed ALP (see picture), but another sample from a different patient did not. Picture 
taken after two weeks in osteogenic media. Note: In this experiment osteogenic media 
recommended by Tulane Stem Cell Center was used (Table 2.2). 
 
 
3.3.2 CULTURE CONDITIONS AND OSTEOGENIC 
MEDIA TITRATION FOR MSCs 
 
3.3.2.1 OPTIMISING THE CULTURE MEDIA FOR MSCs FOR 
MAXIMAL CELL NUMBER  
 
There is no general consensus about the optimal culture media for MSCs in the 
literature (Simmons et al 1991; Yu et al, 2005; Fox et al, 2007); therefore, various 
culture media with either DMEM or -MEM as basal media and either 10 or 20% FBS 
was tested in terms of cell number over time. In order to do this MTT Assay was used; 
MTT Assay assesses the metabolic activity that correlates with cell number (Figure 2.3). 
In general, the yield of MSCs was higher, defined as an increase>1sd, when they had 
been cultured in 20% FBS at day 5 (Figure 3.12). In terms of basal media, the MSCs 
showed stark differences depending on the patient. Most MSCs had higher metabolic 
ALP 
1 mm 
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activity in -MEM compared to DMEM (Figure 3.12), the metabolic activity of MSCs 
from one tested patient barely increased in DMEM (Figure 3.12b); however, the 
metabolic activity of MSCs from one patient did increase in DMEM, but barely in -
MEM (Figure 3.12a). In summary, four out of five, tested MSC batches derived from 
specific patients had higher MSC number i.e. metabolic activity in -MEM; thus, -
MEM was used in standard culture media for MSCs. Sotiropoulou et al (2005) also 
concluded that -MEM was the best basal media after testing 8 different basal media 
for optimal MSC expansion.  These results may explain why there are various different 
culture protocols for MSCs in the literature; as it has been shown here (Figure 3.12) 
MSCs are very patient dependent in their preferences in culture media. 
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a)      b)  
c) 
 
Figure 3.12. Impact of culture media on 
the metabolic activity of MSCs from 
three example patients. a) The metabolic 
activity of MSCs from patient 2 was clearly 
enhanced by DMEM based culture media. 
b) The metabolic activity of the MSCs from 
patient 3 was clearly enhanced by α-MEM 
based culture media, c) patient 5 appeared 
to prefer α-MEM as basal media but there 
was no distinct differences regarding the 
basal media. All experiments performed in 
triplicates. The results are presented as mean + 1sd of the triplicates. Difference is defined as an 
increase/decrease> 1sd. 
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The patient dependent differences in basal media preferences were consistent over time 
(Figure 3.13). Using the correct basal media could increase the number of PD before 
senescence i.e. maximal growth.   
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Figure 3.13. Number of PD of MSCs, over 15 weeks, in -MEM or DMEM based culture 
media. Using a MSCs-matched basal media could increase the number of PD. All culture media 
were supplemented with 20% FBS and antibiotics.  
 
 
In the literature, there have been reports that MSCs have a PD of approximately 20-40, 
depending on the age of the donor (Pittenger et al, 1999; Stenderup et al, 2003). MSCs 
derived from young donors tend to reach a higher PD before senescence compared with 
older donors (Stenderup et al, 2003). Senescent cells have an enlarged, flattened 
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morphology and an irreversible G1 growth arrest (Sethe et al, 2006). The MSCs 
investigated in this study appear to be able to reach a number of PDs in the same range 
as Pittenger et al (1999); however, all the donors in this study were relative young 
(Chapter 2.1.1) and only MSCs from patient 5 managed to reach a PD close to 40 
(Figure 3.13). This could be explained by natural variations of the MSCs between the 
donors.  
 
Studies have shown that human cells can divide between 500-5000 times during a life 
span in vivo, depending on the cell type. In addition to this stem cells should have the 
ability of self-renewal (Phipps et al, 2007). These numbers differ greatly from what was 
seen in this study (Figure 3.13) and in other in vitro studies where 20-70 PD are 
reported (Phipps et al, 2007). Rubin (1997) proposed that the decrease in the number of 
PD was a result of the inability of cells to adapt to the trauma of explant and in vitro cell 
culture.  
 
 
3.3.2.2 TITRATION OF OSTEOGENIC MEDIA FOR MSCs  
 
The use of varying concentrations of the components of osteogenic media have been 
reported in the literature, especially for dex (Ahdjoudi et al, 2001; van den Dolder & 
Jansen, 2007) and β-GP (Aslan et al, 2006; Ozeki et al, 2006). Therefore, in this study 
we have titrated these components, i.e. dex and β-GP, to find the optimal osteogenic 
differentiation media for MSCs. First, the optimal concentrations of dex and β-GP were 
established by analysing metabolic activity, ALP activity, mineralization and the gene 
expression of Runx2, Col1A1 and OP. The tested concentrations of dex were: 1, 10 or 
100 nM in either 2 or 10 mM β-GP. The osteogenic differentiation pathway is very pH 
sensitive (Brandao-Bunch et al, 2005) and, thus, DMEM was chosen as basal media for 
osteogenic differentiation media since it has slightly higher pH than -MEM. 
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3.3.2.2.1 METABOLIC ACTIVITY 
 
When the metabolic activity of MSCs was measured in either 2 mM or 10 mM β-GP, it 
was clear that osteogenic media with 10mM β-GP, for all tested concentration of dex, 
had a negative impact (trend 2/2) on the metabolic activity of MSCs after 2 weeks 
compared to MSCs in control media (Figure 3.14). No decrease of metabolic activity 
was detected when cells were cultured in 2 mM β-GP, for all tested concentration of 
dex, compared to MSCs in control media. It has earlier been established that 
concentrations higher than 5 mM β-GP can cause apoptosis in osteoblasts (Meleti et al, 
2000). This experiment showed that MSCs also start to show decreased metabolic 
activity, which can indicate cell death, after 2 weeks in osteogenic differentiation media 
with 10 mM β-GP (Figure 3.14b). Hence, only osteogenic media with 2mM β-GP was 
used in the following experiments.  
 
CHAPTER 3: RESULT SECTION 1 
- CULTURE AND DIFFERENTIATION CONDITIONS 
 103 
0
10
20
30
40
50
0 1 2 3 4
Weeks
M
et
ab
ol
ic
 a
ct
iv
ity
(P
er
ce
nt
ag
e 
A
la
m
ar
 B
lu
e 
re
du
ct
io
n 
[%
])
Control (DMEM+20
%FBS)
Osteogenic media with
1nM dex+ 2mM β-GP
Osteogenic media with
10nM dex + 2mM β-GP
Osteogenic media with
100nM dex + 2mM β-GP
 
              (a) 
0
10
20
30
40
50
0 1 2 3 4
Weeks
M
et
ab
ol
ic
 a
ct
iv
ity
 
(P
er
ce
nt
ag
e 
A
la
m
ar
 B
lu
e 
re
du
ct
io
n
 [%
])
Control (DMEM+20
%FBS)
Osteogenic media with
1nM dex + 10mM β-GP
Osteogenic media with
10nM dex + 10mM β-
GP
Osteogenic media with
100nM dex + 10mM β-
GP
 
                (b) 
Figure 3.14. Concentration of β-GP has an impact on metabolic activity. Osteogenic media 
with a) 2 mM β-GP b) 10 mM β-GP. Alamar Blue assay was performed at day 0, 7, 14, 21 and 
28. a) MSCs in osteogenic media with 2 mM β-GP compared with control media, b) MSCs in 
osteogenic media with 10mM β-GP compared with control media. There was no consistent 
decrease in metabolic activity  between MSCs that had been in osteogenic media with 2 mM  β-
GP and control media. MSCs in osteogenic media with 10 mM β-GP had lower metabolic 
activity compared to MSCs in control media at week 2, 3 and 4 (trend 2/2 for all three 
conditions). The dex concentration did not appear to have a consistent impact on the metabolic 
activity of MSCs. All osteogenic media consisted of DMEM (low glucose), 20% FBS, 50ug/ml 
L-ascorbic acid and antibiotics. The experiments were performed on two patients (n= 2) in 
triplicates. Results presented as mean ± sem. Sample size calculation estimated that 4 samples 
were required to accept the outcome of a statistical test to see an effect of 10% lower metabolic 
activity, compared with control, at 2 weeks. 
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3.3.2.2.2 ALP ACTIVITY 
 
ALP is an enzyme that hydrolyses β-GP; ALP exists in the bone marrow in vivo and has 
been used as a marker of early osteogenic activity (Ozeki et al, 2006). To test the impact 
of dex on the ALP activity of MSCs, the cells were placed in osteogenic media with 
varying concentrations of dex and ALP activity was assessed after 1 week (Figure 3.15). 
After 1 week, the highest ALP activity levels were detected in MSCs incubated in 
osteogenic media with 100 nM dex (trend 3/3) compared to MSCs in osteogenic media 
with 10 nM or 1 nM dex or control media. 
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Figure 3.15. Impact of dex on ALP activity of MSCs. Highest levels of ALP activity was 
detected in MSCs that had been incubated with 100 nM dex (trend 3/3) compared to MSCs in 
osteogenic media with 10 nM or 1 nM dex or control media. All osteogenic media consisted of 
DMEM (low glucose), 20% serum, 50ug/ml L-ascorbic acid, 2 mM -GP and antibiotics.  The 
experiments were performed on three patients (n=3) and in triplicates. Results presented as 
mean + sem. Sample size calculation estimated that 10 samples were required to accept the 
outcome of a statistical test to see an effect of 1 unit. 
 
3.3.2.2.3 COLLAGEN  
 
The organic part of the osteogenic ECM consists of collagen, mostly collagen 1 
(Mackie, 2003). In order to test the impact of various osteogenic media with different 
dex concentrations on collagen formation, Sirius Red S quantification was performed 
after 3 weeks. The highest mean collagen levels were detected on MSCs incubated in 
100nM dex (Figure 3.16); however, due to the high variation between replicates it was 
not possible to determine if dex has a positive impact, defined as an increase  1sd, on 
collagen formation on MSCs.  
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Figure 3.16. Dex might have an impact on collagen secretion after 3 weeks. Collagen 
secretion was detected by Sirious Red S quantification. All osteogenic media consisted of 
50ug/ml L-ascorbic acid, 2mM β-GP and antibiotics. Result (n=1) presented as mean + 1sd of 
triplicates.  
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3.3.2.2.4 GENE EXPRESSION OF RUNX2, COL1A1 AND OP 
 
The effect of dex concentrations on osteogenesis was also assessed by their expression 
of three important osteogenic genes compared to the gene expression of MSCs in 
control media. The genes analysed were Runx 2, COL1A1 and OP. Runx2 is an 
osteogenic transcription factor involved in osteogenic differentiation (Jonason et al, 
2009), Col 1A1 codes for the major component of type 1 collagen and OP protein is 
involved in bone remodelling (Kazanecki et al, 2007; Chapter 1.2.2). The gene 
expression by the cells was analysed by qPCR when the cells had been incubated for 4 
weeks in osteogenic media.  
 
After 4 weeks, all tested osteogenic genes were upregulated in the MSCs that had been 
in osteogenic media with 100 nM dex (Figure 3.17). The upregulation of Runx2 was 
higher in MSCs that had been in osteogenic media with 100 nM dex compared to 10 nM 
dex and 1nM dex (trend 2/2). In the case of Col1A1 only MSCs in 100 nM upregulated 
this gene (trend 2/2); however, this trend was not detected for OP.  
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Figure 3.17 Gene expression of Runx2, Col 1A1 and OP in MSCs.  MSCs were placed in 
osteogenic media with 1, 10 or 100 nM dex for 4 weeks. All tested genes were upregulated in 
MSCs that had been in osteogenic media with 100 nM dex (trend 2/2). All experiments were 
performed on two patients (n= 2) in triplicates. Results presented as mean+sem. Sample size 
calculation estimated that 5 samples were required to accept the outcome of a statistical test to 
see an effect of 2-fold regulation. 
 
 
3.3.2.2.5 MINERALIZATION 
 
Mineralization was assessed on MSCs by Alizarin Red S quantification after 4 weeks. 
There was no detected difference, defined as an increase/decrease  1sd, in 
mineralization between MSCs in osteogenic media with 10 nM or 100 nM dex after 4 
weeks; however, the mean level of mineralization on both MSCs in 10nM and 100 nM 
was higher than on MSCs in control media or osteogenic media with 1 nM dex, defined 
as an increase/decrease  1sd (Figure 3.18).   
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Figure 3.18. Impact of dex on mineralization by MSCs. There was no difference, defined as 
an increase/decrease  1sd, between the quantity of mineralization on MSCs in 10nM dex and 
100nM dex. All osteogenic media consisted of DMEM (low glucose), 20% serum, 50ug/ml L-
ascorbic acid 2 mM -GP and antibiotics. Results (n=1) presented as mean + 1sd of triplicates. 
 
 
Taking the results as a whole, it appeared, as the optimal osteogenic media for in vitro 
experiments should be supplemented with 100nM dex, 50ug/ml L-ascorbic acid and 2 
mM β-GP.  
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3.3.3 CULTURE CONDITIONS AND OSTEOGENIC 
MEDIA TITRATION FOR MDCs 
 
3.3.3.1 PDs OF MDCs 
 
The population doubling of the MDCs was studied by measuring cell number once a 
week by MTT. The MDCs initial numbers of PD appeared to be relatively consistent 
between the patients; however, there was a difference in the number of population 
doublings before senescence i.e. maximal growth between the patients (Figure 3.19).  
This final number of PD of MDCs ranged from ca 20-30. According to literature MDCs 
from mice can divide more than 30 times (Qu-Petersen et al, 2002), which appears to be 
the in same range as human MDCs (Figure 3.19). 
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Figure 3.19. Growth curves of MDCs over 15 weeks in culture media. The MDCs appear to 
initially have same PD rate, but reach senescence i.e. maximal growth at different PDs.  
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3.3.3.2 TITRATION OF OSTEOGENIC MEDIA FOR MDCs  
 
Optimal concentrations of dex and β-GP were established by analysing metabolic 
activity, ALP activity and mineralization of the MDCs. Dex was tested in 
concentrations of 1, 10 or 100 nM in either 2 or 10 mM β-GP.  It was considered 
important to investigate if the MDCs behaved similar to MSCs in the various osteogenic 
media in terms of metabolic activity, ALP activity and mineralization. 
 
 
3.3.3.2.1 METABOLIC ACTIVITY 
 
The metabolic activity of MDCs was measured in either 2 mM or 10 mM β-GP. It was 
shown that osteogenic media with 10mM β-GP had a negative impact on the metabolic 
activity of MDCs after 3 weeks (trend 3/3 for all conditions) compared to MDCs in 
control media; however, there was no negative impact on MDCs in osteogenic media 
with 2 mM β-GP compared to cells in control media (Figure 3.20 a). For cells in 
osteogenic media with 10 mM β-GP there was a negative trend at week 3 and 4 (Figure 
3.20 b; trend 3/3 for all conditions at both time points).  As previously mentioned, no 
decrease of metabolic activity was seen when the cells were in 2 mM β-GP compared to 
MDCs in control media. Hence, only osteogenic media with varying dex concentrations 
in 2mM β-GP was tested for ALP activity and mineralization.  
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                   (b) 
Figure 3.20. Concentration of β-GP has an impact on metabolic activity of MDCs. a) 
MDCs in osteogenic media with 2 mM β-GP or control media, b) MDCs in osteogenic media 
with 10mM β-GP or control media. MDCs cultured in osteogenic media with 10nM β-GP had 
lower metabolic activity compared to MDCs in control media at week 3 and 4 (trend 3/3 for all 
conditions). All osteogenic media consisted of DMEM (low glucose), 20% FBS, 50ug/ml L-
ascorbic acid, and antibiotics. The experiments were performed on three patients (n=3) in 
triplicates. Results presented as mean  sem. Sample size calculation estimated that 4 samples 
were required to accept the outcome of a statistical test to see an effect of 10% lower metabolic 
activity, compared with control, at 2 weeks. 
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3.3.3.2.2 ALP ACTIVITY 
  
ALP activity has previously been used an early marker for osteogenic differentiation 
(Ozeki et al, 2006) and it has been reported that MDCs start to express ALP when they 
are placed in osteogenic media (Ozeki et al, 2006).  To decide the more potent 
osteogenic media, cells were placed in either control media or osteogenic media with 1, 
10 or 100nM dex and the ALP activity was assessed after 1 week. The highest mean 
ALP activity levels were detected in MDCs in osteogenic media with 100nM dex 
(Figure 3.21): however, the ALP activity differences due to dex concentration were not 
consistent (trend 2/3).  
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Figure 3.21. Impact of dex concentration on ALP activity in MDCs. There was an increase, 
in terms of highest mean, of ALP activity in MDCs that had been in osteogenic media with 100 
nM dex; however, the ALP activity differences due to dex concentration was not consistent 
(trend 2/3) since one sample showed highest ALP activity in osteogenic media with 10 nM dex.  
All osteogenic media consisted of DMEM (low glucose), 20% serum, 50ug/ml L-ascorbic acid, 
2 mM -GP and antibiotics. The experiments were performed on three patients (n=3) in 
triplicates. Results presented as mean + sem. Sample size calculation estimated that 199 samples 
were required to accept the outcome of a statistical test to see an effect of 0.2 units. 
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3.3.3.2.3 MINERALIZATION 
 
The mineralization of MDCs was assessed by Alizarin Red S quantification after 4 
weeks. There was no trend in mineralization between cells in osteogenic media with 10 
nM or 100 nM dex after 4 weeks; however, the mineralization level on both MDCs in 
10nM (trend 3/3) and 100 nM (trend 3/3) were higher than on MDCs in 1nM dex or 
control media (Figure 3.22).  
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Figure 3.22. Impact of dex concentration on mineralization by MDCs. There was no 
difference between mineralization by MDCs in osteogenic media with 10 or 100nM dex. 
However, there was an increase in mineralization between MDCs that had been in osteogenic 
media supplemented with 1 nM and 10 (trend 3/3) or 100 nM dex (trend 3/3). All osteogenic 
media consisted of DMEM (low glucose), 20 % serum, 50ug/ml L-ascorbic acid, 2mM -GP 
and antibiotics. The experiments were performed on three patients (n=3) in triplicates. Results 
presented as mean + sem. Sample size calculation estimated that 10 samples were required to 
accept the outcome of a statistical test to see an effect of 1 unit. 
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Figure 3.23. Staining of MDCs in various osteogenic media by Alizarin Red S. MDCs in a) 
control media (DMEM +20% FBS) or osteogenic media supplemented with b) 1 nM dex, c) 10 
nM dex and d)100 nM dex after 4 weeks. There is clearly more mineralization on MDCs that 
have been in osteogenic media complemented with either 10 or 100 nM dex. The experiments 
were performed on three patients (n=3) in triplicates. Magnification x4. 
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3.4 SUMMARY 
 
There is a general consensus that MSCs are able to differentiate along the osteogenic 
and the adipogenic lineage, which also have been verified in Chapter 3.3.1. In this 
chapter it was also shown that MDCs could differentiate along the myogenic, 
osteogenic and adipogenic lineage. MDCs that had been depleted of CD56 positive cells 
i.e. MDCsCD56- could not form myotubes. However, it was shown that MSCs do not 
differentiate along the myogenic lineage in vitro, at least not with the myogenic media 
used in this study.  
 
The MSCs and the MDCs showed similar range of number of PDs; number of PD were 
for MSCs 33  6 and for MDCs 26  3 (meansem). Furthermore, both cell types 
showed optimal osteogenic response in osteogenic media supplemented with 100 nM 
dex, 50ug/ml L-ascorbic acid and 2mM -GP.   
 
 It has been suggested that concentrations of 10 mM -GP could induce apoptosis in 
osteoblasts (Khouja et al, 1990) and in this study it was shown that both MSCs (Figure 
3.14b) and MDCs (Figure 3.20b) showed decreased metabolic activity in osteogenic 
media supplemented with 10 mM -GP after 2 to 3 weeks. This can be compared with 
MSCs (Figure 314a) and MDCs (Figure 3.20a) in osteogenic media supplemented with 
2 mM -GP that showed comparable metabolic activity as cells in control media. These 
results are consistent since reduced metabolic activity can indicate apoptosis. The 
conclusion was that osteogenic media with 2 mM -GP was optimal in terms of 
metabolic activity and would be used in all following experiments. 
 
Both MSCs and MDCs expressed higher levels of ALP in osteogenic media 
supplemented with 100 nM dex compared to the other media. For both MSCs and 
MDCs there was no difference between the mineralization in osteogenic media 
supplemented with 10 or 100 nM dex.  
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Most importantly, in this chapter it was shown that MDCs and MSCs are able to 
differentiate along the osteogenic lineage and mineralize. Furthermore, an optimised 
protocol for the osteogenic media was developed to be used in this study.  
 
Table 3.1. Summary of results from Chapter 3. MDCs are compared with MSCs. *MDCCD56- 
  
MDCs 
 
MSCs 
 
 
Detected potential to express ALP 
 
 
Yes 
 
Yes 
 
Detected potential to mineralize 
 
 
Yes 
 
Yes 
 
Detected potential to form myotubes 
 
 
Yes 
 
No 
 
Detected potential to form lipid droplets 
 
 
Yes* 
 
Yes 
Metabolic activity response in 
osteogenic media with 10 mM -GP 
compared to control media 
 
Lower 
 
Lower 
Metabolic activity response in 
osteogenic media with 2 mM -GP 
compared to control media 
 
Unaffected 
 
Unaffected 
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4.1 INTRODUCTION SPECIFIC FOR RESULT 
SECTION 2 
 
In Chapter 3, Result section 1, it was shown that the MDCs were able to express ALP 
activity and mineralize i.e. MDCs showed osteogenic potential. It has previously been 
shown by several research groups that there is a subpopulation within the skeletal 
muscles both in humans (Sinanan et al, 2004; Jackson et al, 2009) and in mice (Lee et 
al, 2000) that have the potential to differentiate along the osteogenic lineage. Even 
though the researchers have recognised the possibilities of using these cells for bone 
regenerative applications (Usas & Huard, 2007), no technique has specifically been 
developed to isolate the subpopulations with the highest osteogenic potential. The 
majority of the isolation techniques have been developed to isolate myogenic 
subpopulations of MDCs (Chapter 1.3.1; Sinanan et al, 2004) or the isolation of the 
more stem cell like population in adult tissue (Jones & Watt 1993; Qu-Petersen et al, 
2002). Hence, there is a gap to fill. In this chapter various subpopulations were isolated 
by differential adhesion to three different surfaces and their osteogenic potential were 
tested. 
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4.2 METHODS SPECIFIC FOR RESULT  
SECTION 2 
 
4.2.1 DIFFERENTIAL ADHESION TO FN, GEL OR TCP 
 
In order to isolate the subpopulations, the cells adhesion properties, to three different 
surfaces the plates were coated with Fn, Gel or left uncoated i.e. on TCP. Flasks or 
plates were coated by 1.5ug Fn/cm2 (see Chapter A9.1.3) and stored in 4C over night. 
Gel (see Chapter A9.1.4) was added to flasks/plates, 0.250ul/cm2, and left at room 
temperature for 30 minutes. Before the separation the coating excess was removed by 
pipetting.   
 
 
Figure 4.1. Isolation of MDCs subpopulations by differential adhesion. The plates were 
coated by Fn or Gel, or left uncoated (i.e. TCP). The cells were seeded on plate/flask 1(1) at 
time point 0 (t0) and left for 20 min. After 20 min the supernatant with unattached cells was 
removed and plated on  (2) and left for 40 min i.e. 1h from t0 then the cells were plated on (3) 
for 2 h, i.e. 3 h from t0. For the final plate/flask (4) the cells were left over night (15h) i.e. 18h 
from t0. The differential adhesion was performed under serum-free conditions. Method adapted 
from Davies et al, 2010. 
 
 
The starting density of the MDCs was 2000 cells/cm2 and isolation was performed 
according to Figure 4.1. If the cells did not reach confluency within two weeks, the plate 
with this isolated population was discarded. After isolation the cells were cultured in 
standard serum-based culture media. 
  
 
      
t0 20min 1h 3h 18h 
(1) (2) (3) (4) 
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4.3 RESULTS FOR RESULT SECTION 2 
 
4.3.1 IDENTIFYING THE MORE OSTEOGENIC 
SUBPOPULATION BY DIFFERENTIAL ADHESION 
 
In order to identify the more osteogenic population, ALP activity of the various 
subpopulations was measured after 1 week in osteogenic media. The time points, 
measured from t0, for the differential adhesion were 20 (plate 1), 60 (plate 2), 180 (plate 
3) and 1080 min (plate 4) as previously described (Chapter 4.2.1; Figure 4.1). No 
subpopulations on plate 4 reached confluency within two weeks in culture and were 
therefore discarded. The unsorted parental population of MDCs will be called MDCsPP 
from now on when used in comparison experiments with isolated subpopulations of 
MDCs. 
 
After the isolated subpopulations reached confluency, the cells were incubated in 
osteogenic media for 1 week.  The subpopulation that was early adherent, within 20 
min, to Fn (MDCsFn20) showed higher ALP activity compared to the other isolated 
populations (trend 3/3). Hence, MDCsFn20 was believed to be the more osteogenic 
subpopulation (Figure 4.2). Jones &Watt (1993) and Dowthwaite et al (2004) had found 
that the more stem-cell like population from keratinocytes and cartilage belonged to the 
subpopulation that was early adherent to Fn. 
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Figure 4.2. ALP activity of the isolated subpopulations. The MDCsFn20 showed the highest 
level of ALP expression The ALP activity of MDCsFn20 was consistent higher than the other 
subpopulations (trend 3/3). The experiments were performed on three patients (n=3) in 
triplicates. The unsorted parental population of MDCs was named MDCsPP. Results presented 
as mean+sem. Sample size calculation estimated that 34 samples were required to accept the 
outcome of a statistical test to see an effect of 0.5 units. 
 
 
In order to check that the ALP activity of the different subpopulations was not caused 
by the substrate, the cells that were early adherent to the surfaces were harvested and 
reseeded onto TCP or the same substrate (for experimental details, see Chapter 
2.4.2.1.2) and their ALP activity was assessed (Figure 4.3). Since the highest ALP 
activity was detected on the early adherent MDCs to Fn i.e. within 20 min, only the 
early adherent groups were analysed in this control experiment. 
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MDCsTCP on TCP
 
Figure 4.3. The substrates did not alter the ALP activity in MDCsFn.  The groups were 
compared separately. MDCsFn20 on Fn was compared with MDCsFn20 on TCP, and 
MDCsGel20 on Gel was compared with MDCsGel20 on TCP. All experiments were performed 
on three patients (n=3) in triplicate. Results presented as mean+sem. 
 
 
The Fn substrate did not appear to have an impact on the ALP activity, but in order to 
avoid affecting the results the isolation was performed in coated flasks and thereafter 
seeded onto TCP for the differentiation experiments.  
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4.3.2 COMPARISON OF MDCsFN AND MDCsPP 
 
4.3.2.1 MEASUREMENT OF THE SIZE 
 
The average sizes of the cells in the two populations, MDCsFn and MDCsPP, were 
compared since cell size can be used as an indicator of a cell’s maturity and has been 
used in adult-stem cells isolations (Zuba-Surma et al, 2009). Smaller cells tend to 
indicate that the cells are less differentiated.  The MDCsFn were freshly isolated, by 
early adherence to Fn, and compared with MDCsPP; the sizes of the cells were assessed 
by photograph image analysis by Image-pro. The isolated MDCsFn population appeared 
to contain the smaller and more rounded cell population of MDCsPP (Figure 4.4 – 4.6) 
i.e. more homogeneous in terms of size and less mature population.  
 
The average sizes of the cell populations were quantified (Figure 4.4-4.5). The average 
size of MDCsFn was 4.4x10-3mm2 (95% CI: 4.0-4.8x10-3 mm2) and the average size of 
MDCsPP was 5.7 x10-3mm2 (95% CI: 4.9-6.4 x10-3 mm2).  
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Figure 4.4. Size quantification of MDCsFn and MDCsPP. The different subpopulations of 
MDCs showed differences in size. The mean size of MDCsFn was consistently smaller than 
MDCsPP (trend 3/3). The MDCsFn consist of smaller cells compared to the other isolated 
groups and MDCsPP. The mean cell size of MDCsFn was assessed to be 4.4x10-3mm2 (95% CI: 
4.0-4.8x10-3 mm2) and the mean for MDCsPP was 5.7x10-3mm2. (95% CI: 4.9-6.4x10-3 mm2). 
Thirty cells per well and three wells per population were photographed and measured. The 
experiments were performed on three patients (n=3) in triplicate. The confidence interval is of 
all cells. The results in the graph are presented as the mean + sem. Sample size calculation 
estimated that 5 samples were required to accept the outcome of a statistical test to see an effect 
of 2x10-3 mm2. 
 
 
The percentage of MDCs that attached to Fn was also calculated to be 42 %  4.2 % of 
the unsorted parental population. The attachment experiment was performed according 
to Chapter 2.4.2.1.2. The attachment experiments were performed on three patients 
(n=3) in triplicate and presented as mean± sem. 
e) 
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Figure 4.5. MDCsFn contained the smaller 
cells of MDCsPP. a) MDCsFn, b)+c) 
MDCsPP. MDCsPP consisted of cells of 
various sizes. MDCsFn appeared to contain a 
relative homogeneous population of smaller, 
rounded cells. Thirty cells were measured per 
well. All experiments (n=3) were performed in 
triplicates of wells. Magnification x40. 
 
 
 
 
 
 
 
 
100um 
a) 
b) 
c) 
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MDCsPP 
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  (a) 
Figure 4.6. Density plots of a) 
MDCsFn and b) MDCsPP. MDCsFn 
are smaller in size compared to 
MDCsPP assessed by Forward 
Scattering. All experiments were 
performed on three patients (n=3) in 
triplicate. MDCsPP contained 16.6 ± 8 
% cells that were larger than MDCsFn. 
Result presented as mean±sem. 
  
 
 
 
 
(b) 
 
Both the differences in cell size and range of cell size could be shown by flow 
cytometry (Figure 4.6). The size was measured by Forward Scattering and granularity 
was measured by Side Scattering of the two populations. This result confirmed the 
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previous findings that MDCsFn consisted of a smaller cell population than MDCsPP 
(Figure 4.4 - 4.5). MDCsPP contained 16.6 ± 8 % cells that were larger than MDCsFn. 
 
 
4.3.2.2 MYOGENICITY 
 
Muscle tissue contains a variety of cells (see Chapter 1.3.1), including satellite cells and 
MPCs that can fuse and form myotubes in vitro. As muscle tissue MDCsPP consist of a 
variety of cells and the percentage of myogenic cells to human MDCsPP have 
previously been determined to be between 5-45 % (Lewis et al, 2000), the potential of 
the two subpopulations, MDCsFn and MDCsPP, to form myotubes after 4 days in 
myogenic media was investigated in this section. After 4 days, the MDCsFn clearly 
expressed fewer desmin expressing cells i.e. MPCs (Figure 4.7a), compared to MDCsPP 
cultures (Figure 4.7b). The MDCsPP could easily fuse to multi-nuclei, desmin and -
sarcomeric actin myotubes (Figure 4.7 b). This can have several explanations, either the 
MDCsFn consist of a less myogenic cell population or they consist of a more immature 
cell population, as indicated by previous results (Chapter 4.3.2.1), which need more 
time to differentiate into MPCs and myotubes. Deasy et al (2001) have suggested that 
pluripotent cells derived from mice muscle tissue are in fact precursors to satellite cells.  
It is hard to perform a robust experiment to investigate if either of these hypotheses is 
correct. Myogenic MDCs cultures are known to be very hard to keep in monolayer 
culture for more than 6 days (experience from EDI), so it is impossible to quantify the 
myotube formation over a longer period of time. 
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      (a) 
 
      (b) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 a) MDCsFn and b) MDCsPP after 4 days in myogenic media. The cells in the 
MDCsFn cultures appeared to not be able to form myotubes after 4 days in myogenic media. In 
the MDCsPP cultures there were desmin (green), and -sarcomeric actin (red) expressing 
multinuclei (blue) myotubes. Figure shows a typical image of stained MDCsFn and 
MDCsPP. The experiments were performed on three patients (n=3) in triplicates. 
Magnification x60.  
 
Nuclei  
MDCsFn 
MDCsPP 
Nuclei 
Desmin 
α-sarcomeric actin 
100 um 
100um 
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4.3.2.3 CD56 AND STRO-1 EXPRESSION  
 
The importance of CD56 in myogenesis has previously been studied and it has been 
identified as a satellite stem cell marker (Mackey et al, 2009). As shown in chapter 1, 
pure MDCsCD56- cultures are not able to express myogenin or -sarcomeric actin and 
can therefore not undergo terminal myogenic differentiation. On the other hand it was 
shown that when pure MDCsCD56+ cultures were placed in myogenic media the 
incorporation of nuclei in the myotubes was higher than compared to MDCsPP 
(Sinanan et al, 2004). Sinanan et al (2004) also suggested that MDCs with low 
expression of CD56 could be cells that are not restricted to the myogenic lineage. In this 
part the CD56 expression of MDCsFn and MDCsPP was studied. It was found for all 
tested patients that MDCsFn expressed less CD56 than MDCsPP (trend 3/3). However, 
both the CD56 expression and the magnitude of reduction varied between the 
investigated patients (Figure 4.8).   
 
Stro-1 antibody identifies bone marrow stromal cell population in adult bone marrow 
(Simmons & Torok-Storb, 1991). It has been shown that bone marrow derived Stro-1+ 
cells are able to differentiate into cell types with phenotypic characteristics of 
osteoblast, adipocytes and smooth muscle (Gronthos et al, 1994).  Stro-1+ has also been 
used as an isolation marker, alone (Gronthos et al, 1994) or together with ALP for 
osteogenic precursor cells (van den Dolder & Jansen, 2007). Hence, the expression of 
Stro-1 on MDCsFn and the MDCsPP was analysed by flow cytometry. The results 
between the patients were not consistent; only one tested patient out of three expressed 
Stro-1. For this patient, the MDCsFn expressed higher levels, 10.0  4.7 %, of Stro-1 
than MDCsPP, 4.6 0.8. The result was presented as mean of triplicates  1sd. 
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Figure 4.8. CD56 expression of 
MDCsFn and MDCsPP. Dotplot over 
the expression of CD56 in a) MDCsFn 
and b) MDCsPP.  
c) The difference between the two 
populations was consistent (trend 3/3). 
The experiments were performed on 
three patients (n=3) in triplicates. The 
results are presented as mean + sem. 
Sample size calculation estimated that 3 
samples were required to accept the 
outcome of a statistical test to see an 
effect of 10 %. 
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4.3.2.4 OSTEOGENIC GENE EXPRESSION OF MDCsFN AND 
MDCsPP 
 
To further compare the osteogenic potential of the two populations their gene 
expression was compared by qPCR (Table 4.1). The expression of Runx2, Col1A1 and 
OP was assessed after 2 weeks in culture media i.e. DMEM with 20% FBS and 
antibiotics (Table 2.2). Runx2 is an essential transcription factor for osteogenic 
differentiation (Jonason et al, 2009) and Col1A1 is the major component in the organic 
part of the osteogenic ECM (Pace et al, 2001). OP has a function as an attachment 
protein linking cells to the bone mineral and is also considered to be late osteogenic 
marker (Kazanecki et al, 2007). The MDCsFn expressed higher mean levels of Runx2 
and Col1A1 compared to MDCsPP. However, the upreglation was only consistent for 
Col1A1 (trend 3/3).   
 
 
Table 4.1. The gene expression of Runx2, Col1A1 and OP in MDCsFn compared to 
MDCsPP. Experiments performed in culture media i.e. DMEM with 20% FBS and antibiotics 
(see Table 2.2 for media definition) and measured by qPCR. The experiments were performed 
on three patients (n=3) in triplicates. The samples were normalized to MDCsPP and experiment 
was performed accordingly Chapter 2.9. Results presented as mean  sem. Sample size 
calculation estimated that 4 samples were required to accept the outcome of a statistical test to 
see an effect of a 3-fold regulation. 
 
GENE 
ASSAY 
 
FOLD CHANGE IN GENE EXPRESSION 
(MDCsFN / MDCsPP) 
 
 
TREND 
(UPREGULATION) 
 
Runx2 
 
 
3.1 1.0 
 
2/3 
 
Col1A1 
 
 
3.6 2.0 
 
3/3 
 
OP 
 
 
0.73 0.08 
 
1/3 
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It should be noted that OP was not upregulated when MDCsFn was compared to 
MDCsPP. This might be due to the versatile function of OP. It is known that OP has a 
functional role in the osteogenic ECM (Kazanecki et al, 2007), but it also has a function 
in myogenic and inflammatory processes in the early stages of muscle regeneration 
(Uaesoontrachoon et al, 2008). Hence, is it difficult to draw any conclusion from the 
gene expression of OP. 
4.3.2.5 MINERALIZATION  
 
Mineralization of the cells ECM has been of a measure for terminal differentiation of 
osteogenic cultures and it is, in general, measured by Alizarin Red S (De Oliva et al, 
2009). In this study the mineralization process of the two populations have been 
investigated. Both MDCsFn and MDCsPP in osteogenic media started to express 
consistent higher mineral levels, measured by Alizarin Red S, compared to MDCsFn 
and MDCsPP in control media after 3 week (trend 3/3 for both comparisons). At week 
3, there was no difference between the mineralization of MDCsFn and MDCsPP in 
osteogenic media. MDCsFn in osteogenic media started to have consistent higher levels 
of mineralization, compared with MDCsPP, after 4 weeks (trend 3/3). The MDCsFn and 
MDCsPP in control media did not show any consistent mineralization differences. The 
trend with more mineralization with time and that MDCsFn expressing higher levels 
than MDCsPP was consistent for all mineralization experiments; however, the exact 
amount of mineralization was experiment dependent. Experiments of MDCsFn and 
MDCsPP were performed in parallel. 
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Figure 4.9. Comparison of the mineralisation process by MDCsFn and MDCsPP over 4 
weeks. Mineralisation detected by Alizarin Red S increased with time for both MDCsFn and 
MDCsPP in osteogenic media. At week 4, mineralisation by MDCsFn was consistently (trend 
3/3) higher than MDCsPP in osteogenic media. The experiments were performed on three 
patients (n=3) in triplicate and results presented as mean + sem. Sample size calculation 
estimated that 4 samples were required to accept the outcome of a statistical test to see an effect 
of 3 units at week 4. 
 
 
 
 
CHAPTER 4: RESULT SECTION 2  
- ISOLATION OF OSTEOGENIC SUBPOPULATION OF MDCs 
 135 
  
  
  
  
 
Figure 4.10. Alizarin Red S staining of MDCsFn and MDCsPP in osteogenic media over 4 
weeks. a)-d) MDCsFn and e)-h) MDCsPP after a) + e) 1 week, b)+ f) 2 weeks, c)+g) 3 weeks, 
d) + h) 4 weeks. For both MDCsFn and MDCsPP, there is an accumulation of mineral over 
time. MDCsFn expressed higher levels of mineralization compared to MDCsPP after 4 weeks. 
The experiments were performed on three patients (n=3) in triplicates. Magnification x4.  
a) e) 
g) 
d) h) 
c) 
f) b) 
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4.4 SUMMARY 
 
In this chapter, various subpopulations of MDCs were isolated in order to identify the 
subpopulation with the highest osteogenic potential. The method used for this isolation 
relied on the differential adhesion of the subpopulations to adhere to different substrates 
(Fn, Gel, TCP). It was found that the cells that adhered to Fn within 20 min expressed 
highest levels of ALP activity, compared to the other subpopulations, after the cells had 
been in osteogenic media for 1 week (Figure 4.2). Since ALP activity has been 
described as an early osteogenic marker (Weiss et al, 1986), this subpopulation, 
MDCsFn, was selected for further analyses and comparisons with the unsorted parental 
population, MDCsPP. The MDCsFn population appeared to have a more homogeneous 
size distribution than MDCsPP and consisted of approximately 42% of the original 
MDCs (Chapter 4.3.2.1; Table 4.2). The cells in the MDCsFn population were smaller 
and more rounded cells compared to MDCsPP (Figure 4.4-4.6), this population also 
expressed higher levels Col1A1, measured by qPCR, compared to MDCsPP in control 
media (Table 4.1).  
 
Not surprisingly, the MDCsFn showed higher levels of mineralization compared to 
MDCsPP after the cells had been in osteogenic media for 4 weeks (4.9-4.10). This data 
together suggests that the MDCsFn represent the more osteogenic population of 
MDCsPP.  
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Table 4.2 Summary of results from Chapter 4. Comparison of MDCsFn and MDCsPP. All 
results presented as mean ±sem apart  from Stro-1 result, which is from the only patient that 
expressed Stro-1 and is presented as mean ± 1 std. 
CHARACTERISTICS MDCsFN MDCsPP 
Size (mm2) 4.4x10-3 5.7 x10-3 
Attachment (%) 42 ± 4.2 100 
CD56 expression (%) 18.2 ±9.8 33.9± 21.8 
Stro-1 expression (%) 10.0  4.7 4.6 0.8 
Runx2 gene expression 3.1 1.0 1 
Col1A1 gene expression 3.6 2.0 1 
OP gene expression 0.73 0.08 1 
Mineralization 
- after 4 weeks in osteogenic media 7.21.4 3.6 0.8 
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5.1 INTRODUCTION SPECIFIC FOR RESULT 
SECTION 3 
 
In the previous chapter, Result section 2, the MDCsFn were identified as the more 
osteogenic fraction of the parental population, MDCsPP. In this chapter, the osteogenic 
differentiation of MDCsFn was compared with bone marrow-derived MSCs. The ALP 
activity, ALP expression and mineralization were studied over a time period of 4 weeks. 
Furthermore, at week 2, samples of MDCsFn and MSCs in osteogenic and control 
media were collected and analysed by qPCR Array for 46 osteogenic genes (Table 5.1; 
Table A9.2-A9.3). 
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5.2 METHODS SPECIFIC FOR RESULT  
SECTION 3 
 
5.2.1 Q-PCR ARRAY 
 
A qPCR array was designed in the format of 2x48 genes in a 96-well plate (Figure 5.1; 
Table 5.1), where two genes were used as housekeeping genes: GapdH and 18S, 
ribosomal RNA. The gene assays were designed and supplied by Applied Biosystems 
(Table A9.2). To increase the accuracy both GapdH and S18 were used as control genes 
in the analyses. The gene expression levels were analysed for MDCsFn from 3 patients 
and MSCs from 3 patients; however, the samples were not patient matched and only one 
sample and replicate per patient was performed. 
 
 
 
Figure 5.1. Layout of the qPCR Array with 2x48 gene assays. 
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Table 5.1. Location for gene assays in the 2x48 qPCR array.  
Well 
location 
 Gene 
assay 
Well 
location 
 Gene 
assay 
Well 
location 
Gene 
assay 
Well 
location 
 Gene 
assay 
  
A01/A07 18S  C01/C07 COL1A1  E01/E07 DSPP  G01/G07 TGF-3 
 
A02/A08 GAPDH C02/C08 COMP E02/E08 RUNX2 G02/G08 TGFBR1 
 
A03/A09 ALP C03/C09 DMP1 E03/E09 SMAD1 G03/G09 TGFBR2 
 
A04/A10 AMBN C04/C10 FGFR1 E04/E10 SMAD2 G04/G10 TUFT1 
 
A05/A11 AMELY C05/C11 FGFR2 E05/E11 SMAD3 G05/G11 TWIST1 
 
A06/A12 ARSE C06/C12 FGFR3 E06/E12 SMAD4 G06/G12 TWIST2 
  
B01/B07 BMP2  D01/D07 FLT1  F01/F07 SMAD7  H01/H07 VDR 
 
B02/B08 BMP4 D02/D08 GDF10 F02/F08 SMAD9 H02/H08 VEGFA 
 
B03/B09 BMP7 D03/D09 BSP F03/F09 SOX9 H03/H09 VEGFB 
 
B04/B10 CALCR D04/D10 MMP13 F04/F10 SPARC H04/H10 OSTERIX 
 
B05/B11 CASR D05/D11 MMP2 F05/F11 OP H05/H11 WNT5A 
 
B06/B12 CDH11 D06/D12 MSX1 F06/F12 TGF-1 H06/H12 PTHR1 
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5.3 RESULTS FOR RESULTS SECTION 3 
 
 
In this section, MDCsFn and MSCs were seeded at a density of 5000 cells/cm2 and 
cultured until confluency i.e. 10000 cells/cm2 (as described in Chapter 2.3) before 
osteogenic differentiation medium was added to the cells. 
 
5.3.1 ALP ACTIVITY AND EXPRESSION 
 
The ALP activities of the two cell types i.e. MDCsFn (Figure 5.2) and MSCs  (Figure 
5.3) were compared over a period of 4 weeks in osteogenic media where culture media 
was used as control. 
 
The highest mean level of ALP activity of MDCsFn was found after 2 weeks; thereafter, 
it decreased (Figure 5.2). However, the peak of ALP activity appeared to be patient 
dependent for one patient it occurred at week 2 and for two patients at week 3. MDCsFn 
in osteogenic media showed a trend of higher levels of ALP activity, in all tested 
patients, throughout the tested time period than in control media apart from week 4 
(trend 3/3 for time points 1, 2 and 3). At week 4 the ALP activity of MDCsFn in 
osteogenic media was higher in two patients and lower in one patient compared to 
control media. The ALP activity of MDCsFn in control media also varied between time 
points; the ALP activity was lower for the later time points i.e. week 4 than the earlier 
i.e. week 1 (Figure 5.2; trend 3/3). The patient variations in ALP activity were very 
large for MDCsFn; at week 2, when the ALP activity had its peak, the patient that 
showed the highest ALP activity had 150 times higher ALP activity than the patient 
with the lowest.  
 
In MSCs the ALP activity appeared to also have reached its peak at week 2 and 
decreased rapidly thereafter (Figure 5.3). However, the peak of ALP activity appeared 
to be patient dependent for one patient it occurred at week 1 and for two patients at 
week 2.  MSCs in osteogenic media showed throughout the tested time period higher 
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ALP activity than in control media at each time point tested apart from week 2 (trend 
3/3 for time points 1, 3 and 4). At week 2 the ALP activity of MSCs in osteogenic 
media was higher in two patients and lower than control in one patient.  There was a 
difference in ALP activity for MSCs over time for both MSCs in osteogenic as well as 
control media; the ALP activity was lower at later time points i.e. week 3 and 4 than the 
earlier i.e. week 1 and 2 (Figure 5.3; trend 3/3 for all comparisons). The pattern of ALP 
activity in MSCs in control media was the same as for cells in osteogenic media i.e. the 
highest mean ALP activity was measured at 2 weeks (Figure 5.3; trend 3/3). This result 
could suggest that MSCs in control media underwent a certain level of osteogenic 
differentiation that most likely was initiated by cell contact (Tang et al, 2010). The 
patient variations of ALP activity were moderate for MSCs; at week 2, when the ALP 
activity had its peak, the patient that had the highest ALP activity had only 1.7 times 
higher ALP activity than the patient with the lowest.  
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Figure 5.2. ALP activity in MDCsFn. ALP activity in MDCsFn appeared to increase until 
week 2 or 3; thereafter, it decreased. The peak of ALP activity was patient dependent, for one 
patient it occurred at week 2 and for two patients it occurred at week 3. The experiments were 
performed in three patients (n=3) in triplicates.  Results presented as mean+sem. Sample size 
calculation estimated that 10 samples were required to accept the outcome of a statistical test to 
see an effect of 1 unit. 
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Figure 5.3. ALP activity in MSCs over time. ALP activity in MSCs appeared to peak of ALP 
at 2 weeks; thereafter the ALP activity rapidly decreased. The peak of ALP activity was patient 
dependent for one patient it occurred at 1 week and for two patients it occurred at 2 weeks. The 
experiments were performed on three patients (n=3) triplicates. Results presented as mean+sem. 
Sample size calculation estimated that 10 samples were required to accept the outcome of a 
statistical test to see an effect of 1 unit. 
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Figure 5.4. ALP staining of MDCsFn over 4 weeks. The MDCsFn showed a time-dependent 
pattern of ALP expression (pink). The ALP expression was strongest after 2 weeks. MDCsFn in 
osteogenic media after a) 1 week, b) 2 weeks, c) 3 weeks and d) 4 weeks. The experiments were 
performed in three patients (n=3) in triplicates. Magnification x4.  
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Figure 5.5. ALP staining of MSCs during 4 weeks. The MSCs showed a time-dependent  
pattern of ALP expression (pink). The ALP expression was strongest after 2 weeks.  MSCs in 
osteogenic media after a) 1 week, b) 2 weeks, c) 3 weeks and d) 4 weeks. The experiments were 
performed on three patients (n=3) in triplicates.  Magnification x4. 
 
 
5.3.2 MINERALIZATION  
 
Mineralization was assessed by Alizarin Red S staining and quantification by extracting 
the stain and measuring using a spectrophotometer. The results showed that the 
mineralization increased over the time period studied i.e. 4 weeks by both MDCsFn and 
MSCs.  
 
Mineralization by MDCsFn increased over time, the largest change induced by 
osteogenic media occurred between week 3 and 4 (Figure 5.6 -5.7). At every time point, 
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there were higher levels of mineral on MDCsFn in osteogenic compared to MDCsFn in 
control media (trend 3/3 for all time points). For MDCsFn in control media there was a 
slight increase of mineralization over time (trend 3/3 between week 1 and 4). The 
mineralization of MDCsFn appeared to be less patient dependent than its ALP activity; 
there was only a 1.7-fold difference between the tested MDCsFn that expressed most 
mineralization and the MDCsFn that expressed least mineralization at 4 weeks.  
 
Mineralization by MSCs increased over time, the largest increase in osteogenic media 
occurred between week 3 and 4 (Figure 5.8- 5.9; trend 3/3). At every time point there 
were higher levels of mineral on MSCs in osteogenic compared to MSCs in control 
media (trend 3/3 between all time points). For MSCs in control media, there was also a 
slight increase over time (trend 3/3 between week 1 and 4). Mineralization of MSCs 
appeared to be relatively consistent between patients, with only a 2-fold difference 
between the highest and lowest levels detected at week 4.  
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Figure 5.6 Alizarin Red S-Calcium quantification of MDCsFn. The mineralisation increased 
rapidly from week 3 to 4 (trend 3/3). The experiments were performed on three patients (n=3) in 
triplicates. Result presented as mean+sem. Sample size calculation estimated that 5 samples 
were required to accept the outcome of a statistical test to see an effect of 2 units. 
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Figure 5.7. Alizarin Red S staining of MDCsFn over 4 weeks. After 3 weeks the first 
deposits could be seen on MDCsFn. There was a large increase in mineralization of MDCsFn 
between week 3 and 4. MDCsFn in osteogenic media at a) 1 week, b) 2 weeks, c) 3 weeks and 
d) 4 weeks. All experiments were performed on three patients (n=3) in triplicates. Magnification 
x4. Note: Same images as in 4.10.   
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Figure 5.8. Alizarin Red S-Calcium quantification of MSCs. The mineralization of MSCs in 
osteogenic media increased slowly from week 1 to 2 and thereafter more rapidly, with the 
largest difference between week 3 and week 4 (trend 3/3). The experiments were performed in 
three patients (n=3) in triplicates. Result presented as mean+sem. Sample size calculation 
estimated that 5 samples are required to accept the outcome of a statistical test to see an effect of 
2 units. 
 
 
 
 
 
CHAPTER 5: RESULT SECTION 3 
- COMPARISON OF MDCsFN AND MSCs  
 150 
  
 
  
 
Figure 5.9 Alizarin Red S-Calcium staining of MSCs over 4 weeks. After 3 weeks the first 
deposits could be seen on MSCs. There was a large mineralisation increase between week 3 and 
4. MSCs in osteogenic media at a) 1 week, b) 2 weeks, c) 3 weeks and d) 4 weeks. The 
experiments were performed on three patients (n=3) in triplicates. Magnification x4.  
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5.3.3 Q-PCR ARRAY OF OSTEOGENIC GENES 
 
Gene expression of MDCsFn and MSCs was analysed at 2 weeks in either osteogenic or 
control media by qPCR Array (for experimental details, see Chapter 2.9 and Chapter 
5.2.1). 
 
5.3.3.1 UNDETECTED GENES  
 
There were several genes that were undetected in both MDCsFn and MSCs (Table 5.2).  
Most of these genes are expressed by non-osteblastic lineages; both Ameloblastin 
enamel matrix protein (AMBN) and Amelogenin Y-chromosomal (AMELY) are 
expressed by ameloblasts (Hatakeyama et al, 2009), Calcitonin receptor (CALCR) is 
known to be only detected in osteoclasts (Dacquin et al, 2004), CASR in the parathyroid 
glands (Theman & Collins, 2009), Dentin sialophosphoprotein (DSPP) is odontoblast 
specific (Thyagarajan et al, 2001) and DMP1 is a dentin protein and its expression 
might be restricted to odontoblats in humans (Martinez et al, 2009). Osterix, which 
often has been described as a master regulator for osteogenic differentiation in mice, 
was also negative. There have been indications that Osterix might only be expressed in 
human embryonic tissue, not in adult tissue (Gao et al, 2004). BMP-7 was not detected 
in any of the MSCs samples, but was detected in one of the MDCsFn samples. Several 
BMPs, including BMP-7, are known to induce osteogenic differentiation in osteoblastic 
precursor cells, but BMP-7 is in general considered to be less osteogenic potent than 
other BMPs, such as BMP-2 and -4 (Cheng et al, 2003). Very little research has studied 
the expression of BMPs during osteogenic differentiation in stem cells; in general, 
BMPs, including BMP-2-4 and -7, are added in vitro to induce osteogenesis, and no 
data was found in the literature to explain the absence of BMP-7 in MSCs.  
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Table 5.2. Summary of undetected genes in MDCsFn and MSCs and suggested 
explanation why the genes were not expressed. *Not expressed in MSCs, detected in one 
sample of MDCsFn 
GENE SUGGESTED EXPLANATION 
AMBN Secreted by ameloblasts (Hatakeyama et al, 2009) 
AMELY Secreted by ameloblasts (Hatakeyama et al, 2009) 
BMP-7* - Unknown reason 
CALCR -Expressed on osteoclasts not osteoblasts (Dacquin et al, 2004) 
CASR -Expressed on the parathyroid glands (Theman & Collins, 2009) 
DMP1 - Dentin protein (Martinez et al, 2009).  
DSPP -odontoblast specific expression (Thyagarajan et al, 2001)  
OSTERIX -Only detected in embryonic human tissue not in adult human tissue (Gao et al, 2004)  
 
There were also some genes in MDCsFn, Fibroblast growth factor receptor 1 (FGFR-1), 
FGFR-2, Growth differentiation factor 10 (GDF10), BSP and Matrix metalloproteinase 
13 (MMP13), that were irregularly expressed in the patients i.e. were detected in some 
patient samples but not in others. FGFR-1 and FGFR-2 are involved in the formation of 
long bones as a negative regulator (Deng et al, 1996; White et al, 2005), GDF10 is a 
member of the TGF-β super family but its in vivo function is not clear (Hino et al, 
1996), BSP is expressed in fully differentiated osteoblasts (Kim et al, 1994), and 
MMP13 plays a part in bone remodelling by degrading the ECM (Laush et al, 2009). 
The impact of these genes not being consistently activated, for future bone engineering 
applications, is hard to evaluate without a valid in vivo model.  
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5.3.3.2 UP AND DOWNREGULATION 
 
5.3.3.2.1 MDCsFN 
 
The expression of most up-or-down regulated genes in MDCsFn showed patient-
dependent inconsistency in their expression. This could be due to patient-dependent 
variation in time the cells need to differentiate i.e. how easy the cells commit to the 
osteogenic lineage. There can also be variations in the stage of maturity of the cells 
within and between the patient samples. It was previously established (Figure 5.2) that 
the ALP activity of MDCsFn in osteogenic media was higher than in control media at 2 
weeks (trend 3/3); however, on mRNA level ALP expression was not consistent 
increased (trend 2/3; Figure 5.10). This finding could be explained by the lag period 
there is between gene expression and protein production.  
 
Figure 5.10. Upregulation of genes in MDCsFn after 2 weeks in osteogenic media 
compared to control media. None of the genes were significantly upregulated. Definition of 
upregulation was that there was a  0.2 unit positive difference between the mean gene 
expression in osteogenic media compared to MDCsFn in control media. The experiment was 
performed on three patients (n=3). Results presented as mean+sem. The gene expression of cells 
in osteogenic media was normalized to cells in control media (for more experimental details see 
Chapter 2.9). Sample size calculation estimated that 199 samples are required to accept the 
outcome of a statistical test to see an effect of 0.2 unit. 
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The gene that was most upregulated in 2 patients was PTH1R; however, it was not 
consistent upregulated (trend 2/3) in MDCsFn. PTH1R is considered to be an 
osteoblastic marker since it is expressed on osteoblasts (Ahlstrom et al, 2009). PTH1R 
is the receptor for PTH and together they are considered to be the most important 
regulators of calcium ion homeostasis in vivo (Mannstadt et al, 1999; Huang et al, 2001; 
Pioszak & Xu, 2008).  
 
Despite the upregulation of PTH1R, in 2 patients, it appeared as at 2 weeks in 
osteogenic media the MDCsFn were still in an early stage in their osteogenic 
differentiation, since Runx2 was not upregulated (Figure 5.10). 
 
 The two TWIST factors, 1 (trend 2/3) and 2 (trend 1/3), might be slightly upregulated, 
at least in some patients (Figure 5.10). It has been hypothesized that the expression of 
TWIST 1 and TWIST 2 must be decreased to allow Runx2 expression to increase 
(Bialek et al, 2004; Chapter 1.2.2). It is believed that the expression of TWIST1 and 
TWIST2 maintains cells in an osteoprogenitor or preosteoblast-like state to prevent 
premature osteoblast differentiation (Lee et al, 2000; Bialek et al, 2004). 
 
These results suggest that the cells were at a crossroad at 2 weeks, where they could be 
ready to commit to an osteoblastic phenotype. The upregulation of VDR (trend 2/3) and 
VEGFA (trend 3/3; Figure 5.10) in some patients is hard to interpret since VDR is 
known to have dual effects; in early osteogenic cultures it can inhibit osteogenic 
differentiation and in later cultures it can promote osteogenic differentiation (St-Arnaud, 
2008). The impact of VEGFA on osteogenic differentiation is controversial; studies 
have claimed that VEGFA can enhance osteogenesis (Mayer et al, 2005) as well as it 
can have a suppressive effect (Shonmeyr et al, 2010).  In experiments performed by 
Shonmeyr et al (2010), VEGFA suppressed the mRNA expression of BMP-2. This is in 
accordance with results in this study; VEGFA is upregulated in MDCsFn while (Figure 
5.10) BMP-2 (trend 3/3) is downregulated (Figure 5.11). 
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Figure 5.11. Downregulation of genes in MDCsFn after 2 weeks in osteogenic media 
compared to control media. Muscle segment homeobox 1 (MSX1; trend 3/3) and OP (trend 
3/3) were consistently downregulated in MDCsFn after 2 weeks in osteogenic media compared 
to cells control media. Definition of downregulation was that there was a  0.2 unit negative 
difference between the mean gene expression in osteogenic media compared to MDCsFn in 
control media. The experiments were performed on three patients (n=3). Results presented as 
mean-sem. The gene expression of cells in osteogenic media was normalized to cells in control 
media (for more experimental details see Chapter 2.9). Sample size calculation estimated that 
199 samples were required to accept the outcome of a statistical test to see an effect of 0.2 units. 
 
 
As mentioned above, BMP-2 (trend 3/3) was downregulated after 2 weeks in osteogenic 
media. BMPs, e.g. BMP-2, induce osteogenesis by binding to BMPs receptors, which 
then phosphorylate transcription factors, such as Smad1 that forms a complex with 
Smad4 in the nucleus. Hence, it is logical that when BMP-2 is downregulated Smad1 
(trend 2/3) and Smad4 (trend 2/3) are also downregulated (Figure 5.11). 
 
Indication that osteogenesis was undergoing was that Sox9 (trend 2/3) was found to be 
downregulated in MDCsFn in two patients. Sox9 is mostly known as a marker for 
chondrogenesis, and researchers have found it can suppress bone formation (Hattori et 
al, 2010).  
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Two genes to encode mineralization proteins, OP and MSX1 were downregulated 
(Kazanecki et al, 2007). These two proteins are considered markers for terminal 
differentiation (Blin-Wakkach, 2001) is not surprisingly since at 2 weeks, MDCsFn had 
not started to mineralize (Figure 5.6 and 5.8). These results suggested that MDCsFn 
could differentiate along the osteogenic lineage despite their muscle origin. 
 
 
5.3.3.2.2 MSCs 
 
The gene expression of MSCs was more consistent than for MDCsFn. Both the ALP 
activity of MSCs in osteogenic media (Figure 5.3) and the mRNA levels of ALP 
expression were not consistently increased (trend 2/3; Figure 5.12). One patient sample 
had its ALP activity peak at week 1, this could explain the inconsistency in the mRNA 
expression of the MSCs.  
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Figure 5.12. Upregulation of genes in MSCs after 2 weeks in osteogenic media compared 
to control media. PTH1R was consistently increased in MSCs in osteogenic media compared 
with control media (trend 3/3). Definition of upregulation was that there was a  0.2 unit 
positive difference between the mean gene expression in osteogenic media compared to 
MDCsFn in control media. The experiments were performed on three patients (n=3). Results 
presented as mean+sem. The gene expression of cells in osteogenic media was normalized to 
cells in control media (for more experimental details see Chapter 2.9). Sample size calculation 
estimated that 199 samples are required to accept the outcome of a statistical test to see an effect 
of 0.2 units. 
 
 
PTH1R was upregulated in MSCs (Figure 5.12; trend 3/3); it is known that dex can 
induce upregulation of PTH1R (Ahlstrom et al, 2009). This has been described as a 
combined event with upregulation of ALP and Runx2 (Ahlstrom et al, 2009). Whilst 
this is in accordance with this study in terms of ALP, the MSCs expressed decreased 
levels of Runx2 (Figure 5.13; trend 3/3).  
 
Many genes were downregulated in MSCs that had been in osteogenic media compared 
with MSCs in control media (Figure 5.13). Both BMPs that were expressed, BMP-2 
(trend 3/3) and-4 (trend 3/3), and the BMP related protein GDF10 (trend 3/3) were 
downregulated at 2 weeks in osteogenic media. Consequently, as explained in Chapter 
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5.3.3.2.1, the following cascade of Smad proteins was also downregulated (Figure 5.13; 
trend 3/3 for both Smad 1 and 4).  
 
In contrast to MDCsFn, the VEGFA in MSCs was downregulated (Figure 5.13; trend 
3/3) in all patients. Genes that encode protein that characterize late or terminal 
differentiation i.e. MSX1 (trend 3/3), OP (trend 3/3) and Secreted protein, acidic, 
cysteine-rich (SPARC; trend 3/3) were also downregulated (Figure 5.13) in all tested 
patients.   
 
The expression of the TWIST factors in MSCs in osteogenic media were in level with 
the gene expression in control media and the lack of downregulation of these factors 
could mean that the cells still have to decrease for Runx2 to get upregulated. 
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Figure 5.13. Downregulation of genes in MSCs after 2 weeks in osteogenic media 
compared to control media. Definition of downregulation was that the mean gene expression 
of the three patients is  0.2 units negative difference in MSCs in osteogenic media compared to 
MSCs in control media. The experiments performed on three patients (n=3). Results presented 
as mean-sem. The gene expression of cells in osteogenic media was normalized to cells in 
control media (for more experimental details see Chapter 2.9). Sample size calculation 
estimated that 199 samples were required to accept the outcome of a statistical test to see an 
effect of 0.2 units. 
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5.4 SUMMARY 
 
In this chapter, MDCsFn and MSCs were compared in terms of mineralization and ALP 
activity and expression over 4 weeks. Thereafter, the gene expression of 46 genes 
involved in the osteogenic differentiation were analysed by qPCR when the cells had 
been 2 weeks in osteogenic media alternative control media.  
 
For both cell types, MDCsFn and MSCs, the ALP activity first increased until week 1-3, 
thereafter it decreased. The decrease was more rapid for MSCs (Figure 5.3) than for 
MDCsFn (Figure 5.2). This agrees with the results of Jackson et al (2009), who 
compared the ALP activity of MDCs from traumatized muscle from unspecific 
anatomical location with MSCs.  They found that the ALP activity of both MDCs and 
MSCs first increased and then later decreased.  
 
As showed previously in this study, both MDCsFn and MSCs were able to mineralise 
(Chapter 3-5) and the mineralization process for the two cell types appeared to require 
approximately 4 weeks (Figure 5.6-5.9). In general, researchers incubate MSCs 1 to 2 
weeks in osteogenic media before ALP analysis (Gronthos et al, 1994; Romanov et al, 
2005; Aslan et al, 2006) and 3 to 4 weeks before mineralisation assay (Gronthos et al, 
1994; Aslan et al, 2006).  
 
In order to analyse the gene expression during osteogenic differentiation, the cells were 
analysed at 2 weeks in either osteogenic or control media. Many genes were 
downregulated in osteogenic media compared to cells in control media, especially for 
MSCs (Figure 5.13). At 2 weeks, it was not expected that late markers such as BSP or 
OP to be upregulated; however, also early markers such as Runx2 and Cadherin-11 
(CDH11) were downregulated for MSCs. One explanation could be that the TWIST 
factors 1 and 2 regulate Runx2 by preventing premature differentiation (Chapter 1.2.2).  
Liu et al (2008) also found that Runx2 and Col1A1 was not upregulated by 2 weeks in 
osteogenic media in MSCs. The role of CDH11 in human osteogenesis is not clear; in 
mice it has been proven to promote cancer metastasis to bone (Chu et al, 2009). It is 
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also important to remember that throughout osteogenic differentiation there is a constant 
crosstalk between signals (Katoh, 2008), so the results might due to the time point. It is 
likely that many of the genes that were downregulated at 2 weeks either already have 
been upregulated or would be upregulated if different time point had been chosen. 
 
Whilst there was a reasonably consistent gene regulation for the MSCs, the regulation of 
MDCsFn was more inconsistent (Chapter 5.3.3.1 and Chapter 5.3.3.2.1). This could be 
due to the higher patient variations within the MDCsFn or that the MDCsFn are more 
heterogeneous in terms of their differential potential capacity than the MSCs. This is 
expected since bone marrow-derived MSCs have their niche in the bone and MDCsFn 
have their’s in the muscle. It appeared as MSCs had a higher osteogenic capacity 
compared to MDCsFn in terms of PTH1R upregulation, ALP expression and 
mineralization (Figure 5.10; Figure 5.12). However, in this chapter it was proven that 
MDCsFn were remarkable similar to MSCs, despite their different anatomical origin, in 
terms of gene expression, ALP activity and expression and mineralisation capacity 
(Figure 5.2-5.9). 
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Table 5.3. Summary of results from Chapter 5. Comparison of the osteogenic potential of 
MDCsFn and MSCs. ALP activity and mineralisation presented as meansem. *Not 
expressed in MSCs, detected in one sample of MDCsFn 
 MDCsFn MSCs 
ALP activity  
- at 2 weeks 
5.42.9 8.01.5 
Mineralisation 
 -at 4 weeks 
11.21.9 5.80.16 
Undetected gene 
expression  
AMBN, AMELY, BMP-
7*, CALCR, CASR, 
DMP1, DSPP, OSTERIX 
AMBN, AMELY, BMP-7, 
CALCR, CASR, DMP1, 
DSPP, OSTERIX 
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6.1 INTRODUCTION SPECIFIC FOR RESULT 
SECTION 4 
 
The results from the previous chapter, Chapter 5, demonstrated that MDCsFn and 
MSCs exhibit several similarities in osteogenic differentiation behaviour. Both 
populations had similar ALP and mineralization pattern and they also expressed a 
similar subset of osteogenic genes (see Chapter 5). In this chapter, the interaction of 
MDCsFn and MSCs on three different Ti surfaces that are or have been commercially 
available as dental implants have been studied. The surfaces were 1) SMO, a polished, 
smooth surface, 2) SLA, a rough sandblasted, acid-etched hydrophobic surface and 3) 
SLActive, a hydrophilic SLA surface.  The impact of Ti surfaces on MDCsFn and 
MSCs was assessed in terms of metabolic activity and cell death.  
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6.2 METHODS SPECIFIC FOR RESULT  
SECTION 4  
 
6.2.1 PRE-TREATMENT OF SMO AND SLA DISCS* 
*Performed by Straumann AG 
 
In order to form pre-treated Ti discs, grade 2 Ti sheets, i.e. commercially pure Ti, were 
used and degreased by acetone and thereafter treated by a mixture of 2% ammonium 
fluoride/ 2 % hydrofluoric acid/10 % nitric acid solution   (Figure 6.1).  
 
The SMO was polished to a mirror finish with a 10 um diamond paste in oil and finally 
with a 0.06 um SiO2 suspension (as described in Rupp et al, 2006). The SLA were made 
of pre-treated surfaces that had been coarse grit-blasted with corundum grit, 0.25-0.50 
mm, at 5 bar until the surface became uniform grey before they were acid-etched with 
hydrochloric acid and sulphuric acid solution (as described in Martin et al, 1995; Rupp 
et al, 2006). The preparation of the discs, both SMO and SLA, were finalised by the 
discs being rinsed in deionised water before steam autoclaving. 
 
The SLActive discs were produced with same sandblasting and acid-etchning procedure 
as SLA surfaces, but to increase their wettability or hydrophilicity the SLActive discs 
were rinsed under nitrogen to prevent exposure to air and stored in degassed isotonic 
sodium chloride solution in a sealed glass tube (Figure 6.2). This was done in order to 
protect the surface from hydrocarbon and carbide contamination of Ti surface i.e. 
contamination that increases the hydrophobicity of the oxidelayer on the Ti surface 
(Rupp et al, 2006). The sterilization of SLActive was performed by -irradiation 
overnight (as described in Zhao et al, 2005). 
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Figure 6.1. Scheme over production of SMO and SLA discs.  Ti discs, 15 mm in diameter, 
were cut out from a sheet of 1.1 mm thick grade 2 Ti i.e. commercially pure Ti. Ti discs were 
degreased by acetone before pre-treated by a mixture of 2% ammonium fluoride/ 2 % 
hydrofluoric acid/10 % nitric acid solution at 55 C for 30 s. Thereafter, SMO was polished to a 
mirror finish with a 10 um diamond paste in oil and finally with a 0.06 um SiO2 suspension, 
whereas SLA were treated by coarse grit-blasted with 0.25-0.50 mm corundum grit at 5 bar until 
the surface became uniform grey, followed by acid-etching. Both surface types were rinsed in 
deionised water before steam autoclaving in 121 °C for 15 min. 
 
 
 
Figure 6.2. Hydrophobic SLA is transformed to hydrophilic SLActive. SLActive are SLA 
discs that have increased hydrophilicity. SLActive surfaces have been protected from air by 
nitrogen before they were stored in glass tubes containing isotonic NaCl solution. The discs 
were finally sterilized by -irradiation at 25 kGreys overnight.  
 
 
The protection from air gives the SLActive surface a water contact angle of 0 (Table 
6.1). A water contact angel of 0 means that that the surface’s has an extremely 
hydrophilic character (Table 1.4; Rupp et al, 2006; Zhao et al, 2005).  
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6.2.2 FURTHER TREATMENT OF TI SURFACES 
 
Before use in the cell culture experiments SMO and SLA surfaces were cleaned in 10% 
nitric acid for 10 min on each side before they were washed thoroughly with sterile 
deionised water to remove all nitric acid residues. The discs were left to dry in a sterile 
environment before treated by UV in a Coast-air Steristrom 2537å for an hour on each 
side. Using nitric acid in combination with UV to sterilise the discs means the use of 
alcohol or autoclaving can be avoided; alcohol and autoclaving can increase 
hydrophobicity (Zhao et al, 2005). The SLActive discs were delivered sterilised in a 
sealed glass vial (Figure 6.2) and were used straight after the package was broken.  
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Table 6.1. Physical data of the three tested Ti discs SMO, SLA and SLActive. Data taken 
from Brett et al, 2004; Zhao et al, 2005; Rupp et al, 2006; Straumann communication) 
 
DISC 
 
SMO 
 
SLA 
 
SLActive 
 
 
Treatment 
 
 
Polished 
 
Sandblasted, 
 acid-etched 
 
SLA protected 
from air 
 
Attachment area 
(mm2) 
 
25 
 
33.9 
 
33.9 
 
Roughness levels 
(Ra/um)  
 
0.06 
 
4.0 
 
4.0  
 
Hydrophilic/ 
hydrophobic 
 
Hydrophobic 
 
Hydrophobic 
 
Hydrophilic 
 
Thickness 
 (mm) 
 
1.1 
 
1.1 
 
1.1 
 
Diameter 
(mm) 
 
15 
 
15 
 
15 
 
Water contact angle  
() 
 
95.764.0  
 
138.34.2 
 
0 
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6.3 RESULTS FOR RESULT SECTION 4 
 
6.3.1 THE IMPACT OF TI ON METABOLIC ACTIVITY 
 
6.3.1.1 MDCsFN ON TI  
 
MDCsFn were seeded, at a density of 1000 cells/cm2 in culture media, onto the three Ti 
surfaces i.e. SMO, SLA and SLActive, and TCP to study if the roughness and 
hydrophilicity of the surfaces had any impact on the metabolic activity of MDCsFn over 
5 weeks in culture media. The metabolic activity measured by Alamar Blue is used as a 
measurement for the cell number. 
 
MDCsFn cultured on SLA and SLActive showed throughout the test period a lower 
metabolic activity than on SMO and TCP (trend 3/3 for both conditions for all time 
points). There was no consistent difference between TCP and SMO or between SLA 
and SLActive throughout the test period (Figure 6.3).  
 
The metabolic activity of MDCsFn increased over time on all the surfaces.  After 4 
weeks the metabolic activity on TCP and SMO appeared to have reached a plateau, 
probably due to confluency (Figure 6.3). There was a lag period, week 0-2, on both 
SLA and SLActive before the cell number i.e. metabolic activity started to increase 
(Figure 6.3). After 5 weeks, it appeared that the cell number on SLA and SLActive still 
had not reached its plateau (Figure 6.3).  
 
The initial metabolic activity, at time point 0, was lower on SLA and SLActive 
compared to SMO and TCP (trend 3/3 for both conditions). This indicates that the rough 
surface is causing cell death of MDCsFn and it is very likely that this cell death is 
responsible for the lag phase on SLA and SLActive (Figure 6.3).  
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Figure 6.3. Metabolic activity of MDCsFn on the Ti surfaces over 5 weeks. There was a lag 
period for the MDCsFn on SLA and SLActive of approximately 2 weeks. Seeding cell density 
was 1000 cells/cm2. There was a consistent difference between SMO/TCP and SLA/SLActive 
during the whole tested period (trend 3/3 for both conditions for all time points). Experiments 
were performed in three patients (n=3) and in triplicates. Results presented as mean  sem. 
Sample size calculation estimated that 4 samples were required to accept the outcome of a 
statistical test to see an effect or variation of 10% of the metabolic activity compared to TCP at 
5 weeks. 
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6.3.1.2 MSCs ON TI  
 
MSCs were seeded, at a density of 1000 cells/cm2 in culture media, onto the three Ti 
surfaces i.e. SMO, SLA and SLActive, and TCP to study if the roughness and 
hydrophilicity of the surfaces had any impact on the metabolic activity of MSCs over 4 
weeks. The metabolic activity measured by Alamar Blue is used as a measurement for 
the cell number. 
 
Initially, MSCs on SLA and SLActive showed lower metabolic activity than on SMO 
and TCP; there was also a decrease in metabolic activity on SMO compared to TCP at 
time point 0. The difference between SLA or SLActive and SMO or TCP was consistent 
(trend 3/3 at week 0 and 1) until week 2 (Figure 6.4). After 3 weeks, there were no 
consistent trends in metabolic activity on TCP, SMO, SLA and SLActive (Figure 6.4).  
 
A likely explanation is that the cells had reached confluency on all the surfaces after 3 
weeks. Interestingly, there was lower metabolic activity, on SLActive (trend 3/3) at 4 
weeks compared to TCP, SMO and SLA (Figure 6.4). The explanation for this 
behaviour might lay in the hydrophilicity of SLActive and that the cells on the 
hydrophilic surfaces are not able to use the surface area as efficiently as on the 
comparable SLA surface.  
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Figure 6.4. Metabolic activity of MSCs on the Ti surfaces over 4 weeks in culture media. 
There was a lag period during the first week for the MSCs proliferating on the SLA and 
SLActive (trend 3/3).  Seeding cell density was 1000 cells/cm2.  Experiments were performed 
with three sets of patients (n=3) and in triplicates for each set. Results presented as mean  sem. 
Sample size calculation estimated that 4 samples are required to accept the outcome of a 
statistical test to see an effect or variation of 10% of the metabolic activity compared to TCP at 
5 weeks. 
 
6.3.1.2.1 MSCs ON TI OVER 10 DAYS MEASURED BY MTT 
 
The metabolic activity of MSCs for day 1, 5 and 10 was studied by MTT in order to 
confirm and investigate the lag period detected in Chapter 6.3.1.2. The cells were 
seeded at the same density, 1000 cells/cm2, as in Chapter 6.3.1.2.  The metabolic 
activity measured by Alamar Blue is used as a measurement for the cell number. 
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At day 1, there were no consistent differences between the metabolic activity by MSCs 
on TCP, SMO or SLA but there was a consistent difference between TCP and SLActive 
(tren 2/2; Figure 6.5). At day 5, there was a consistent difference of the metabolic 
activity between TCP or SMO and SLA or SLActive (trend 2/2 for all comparisons), but 
not between TCP and SMO or between SLA and SLActive.  At day 10, there was a 
consistent difference between the metabolic activity on TCP and the other surfaces i.e. 
SMO, SLA and SLActive (trend 2/2 for all three comparisons); however, there was no 
consistent difference between SLA and SLActive. On all surfaces the metabolic activity 
increased between day 1 and day 10; this increase was only consistent between day 5 
and 10 (Figure 6.5; 2/2 for all conditions). Since metabolic activity could be used as a 
measurement for cell number, this is in accordance with Wall et al (2009) findings that 
MSCs cultured on the rough surfaces underwent a decrease in cell number early in 
culture.  
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Figure 6.5. Metabolic activity of MSCs on Ti surfaces over 10 days. The cell number, 
measured by MTT, was increased over 10 days for cells on all the surfaces. The increase was 
consistently higher on SMO and TCP surfaces compared to SLA and SLActive at day 10 (trend 
2/2). Seeding density was 1000 cells/cm2. Experiments were performed on two patients (n=2) 
and in triplicates for each set.  Results presented as mean + sem. Sample size calculation 
estimated that 52 samples were required to accept the outcome of a statistical test to see an 
effect of 0.4 units.   
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6.3.2 THE IMPACT OF TI ON CELL DEATH 
 
6.3.2.1 MDCsFN 
 
It was hypothesized that the initial lag period (Figure 6.3) detected on SLA and 
SLActive was caused by cell death. In order to investigate this hypothesis, cells were 
seeded, 10 000 cells/cm2, on Ti discs and analyzed for apoptosis and necrosis by flow 
cytometry after 24 h.  
 
Cells on SLActive underwent both more apoptosis and necrosis compared with the other 
surfaces; however, there was a clear pattern of the impact of the surfaces on both 
apoptosis and necrosis, where SLA had less apoptosis and necrosis than SLActive, but 
more than on SMO and TCP (trend 3/3 for both comparisons); there were no consistent 
difference between apoptosis and necrosis on TCP and SMO. 
 
Table 6.2. Percentage apoptosis, necrosis and metabolic activity of MDCsFn detected on 
the four surfaces i.e. TCP, SMO, SLA and SLActive. Experiments were performed on three 
patients (n=3) and in triplicates for each set.  Results presented as mean  sem.  
 TCP SMO SLA SLActive 
APOPTOSIS 
(%) 
1.50.4 2.00.6 4.70.3 10.21.5 
NECROSIS 
(%) 
3.40.2 3.40.5 6.61.1 8.40.7 
METABOLIC 
ACTIVITY(%) 
950.5 94.71.0 88.71.4 77.40.6 
 
 
MDCsFn on SLActive underwent approximately 2.2-fold more apoptosis (Table 6.2; 
Figure 6.7a) compared to cells on SLA. This increment in apoptosis could be due to the 
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higher hydrophilicity of the SLActive compared to SLA; cells on SLActive also 
underwent consistently more necrosis than cells on SLA (trend 3/3). Cells on SLA 
underwent both more apoptosis and necrosis than cells on SMO or TCP (trend 3/3). 
There was no consistent difference in the amount of apoptosis or necrosis of the cells on 
TCP and SMO.  There was a reverse relationship between live cells and dying or dead 
cells (Figure 6.7 c). The increased cell death on SLA and especially SLActive, explains 
the earlier detected lag period of MDCsFn (Figure 6.3). 
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Figure 6.6. Dot plots of early apoptosis and necrosis of MDCsFn on TCP, SMO, SLA and 
SLActive assessed by flow cytometry. Cells on SLActive underwent more apoptosis and 
necrosis compared with the other surfaces; however, there was a clear pattern for both apoptosis 
and necrosis where: TCP=SMOSLASLActive. Early apoptotic cells stained only positive for 
Annexin-V, necrotic cells stained positive for both Annexin-V and PI and live cells were 
negative for both Annexin-V and PI.   
CHAPTER 6: RESULT SECTION 4   
- IMPACT OF TI SURFACES ON MDCSFN AND MSCS  
 178 
a)        b) 
 
 
 
c) 
 
Figure 6.7. Percentage of MDCsFn on 
TCP, SMO, SLA and SLActive that 
underwent a) apoptosis, b) necrosis, or c) 
were alive after 24 h. Cells on SLActive 
underwent more a) apoptosis and b) necrosis 
compared with the other surfaces (trend 3/3); 
however, there was a clear pattern for both 
apoptosis and necrosis where: 
TCP=SMOSLA SLActive. There were 
more viable cells on TCP and SMO compared 
to SLA and SLActive (trend 3/3 for all 
comparisons). Experiments were performed with three patients (n=3) in triplicates. Results 
presented as mean + sem. Sample size calculation estimated that 5 samples are required to 
accept the outcome of a statistical test to see an effect of 2%.   
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6.3.2.2 MSCs 
 
It was hypothesized that the initial lag period (Figure 6.4) detected on SLA and 
SLActive was caused by cell death. In order to investigate this hypothesis cells were 
seeded, 10000 cells/cm2, on Ti discs and analyzed for apoptosis and necrosis by flow 
cytometry after 24 h.  
 
In terms of necrosis there was no detected difference between SLActive and SLA but 
MSCs on SLActive underwent approximately 1.7-fold more apoptosis compared to cells 
on SLA (Table 6.3). This is likely caused by the increment in hydrophilicity of the 
SLActive compared to SLA.  There was more apoptosis and necrosis on SLActive or 
SLA than on SMO or TCP (trend 3/3 for all comparisons). There was consistently more 
necrosis on SMO than on TCP surfaces after 24 hours (trend 3/3). As a consequence of 
the increased apoptosis and necrosis on SLActive, there was a decrease in its number of 
viable cells compared to the other surfaces (Figure 6.8 and 6.9c; trend 3/3). The 
detected increment in cell death on SLA and especially SLActive could explain the 
earlier detected lag period of MSCs (Figure 6.4). 
 
Table 6.3. Percentage apoptosis, necrosis and metabolic activity of MSCs detected on the 
four surfaces i.e. TCP, SMO, SLA and SLActive. Experiments were performed on three 
patients (n=3) and in triplicates for each set.  Results presented as mean  sem.  
 TCP SMO SLA SLActive 
APOPTOSIS 
(%) 
10.0 1.8 12.0 1.0 14.9  2.2 26.0 0.4 
NECROSIS 
(%) 
6.41.8 12.00.6 16.9 1.6 18.3  0.4 
METABOLIC 
ACTIVITY(%) 
83.6 1.8 76.0 1.3 68.22.4 55.70.3 
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Figure 6.8. Dot plots of early apoptosis and necrosis of MSCs on TCP, SMO, SLA and 
SLActive assessed by flow cytometry. Cells on SLActive underwent more apoptosis compared 
with the other surfaces; MSCs on SLA and SLActive underwent more apoptosis and necrosis 
than SMO or TCP. Early apoptotic cells stained positive for only Annexin-V, necrotic cells 
stained positive for both Annexin-V and PI and live cells were negative for both Annexin-V and 
PI.  All experiments were performed on three patients (n=3) in triplicates. 
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a)       b) 
 
 
c) 
 
Figure 6.9. Percentage of MSCs on TCP, 
SMO, SLA or SLActive that underwent a) 
apoptosis, b) necrosis, or c) were alive after 
24 h.  MSCs on SLActive underwent more 
apoptosis and necrosis compared to the other 
surfaces (trend 3/3). There were more viable 
cells on TCP compared to SMO, SLA and 
SLActive (trend 3/3).  All experiments (n=3) 
were performed in triplicates. Results 
presented as mean + sem. Results presented 
as mean + sem. Sample size calculation 
estimated that 5 samples are required to  
accept the outcome of a statistical test to see an 
effect of 2%.   
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6.3.3 ANALYSIS OF BONE FORMATION ON TI 
 
There are several issues associated with analyzing osteogenic differentiation and 
mineralization on Ti. Ti is opaque, which makes it difficult to study the differentiation 
pathway, using microscopy. Using the quantitative method of Alizarin Red S that 
previously been used in this thesis also has limitations when used on Ti. 
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Figure 6.10. Alizarin Red S quantification of MSCs on various Ti surfaces at 1 week. More 
calcium was detected on SLActive than on TCP after 1 week in osteogenic media. Experiment 
was performed in triplicates and results presented as mean + 1std. 
 
 
 Alizarin Red S forms complex with calcium in the hydroxyapatite; however, calcium is 
also secreted when cells undergo cell death. As shown in this chapter, cells on SLActive 
undergo more cell death than on SMO (Figure 6.7; Figure 6.9) and can cause a bias 
interpretation of the results. 
 
In order to analyse the cells’ ALP activity MDCsFn were first seeded on Ti for 24 h 
before harvesting and then reseeded on TCP in osteogenic media. In this experiment 
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higher levels were detected in cells that had been seeded onto TCP or SMO than 
SLActive (trend 3/3). This is the opposite result to the expected since SLActive has 
been superior in terms of bone formation in vivo (Schwartz et al, 2008; Zöller et al, 
2008; Morton et al, 2010).  
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Figure 6.11. Measured ALP activity on MDCsFn at 1 week in osteogenic media. First, the 
cells had been harvested from various Ti discs and then reseeded on TCP.  Higher ALP activity 
was detected in MDCsFn that had been harvested from TCP or SMO (trend 3/3) than from 
SLActive.  Experiments were performed on three patients (n=3) in triplicates and results 
presented as mean+sem. Results presented as mean + sem. Sample size calculation estimated 
that 10 samples are required to accept the outcome of a statistical test to see an effect of 1 unit. 
 
 
Partly due to the limitations of in vitro techniques in terms of studying cells interaction 
with scaffolds, a lot of researchers have used in vivo models to analyse the bone formed 
on scaffolds (Schwartz et al, 2008). Another reason is that bone is a complex tissue 
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(Chapter 1.2) and consists of several types of cells i.e. osteoblast, osteocytes and 
osteoclasts. In vitro assays, such as Alizarin Red S, can give a good indication of the 
cells capacity to mineralize, but cannot predict the bone remodeling process and the 
impact of the various cell types.  
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6.4 SUMMARY 
 
In this chapter the biocompatibility of different Ti surfaces with MSCs and MDCsFn 
was studied.  The two cell types exhibit many similarities, but also differences. 
 
When cells were seeded on SLA and SLActive, there was a lag period for both 
MDCsFn (Figure 6.3) and MSCs (Figure 6.4) before the metabolic activity, which was 
interpreted as cell number, started to increase; this lag period could not be detected on 
SMO or TCP. The lag period appeared to last 1 week for MSCs and 2 weeks for 
MDCsFn. Throughout the test period, MDCsFn showed consistent lower cell number on 
SLA or SLActive compared to SMO or TCP. Initially for MSCs, there was the same 
pattern but this only lasted until week 2 between the tested surfaces thereafter there was 
no difference.   
 
It is previously known that MSCs (Wall et al, 2009), MG63, an immature osteoblastic 
cell line, (Zhao et al, 2005; Kim et al, 2006) and osteoblasts (Brett et al, 2004) initially 
have lower viability on rough Ti surfaces compared to smooth. In this chapter, it has 
been shown that this is also true for MDCsFn (Figure 6.3; Figure 6.6-6.7).  
 
It should be noted that MDCsFn expressed a higher percentage (Figure 6.7) of viable 
cells on all surfaces, compared to MSCs (Figure 6.9). For example, on SLActive 
approximately 80% of MDCsFn were viable after 24 hours (Table 6.2) compared to 
55% of MSCs (Table 6.3). 
  
Interestingly, the surface that induced highest levels of cell death, SLActive, is the 
surface that has shown superior osseointegration in bone implants in vivo (Rupp et al, 
2006; Schwartz et al, 2008; Zöllner et al, 2008; Morton et al, 2010). This leads to the 
question if the cell death plays a role in osseointegration. If no, this could imply that the 
increased metabolic activity of MDCsFn on SLActive could mean that MDCsFn would 
be better to osseointegrate than MSCs.  
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Table 6.4. Summary of results from Chapter 6. Comparison of the impact various Ti discs, 
with different roughness and hydrophilicity, have on MDCsFn and MSCs.  
  
MDCsFn 
 
MSCs 
 
 
Lag period on SMO 
compared to TCP 
 
No 
 
No 
 
Lag period on SLA 
compared to TCP 
 
Yes  
– 2 weeks 
 
Yes 
 – 1 weeks 
Lag period on 
SLActive compared 
to TCP 
 
Yes 
 – 2 weeks 
 
Yes 
 – 1 weeks 
 
Trend for apoptosis 
 
TCP=SMOSLA SLActive 
 
TCP<SMOSLA SLActive 
 
 
Trend for necrosis 
 
TCP=SMOSLA SLActive  
 
TCP<SMOSLA SLActive.  
 
 
Trend for viability 
 
SLActive<SLA<SMO=TCP 
 
SLActive<SLA<SMO<TCP 
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7.1 DISCUSSION 
  
The main aim for this thesis was to investigate the potential to use MDCs or the 
osteogenic subpopulation of MDCs, which were isolated by adherence within 20 min to 
Fn and named MDCsFn (Chapter 4), in bone engineering applications. It is probable 
that a scaffold of some sort will be needed to form engineered bone. Ti has been 
suggested as a suitable scaffold material due to its osseointegrative capacity 
(Granström, 2007).  
 
The use of osteogenic cells seeded onto a Ti scaffold could have at least two 
applications in clinical bone regeneration. First, osteogenic cells could be used to 
regenerate new bone to replace bone tissue that had to be removed due to trauma or 
cancer. In order to regenerate new bone an anatomical mesh will most likely will be 
needed to form the new tissue. Second, osteogenic cells could be seeded onto Ti 
implants, e.g. dental hip or knee implants, to enhance osseointegration. 
 
Bone marrow-derived MSCs have already shown promising results in bone regeneration 
applications in human (Warnke et al, 2004) and in sheep (Frosch et al, 2006); the 
advantage of using progenitor cells, and not mature cells, such as osteoblasts in tissue 
regeneration, is the progenitor cells possibility to expand (Alhadlaq & Mao, 2005). 
However, in order to obtain bone marrow-derived MSCs whole bone marrow is 
aspirated. This can cause morbidity and have a negative impact on the patient’s immune 
system. Thus, in order to regenerate new bone tissue without lowering the patient’s 
immune system an alternative source of osteogenic cells must be used. One potential 
source is adult adipogenic stem cells (ASCs); ASCs are more abundant than bone 
marrow-derived MSCs and can differentiate along the osteogenic, chondrogenic, 
adipogenic and neurogenic lineage. Due to these properties ASCs are used in clinical 
trials (Lindroos et al, 2010). However, in this study we have evaluated the potential to 
use osteogenic MDCs as an alternative source for MSCs in bone regeneration 
applications. 
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7.1.1 THE DIFFERENTIAL POTENTIAL OF THE CELLS 
 
The cells’ “stem cellness” in terms of their differentiation potential was studied. There 
is a consensus among many researchers that to qualify as stem cells, the cell should be 
clonogenic, self-renewing and multipotent, giving rise to at least three different lineages 
(Torella et al, 2007). In this study, differentiation along the osteogenic, myogenic and 
adipogenic lineages were tested. There were cells within the MDCs population that 
could mineralize in osteogenic media (Figure 4.10), fuse to myotubes in myogenic 
media (Figure 3.6) and form lipid droplets in adipogenic media (Figure 3.10). This 
might indicate that there are cells within MDCs that are truly multipotent or MDCs 
consist of various cell types that can differentiate along one lineage or a combination of 
both.  
 
Differentiation experiments of isolated subpopulations of MDCs conducted for this 
thesis suggested that the myogenic MDCs are different from the osteogenic MDCs 
(Figure 4.7). This indicates that MDCs consist of various cell types that can differentiate 
along various lineages. This claim would contradict the hypothesis of a communal 
precursor or stem cell for osteogenic cells and myogenic MDCs that various researchers 
have suggested (Bosch et al, 2000; Deasy et al, 2001). One theory that would explain 
the findings of this thesis that osteogenic MDCs differ from myogenic MDCs is that the 
osteogenic cells residing within muscle tissue not are precursor cells to myoblasts but 
belong to another cell type e.g. pericytes. Craniofacial muscle is derived from the 
mesoderm lineage, but bone and pericytes are neural crest derived. Neural crest cells are 
known for their affinity for Fn (Hall, 2009) and it has also been discovered that there are 
neural crest cells with progenitor and stem cell capacity in adults (Dupin et al, 2007). 
 
Furthermore, there are several important differences between this study and the study by 
Bosch et al (2000) that led up to the communal precursor hypothesis. Firstly, the two 
studies were performed in different species, human versus mouse, secondly, the muscle 
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was derived from different anatomical parts and thirdly, Bosch et al (2000) used a 
different isolation method than the one used in this study.  
 
There is a possibility that the decreased level of myogenicity of MDCsFn (Figure 4.7) is 
simply due to the technical difficulties of keeping myotubes in long-term culture 
(Chapter 4.3.2.2). If the more ‘stem cell’-like MDCs with osteogenic potential are 
precursor cells to satellite cells they might need longer than 4 days in myogenic media 
to express myogenic markers, such as desmin or fuse to myotubes; therefore, MDCsFn 
might appear less myogenic than the parent population which consist of a mixture of 
cell types, such as myogenic precursor cells and the more immature ‘stem cell’-like 
population.  
 
When Ozeki et al (2006) studied myogenic differentiation of MDCs, they found that 
there was high degree of heterogeneity within their isolated 7-fraction; MDCsFn 
population might also be heterogeneous.  It is possible that there is a smaller subset of 
‘stem cell-like’ cells within the MDCs that can differentiate along all of the lineages in 
this study and that other cells are immature lineage-specific progenitor cells.  
 
As mentioned previously in this chapter, it was established in this thesis that the cells 
early adherent, with the first 20 min, to Fn i.e. MDCsFn belonged to the more 
osteogenic subpopulation compared to the cells in the parental population, MDCsPP 
(Chapter 4). Also previously, Fn has been used for the isolation of progenitor cells with 
multipotentiality from various tissues, such as neonatal foreskin (Jones & Watt, 1993) 
and cartilage (Dowthwaite et al, 2004). Fn is an important ECM protein during tissue 
repair where Fn-rich ECM has multiple biological functions acting as a chemo-
attractant and adhesive substrate for mesenchymal and epithelial cells that migrate into 
damaged tissues (Limper & Roman, 1992). This could explain why a more stem cell-
like population has a high affinity to Fn. It has been suggested by some researchers 
(Jones & Watts, 1993) that this selection is due to the high expression of 1 integrin on 
Fn adherent cells.  However, it is known that 1-integrin is expressed on various cell 
types in the human body, such as mesenchymal cells, inflammatory cells (Limper & 
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Roman, 1992), smooth muscle cells (Deb et al, 2004) and skeletal muscle cells (Lewis 
et al, 2001).  Thus, using 1-integrin to identify and isolate the multipotent cells is not 
sufficient. Unfortunately, today there is no reliable single marker to use for isolation of 
“stem cell-like” cells. This makes it more difficult in the quest of identifying cells for 
tissue engineering applications. Nevertheless, it might be vital to establish if MDCs 
consists of a multipotent stem cell population or a population of multipotent cells or 
maybe both before the cells are used in clinical applications to avoid trans-
differentiation.  
 
MSCs mineralized in osteogenic media and formed lipid droplets in adipogenic media; 
however, MSCs alone did not fuse to myotubes in vitro at least not with the myogenic 
media used in this study.  It is mentioned in the literature that MSCs are able to 
differentiate along the myogenic lineages; however, very little research has actually 
been published, especially regarding human cells, in this area. Thus, in this study MSCs 
have not been proven to be able to differentiate along three different lineages but there 
is a consensus that MSCs are capable to differentiate along, apart from the mentioned 
osteogenic and adipogenic, the chondrogenic lineage (Pittenger et al, 1999). It should be 
noted that not all MSCs are multipotent. When cloned MSCs were placed in osteogenic, 
adipogenic or chondrogenic differentiation media, it was found that only a small 
proportion of cells were able to differentiate along all three lineages. Fukiage et al 
(2008) found that within a group of 100 MSC clones only five of them showed tri-
directional differentiation, 78 clones showed the potential to differentiate into either 
one-or two lineages, and 17 clones did not show any differentiation potential. For 
clinical bone regeneration applications it is important to identify the MSCs with the 
osteogenic potential. 
 
 
7.1.2 OSTEOGENIC CAPACITY 
 
The osteogenesis of MDCsFn and MSCs showed remarkable similarities in terms of 
mineralization, gene expression, ALP activity and expression.  The results of the qPCR 
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Array in chapter 5 showed that PTH1R was upregulated under osteogenic conditions by 
MSCs, consistently, (Figure 5.12) and by MDCsFn, inconsistently (Figure 5.10). It has 
previously been established that PTH1R and PTH are the most important regulators of 
calcium ion homeostasis in vivo (Mannstadt et al, 1999; Huang et al, 2001; Pioszak & 
Xu, 2008). PTH is used in the clinic to treat osteoporosis (Borba & Mañas, 2010). In 
vivo the synthesis and secretion of PTH and PTH1R are known to be largely regulated 
by the extracellular concentration of calcium and phosphate, which is monitored by the 
CASR of the parathyroid glands (Mannstadt et al, 1999; Pioszak & Xu, 2008).  This 
cannot be the case in this in vitro study since CASR is only expressed in the parathyroid 
glands (Theman & Collins, 2009) and was not detected in either MDCsFn or MSCs 
cultures (Table 5.3). The upregulation of PTH1R can therefore be seen as an indication 
that PTH1R can have several functions in osteogenesis.  
 
It should be noted that the gene expression of the qPCR Array were analysed at 2 
weeks. If another time point had been chosen, most likely the expression pattern would 
have been different. For early genes such as ALP and Runx2 an earlier time point e.g. 1 
week would have been suitable and for late genes such as SPARC and OP a later time 
point e.g. 3 weeks would have been suitable. Hence, it would have been optimal to do a 
time course; however, this was not possible due to financial restrictions. 
 
There appeared to be more consistency of the gene regulations for MSCs compared to 
MDCsFn (Figure 5.10; 5.11) between patients. This is probably due to natural higher 
patient variations within the MDCsFn in terms of osteogenesis or that the MDCsFn 
consist of a more heterogeneous population compared to MSCs. This might have an 
impact for clinical applications; MDCsFn might be an excellent alternative to MSCs in 
future clinical applications for some patients, but not in others. 
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7.1.3 THE USE OF SCAFFOLDS  
In general it is considered that a scaffold is needed to direct the proliferated cells into 
the desired 3-D structure of the formed bone tissue.  For successful osseointegration 
between the material and the cells, several factors have been suggested, such as implant 
material and design, bone status and surgical techniques (Ellingsen et al, 2000). 
 
Various types of material have been used as scaffolds in bone applications, such as 
ceramics, polymers and metals. Calcium-sulphate-hemihydrate (2CaSO4H2O) and 
hydroxyapatite are included in the group of ceramics and have been used as bone graft 
substitute in bone cancer treatment (Schindler et al, 2008). Polymers, such as polylactic 
acid and polyglycolic acid, are resorbable biomaterials that are characterized by 
degradation that is mainly caused by hydrolysis and enzymatic disintegration 
(Pneumaticos et al, 2009). Polymers have been used in the healing bone fractures 
(Pneumaticos et al, 2009). However, for the majority of long-term implanted materials 
in bone, it is preferred to use an inert material, such as Ti (Ellingsen et al, 2000). 
 
The similarities between the two cell types, MDCsFn and MSCs, were also seen when 
they were placed on the various Ti surfaces i.e. SMO, SLA and SLActive. Both 
MDCsFn (Figure 6.3) and MSCs (Figure 6.4) showed initially low levels of increased 
metabolic activity i.e. a lag period on SLA and SLActive compared to SMO and TCP. 
This phenomenon with initial decrease of metabolic activity on rough compared to 
smooth Ti surfaces has been reported earlier for MSCs (Wall et al, 2009), MG63 an 
immature osteoblastic cell line  (Zhao et al, 2005; Kim et al, 2006) and osteoblasts 
(Brett et al, 2004). In this thesis, it has been shown that this is also the case for 
MDCsFn (Figure 6.3, 6.6-6.7). The unsolved question is if initial decreased metabolic 
activity on rough compared to smooth Ti surfaces is a general cell response or a specific 
response for mesenchymal cells. It is known that OP has an anti-apoptotic effect 
(Denhart et al, 2001), so by having a surface that induces apoptosis, the cells with 
higher level of OP, i.e. the more osteogenic cells, would survive preferentially. 
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The surface that expresses highest levels of cell death, SLActive, is the surface that has 
shown superior osseointegration in bone implants in vivo (Schwartz et al, 2008). The 
effect of Ti surfaces on the metabolic activity and cell death appeared to be cell type 
dependent; there was a higher percentage MDCsFn approximately 80% that survived on 
SLActive compared to MSCs, where approximately only 55% were viable. It would be 
interesting to investigate if this is correlated with the cells’ levels of OP. This raises the 
question if the SLActive surface is selecting the more osteogenic population, i.e. the 
population that expresses more OP, or if the cell death initiates the body’s regenerative 
system. MSCs are believed to migrate to the regenerative site i.e. the implant site; 
however, it cannot be excluded that osteogenic precursor cells are also recruited from 
muscle tissue near to the implant site i.e. osteogenic MDCs. 
 
 
7.1.4 COMPARISON OF MDCs RESULTS COMPARED 
WITH LITERATURE  
In this thesis an osteogenic subpopulation was isolated from the parental population of 
MDCs. The cells were isolated by differential adhesion to Fn; other researchers have 
previously used the cells’ adhesion properties to Fn to isolate stem cell-like populations 
(Chapter 1.4.3). However, the previously isolated cells, by Fn adhesion, have all been 
isolated from non-myogenic tissue, such as neonatal foreskin (Jones & Watt, 1993), 
cartilage (Dowthwaite et al, 2004) and oral mucosa (Davies et al, 2010).  
 
In order to isolate stem cell-like MDCs, researchers have in general used the cells 
adhesion properties to collagen where the more stem cell-like population is considered 
to adhere to collagen after several hours. Qu-Petersen et al (2002) developed an 
isolation method for MDCs derived from mice where the muscle was first 
enzymatically digested before the cells were isolated by differential adhesion to 
collagen. This method was developed for mouse-derived MDCs. In mice, cells isolated 
according to Qu-Petersen et al (2002) protocol have shown differentiation capacity 
along myogenic, neural, endothelial (Qu-Petersen et al, 2002) and osteogenic lineages 
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(Bosch et al, 2000).  They have also been characterized and demonstrated the 
expression of marker Bcl-2, all MRFs and Sca-1 (Deasy et al, 2001), which is not 
expressed on human cells. Differential adhesion to collagen has also been used to 
isolate human cells from orbicular oris muscle (Bueno et al, 2009). It is not possible to 
apply this method to massetter muscle since it is too hard to enzymatically digest 
(previous experience in the lab at EDI). It is considered that the MDCs that migrate out 
of the tissue by using the explant method is a more homogeneous population than you 
get by enzymatically digesting whole tissue.  
 
The main advantages of isolating osteogenic MDCs by Fn adhesion compared to 
collagen adhesion are that it is quicker and less labour intensive. In addition, it is 
developed to isolate the more osteogenic population in humans.  
 
 
7.1.5 ORIGIN OF OSTEOGENIC MDCs 
 
The origin of osteogenic MDCs has been discussed in the literature; some researchers 
have suggested that MDCs that are not restricted to the myogenic lineage actually are 
MSCs (Jankowski et al, 2002). Another suggestion is that osteogenic MDCs are related 
to pericytes (Peng & Huard, 2004; Crisan et al, 2008) i.e. pericytes and non-myogenic 
linage restricted MDCs and MSCs have a common origin.  Pericytes, which are located 
along the vasculature, were originally described as a population of osteoprogenitor cells 
because pericytes participate in bone regeneration after injury (Diaz-Flores et al 1992), 
they can undergo osteogenic differentiation in vitro (Brighton et al, 1992; Doherty et al, 
1998) and in vivo (Doherty et al, 1998). Other researchers consider that some bone 
marrow stem cells can circulate through different tissues and possibly contribute to the 
stem cell pool of local tissues; much evidence indicates that resident stem cells are the 
cells primarily responsible for the regeneration or repair of local tissues (Sethe et al, 
2006). In addition, the niche, i.e. muscle or bone, of these cells might have affected the 
cells even though they have a common origin.  
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7.1.6 OSTEOGENIC MDCs IN VIVO 
 
It should be remembered that this study has been performed in monolayer. It is not clear 
how well a monolayer of MSCs represent the in vivo surrounding in the bone where the 
MSCs represent only a small fraction of the cells present. Bone tissue with bone 
marrow consists of a 3-D network of ECM and various cell types, such as 
haematopoietic cells, stromal cells, adipocytes, endothelial cells and pericytes. 
Therefore, it is hard to predict how suitable MDCsFn would be in vivo in bone 
regeneration applications. This question is especially important since even though 
osteoblasts and myoblasts have very different phenotypes, they have an over lap in 
proteins e.g. IGF-1 and OP. The question is if the niche and pre-differentiation will keep 
the MDCsFn in the osteogenic lineage in vivo or if, they are truly multipotent, there will 
be transdifferentiation along the myogenic lineage.  
 
The osteogenic cocktail of dex, L-ascorbic acid and -GP has been proven to be 
effective in vitro; however, BMPs might be a more representative method to activate 
bone formation in vivo. Shen et al (2004) demonstrated that genetically engineered 
MDCs expressing BMP-4 could heal a skull bone defect. However, to translate this 
method in to clinical practice, the vectors have to be safe, which today appears to be a 
major obstacle (Wu & Ertl, 2008). Therefore, to take this research into a clinical setting 
other methods to deliver the osteogenic cues must be used.  
 
Finally, it can be concluded that the osteogenic fraction i.e. MDCsFn could be used as 
an alternative to MSCs in bone regeneration applications due the similar osteogenic 
behavior of the two cell types established in this thesis. The MDCsFn might, however, 
consist of cells with lower osteogenic potential compared to MSCs. It should be 
remembered that obtaining MDCsFn does have the advantage over MSCs of reducing 
morbidity and not lowering the immune system. Thus, the future decision to whether 
use MSCs or osteogenic MDCs in clinical bone regeneration applications might be 
taken on a patient-to-patient basis.  
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7.2 FUTURE PERSPECTIVES 
 
As discussed in Chapter 7.1, it might be important for transferring this work to the 
clinic to establish if the MDCs consist of a multipotent population or a population of 
multipotent cells or both.  In order to establish this, clonal experiments on MDCs or 
MDCsFn should be performed in a similar manner as Fukiage et al (2008) perfomed on 
MSCs. It would also be useful to screen the MDCsFn for surface markers (Table 7.1); a 
full screen was not performed in this thesis due to time restraints.  
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Table 7.1. Suggested markers to study the MDCsFn phenotype. 
MARKER DESCRIPTION 
CD34 
- Transmembrane protein (D’Alessandro et al, 2009) 
- Expressed on HSCs (D’Alessandro et al, 2009) and mouse 
MSDCs (Deasy et al, 2001) 
CD44 
- Glycoprotein involved in cell-cell interactions, cell 
adhesion and migration (Jothy, 2003) 
- Expressed on various cell types, including human MSCs 
(Lin et al, 2008) 
CD45 
- Transmembrane protein (Saunders & Johnson, 2010) 
- Leukocyte specific (Saunders & Johnson, 2010) 
CD56 
- Adhesion molecule (Sinanan et al, 2004) 
- Used as a satellite cell marker (Mackey et al, 2009) 
CD90 - Used as a marker for MSCs (Abdallah & Kassem, 2008) 
CD105 
- Used to isolate osteogenic cells (Aslan et al, 2006) 
- Expressed on MSCs (Abdallah & Kassem, 2008) 
CD106 
- Vascular cell adhesion molecule 
- Expressed on various cell types, including MSCs and 
endothelial cells (Liu et al, 2008) 
C-kit 
- Expressed on cardiac muscle stem cells (Miyamoto et al, 
2010) 
M-cadherin 
- Cell surface protein involved in promyogenic signaling 
initiated by cell-cell contact (Krauss, 2010) 
- Used as a satellite cell marker (Krauss, 2010) 
Stro-1 
- Uncharacterized cell surface epitope (Gronthos et al, 1994) 
- Expressed by human MSCs and erythrocytic cells 
(Gronthos et al, 1994) 
- Has been used as a marker for osteogenic progenitor cells 
(Marie & Fromigue, 2006) 
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In order to fully evaluate the potential to use osteogenic MDCs in clinical bone 
regeneration applications in vivo experiments will ultimately need to be performed. As 
mentioned earlier, the 2-D in vitro model might not be a very representative model for 
the mechanisms in vivo. There have been attempts to mimic the in vivo structure by the 
use of 3-D collagen gels (Buxton et al, 2008); however, these gels have not been 
evaluated as to how representative they are in comparison to in vivo environment. It is 
important to remember, when research is transferred from in vitro human cell work to in 
vivo animal work, that there will always be species differences. 
 
In order to analyze the in vivo bone regeneration potential of MDCsFn and decide 
which Ti surface, i.e. out of SMO, SLA and SLActive, is the more suitable. It has been 
well established that SLActive is better for osseointegration in vivo (Schwartz et al, 
2008), but it is important to establish if it is the optimal surface for bone regeneration as 
well. By testing Ti scaffolds of various roughness and hydrophilicity it might be able to 
decide which one would be more suitable for bone regeneration. One could adapt 
Warnke et al (2004) protocol (read reference for more details). In this case Ti scaffolds, 
full with bone mineral and osteogenic cells, of the three different Ti surfaces would be 
constructed. Hydroxyapatite coating has shown to increase the amount of ingrowth and 
attachment of bone over the implant surface (Coathup et al, 2001).  The MDCsFn could 
be marked e.g. with quantum dots to decide if the MDCsFn are responsible for the bone 
formation or if the cells only function as recruiter of other regenerative cells.  
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A9.1.1 PROTOCOLS 
 
A9.1.2 PFA 
 
The 4% PFA was prepared by dissolving 20 g PFA in 250 ml deionised water. To the 
solution, 5 drops of 10 M NaOH was added. The solution was stirred and heated to 60 
C in a water bath until the solution was clear. Finally, 2xPBS was added to the solution 
and the pH was adjusted to 7.3. 
 
 
A9.1.3 PBS+ 
PBS was made up from tablets and 1 mM of CaCl2 and 1mM MgCl2 was added to the 
PBS solution. The pH was adjusted to 7.4.  
 
 
A9.1.4 FN 
 
The Fn was diluted in PBS+ to a concentration of 10 ug/ml. The Fn/PBS+ solution was 
aliquoted a 40 ml and stored at -20 C.  
 
 
A9.1.5 GEL 
 
The purchase Gel solution was diluted from 2% to 0.2 % by sterile PBS. The solution 
was stored at 4 C.  
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A9.1.6 MATERIAL 
 
Table A9.1. List of purchased cells. 
PRODUCT COMPANY      CAT# NO 
MSCs Tulane Centre for Gene Therapy N/A 
 
Table A9.2. List of gene assays. 
PRODUCT COMPANY      CAT# NO 
ALPL Applied Biosystems Hs00758162_m1 
AMBN Applied Biosystems Hs00212970_m1 
AMELY Applied Biosystems Hs00795181_m1 
ARSE Applied Biosystems Hs00163677_m1 
BMP2 Applied Biosystems Hs00154192_m1 
BMP4 Applied Biosystems Hs00370078_m1 
BMP7 Applied Biosystems Hs00233477_m1 
BSP Applied Biosystems Hs00173720_m1 
CALCR Applied Biosystems Hs00156229_m1 
CASR Applied Biosystems Hs00173436_m1 
CDH11 Applied Biosystems Hs00156438_m1 
COL1A1 Applied Biosystems Hs00164004_m1 
COMP Applied Biosystems Hs00164359_m1 
Desmin Applied Biosystems Hs00157258_m1 
DMP1 Applied Biosystems Hs00189368_m1 
DSPP Applied Biosystems Hs00171962_m1 
FGFR1 Applied Biosystems Hs00241111_m1 
FGFR2 Applied Biosystems Hs00240796_m1 
FGFR3 Applied Biosystems Hs00179829_m1 
FLT1 Applied Biosystems Hs00176573_m1 
GAPDH Applied Biosystems Hs99999905_m1 
GDF10 Applied Biosystems Hs00192033_m1 
MMP13 Applied Biosystems Hs00233992_m1 
MMP2 Applied Biosystems Hs00234422_m1 
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MSX1 Applied Biosystems Hs00427183_m1 
Myogenin Applied Biosystems Hs00231157_m1 
OP Applied Biosystems Hs00959010_m1 
Osterix  Applied Biosystems Hs00541729_m1 
PPAR-2 Applied Biosystems Hs00234592_m1 
PTHR1 Applied Biosystems Hs00174895_m1 
RUNX2 Applied Biosystems Hs00231692_m1 
SMAD1 Applied Biosystems Hs00195432_m1 
SMAD2 Applied Biosystems Hs00183425_m1 
SMAD3 Applied Biosystems Hs00232222_m1 
SMAD4 Applied Biosystems Hs00232068_m1 
SMAD7 Applied Biosystems Hs00178696_m1 
SMAD9 Applied Biosystems Hs00195441_m1 
SOX9 Applied Biosystems Hs00165814_m1 
SPARC Applied Biosystems Hs00277762_m1 
TGF1 Applied Biosystems Hs99999918_m1 
TGF3 Applied Biosystems Hs00234245_m1 
TGFBR1 Applied Biosystems Hs00610319_m1 
TGFBR2 Applied Biosystems Hs00559661_m1 
TUFT1 Applied Biosystems Hs00360629_m1 
TWIST1 Applied Biosystems Hs00361186_m1 
TWIST2 Applied Biosystems Hs00382379_m1 
VDR Applied Biosystems Hs01045840_m1 
VEGFA Applied Biosystems Hs00900054_m1 
VEGFB Applied Biosystems Hs00173634_m1 
WNT5A Applied Biosystems Hs00180103_m1 
18S Applied Biosystems Hs99999901_s1 
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Table A9.3. Description of osteogenic genes analysed in chapter 5, result section 3. 
 
 GENE  
 
 
DESCRIPTION OF 
CODED PROTEIN 
 
ROLE IN OSTEOGENIC DIFFERENTIATION 
ALP - Enzyme 
- Bone ALP is used as an osteogenic marker (Weiss et al, 1986); however its 
specific role in osteogenesis is unknown (Goseki-Sone et al, 1998). 
- Deficiency of ALP leads to defects in skeletal mineralization in mice  
(Gosike-Sone et al, 1998). 
AMBN  
- Enamel matrix glycoprotein 
(Hatakeyama et al, 2009) 
- AMBN is secreted by ameloblasts and is involved in the mineralization of 
enamel 
 (Hatakeyama et al, 2009). 
AMELY  
- Enamel matrix protein 
(Hatakeyama et al, 2009) 
- AMBN is secreted by ameloblasts and is involved in the mineralization of 
enamel 
 (Hatakeyama et al, 2009). 
ARSE  - Enzyme 
- ARSE catalyzes the hydrolysis of sulphate ester bonds but its role in 
osteogenesis is unknown (Parenti et al, 1997). 
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BMP2  
- Growth factor 
- Belong to TGF- family 
(Chen et al, 2004) 
- BMP2 induces bone formation (Chen et al, 2004). 
BMP4  
- Growth factor 
- Belong to TGF- family 
(Chen et al, 2004) 
- BMP4 induces bone formation (Chen et al, 2004). 
BMP7  
- Growth factor 
- Belong to TGF- family 
(Chen et al, 2004) 
- BMP7 induce bone formation (Chen et al, 2004), and is timely expressed in 
fraction healing, i.e. after 14 days (Marsell et al, 2009). 
BSP  - Glycoprotein  
- BSP is expressed by fully differentiated osteoblast and function as structural 
protein in the bone matrix i.e. can  bind to hydroxyapatite (Kim et al, 1994). 
CALCR  - Receptor 
- CALCR regulates bone formation but is only expressed on osteoclasts, not 
osteoblasts (Dacquin et al, 2004). 
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CASR  
- G protein-coupled receptor 
(Theman & Collins, 2009) 
- Expressed on the parathyroid glands and regulates PTH on the basis of Ca2+  
(Theman & Collins, 2009). 
CDH11 
- Cell adhesion molecule  
(Bourne et al, 2004) 
- CDH11 is upregulated during early stage of differentiation (Bourne et al, 2004). 
COL1A1 
- Part of  type 1 collagen, i.e. 
abundant ECM protein  
(Uttering et al, 2006) 
- Type 1 collagen forms the template for mineralisation of bone (Pace et al, 
2001). 
COMP  
- Matrix protein 
- Member of thrombospondin 
gene family 
(Newton et al, 1994) 
- COMP is secreted by chondrocytes (Newton et al, 1994). 
DMP1 
- Acidic phosphoprotein  
- Member of SIBLING family 
(Ling et al, 2005) 
- ECM protein expressed by osteocytes (Khosla et al, 2008) and is involved in 
mineralization by binding Ca2+ and apatite (Ling et al, 2005). 
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DSPP 
- Sialophosphoprotein 
(Thyagarajan et al, 2001) 
- Odontoblast specific expression (Thyagarajan et al, 2001). 
FGFR1 
- Tyrosin kinase resceptor 
(White et al, 2005) 
- FGFR1 is involved in the growth of long bones (White et al, 2005). 
FGFR2 
- Tyrosin kinase resceptor 
(White et al, 2005) 
- FGFR2 is involved in the growth of long bones (White et al, 2005) and 
mutations can cause various skeletal abnormalities (Katoh, 2008). 
- Is regulated by TWIST1 (Katoh, 2008). 
FGFR3 
- Tyrosin kinase resceptor 
(White et al, 2005) 
- Involved in the growth of long bones (White et al, 2005). 
- Function as a negative regulator (Deng et al, 1996). 
FLT1 
- Tyrosin kinase resceptor 
(Niida et al, 2005) 
- Involved in osteoclastogenesis (Niida et al, 2005). 
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GDF10  
- Closely related to BMP3 
- Belongs to TGF- family 
(Hino et al, 1996) 
- Believed to have a role in the chondrogenic phase in endochondral bone 
formation (Marsell & Einhorn, 2009). 
MMP13 - Enzyme 
- MMP13 catalyzes the degradation of ECM and release factors stored in ECM 
e.g. VEGFA (Laush et al, 2009). 
- Is expressed by hypertrophic chondrocytes or osteoblasts (Laush et al, 2009) 
and  
MMP2  - Enzyme - MMP2 is expressed by MSCs (Adhalaq & Mao, 2004). 
MSX1  
- Homeobox gene 
(Blin-Wakkach, 2001)  
- MSX1 is involved in the terminal differentiation of tooth and craniofacial 
skeleton and downregulates Runx2 (Blin-Wakkach, 2001). 
OP - Matrix protein 
- Serves as an attachment protein linking cells to the bone mineral and is 
involved in bone remodelling (Kazanecki et al, 2007). 
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OSTERIX 
- Zinc finger transcription 
factor 
- Member of the SP family 
(Gao et al, 2004)  
- Only detected in embryonic human tissue not in adult human tissue (Gao et al, 
2004).  
PTHR1 
- G protein–coupled receptors 
(Mannstadt et al, 1999) 
- PTH1R is a part of the calcium ion homeostasis in vivo together with PTH  
(Pioszak & Xu, 2008). 
RUNX2  
- Transcription factor 
(Khosla et al, 2008) 
- Belongs to Runx family 
(Jonason et al, 2009) 
- Runx2 is considered to be one of the earliest marker of osteogenic commitment 
and essential for osteogenic differentiation (Khosla et al, 2008). 
SMAD1 
- Glycoprotein  
(Farhadien et al, 2004) 
- Smad 1 is an immediate downstream molecule of BMP receptors  
(Chen et al, 2004; Farhadien et al, 2004) and signal through Smad4 (Farhadien et 
al, 2004). 
SMAD2  
- Glycoprotein  
(Farhadien et al, 2004) 
- TGF- stimulation leads to Smad-2 activation (Inman et al, 2002). 
- Smad-2 forms complexes with Smad-4 that regulates transcription of target 
genes (Inman et al, 2002). 
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SMAD3  
- Glycoprotein  
(Frahadien et al, 2004) 
- Smad-3 is mainly responsible for TGF-1-induced migration of MSCs  
(Tang et al, 2009). 
- Smad-3 forms complexes with Smad-4 that regulates transcription of target 
genes (Inman et al, 2002). 
SMAD4 
- Glycoprotein  
(Frahadien et al, 2004) 
- Smad-2 or-3 forms complexes with Smad-4 to regulate transcription of target 
genes (Inman et al, 2002). 
SMAD7 
- Glycoprotein  
(Frahadien et al, 2004) 
- Regulates TGF- and BMPs by inhibiting Smad pathways in chondrocytes  
(Iwai et al, 2008). 
SMAD9 
- Glycoprotein  
(Frahadien et al, 2004) 
- Immediate downstream molecule of BMP receptors and is a part of BMP 
signaling 
(Chen et al, 2004).  
SOX9 
- Transcription factor  
(Huang et al, 2001) 
- Required for chondrocyte differentiation and cartilage formation (Huang et al, 
2001). 
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SPARC 
- Bone tissue specific protein 
(Termine et al, 1981) 
- Initiate the mineralisation process in normal skeletal tissues and binds to both 
hydroxyapatite and collagen (Termine et al, 1981). 
TGF-1 
- Belongs to the TGF- 
superfamily  
(Thyagarajan et al, 2001)  
- TGF-1 recruits MSCs to bone remodelling sites in vivo and  stimulate 
proliferation of progenitors and inhibit osteoblastic differentiation (Tang et al, 
2009). 
TGF-3 
- Belongs to the TGF- 
superfamily (Hao et al, 2008) 
- Inhibit osteogenesis of MSCs (Hao  et al, 2008). 
TGF-BRI - Receptor (Hao et al, 2008) - TGF-BRI is recruited by TGF-BRII and activates Smad (Hao et al, 2008). 
TGF-BRII - Receptor (Hao et al, 2008) - TGF-BRII activate TGF-BRI (Hao et al, 2008). 
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TUFT1 
- Tuftelin belongs to the 
enamelin group of proteins 
(Huang et al, 2001) 
- Codes the enamel protein tuftelin (Deutsch et al, 1991). 
TWIST1 
- Transcription factors 
- Member of TWIST family 
(Isenmann et al, 2009) 
- TWIST 1regulates the bone remodelling by decreasing Runx2 and OP  
(Isenmann et al, 2009). 
TWIST2 
- Transcription factors 
- Member of TWIST family 
(Isenmann et al, 2009) 
- TWIST2 regulates the bone remodelling by decreasing Runx2 and OP  
(Isenmann et al, 2009). 
VDR - Receptor (St-Arnaud, 2008) 
- VDR regulate mineral ion homeostasis by binding to 1,25-dihydroxyviatmin D 
(St-Arnaud, 2008).  
VEGFA 
- Growth factor  
(Shonmeyr et al, 2010) 
- VEGFA inhibits BMP2 mRNA expression (Shonmeyr et al, 2010). 
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VEGFB 
- Growth factor 
(Fischer et al, 2008) 
- Anti-VEGFB inhibits arthritis (Fischer et al, 2008). 
WNT5A 
- Glycoprotein 
(Khosla et al, 2008) 
- Wnt5a  promotes osteogenesis in adult MSCs (Marie & Fromigue, 2006). 
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Table A9.4. List of antibodies. 
PRODUCT COMPANY CAT# NO 
1 Antibodies   
Anti-h-sarcomeric actin 
Ms monoclonal IgM 
Clone 5C5 
Sigma-Aldrich A2172 
Anti-hdesmin 
Ms monoclonal IgG1 
Clone D33 
DAKO M0760 
Anti-hCD56  
Ms monoclonal IgG1  
Clone 123C3  
Santa Cruz Sc-7326 
hStro-1 
Ms monoclonal IgM 
Clone Stro-1 
R&D Systems MAB1038 
2 Antibodies   
Cy3 conjugated  
Goat Anti-Ms IgM specific  
Jackson ImmunoResearch 
Laboratories, Inc 
115-165-075 
FITC-conjugated  
Goat Anti-Ms IgG specific 
Jackson ImmunoResearch 
Laboratories, Inc 
115-095-164  
 
AlexaFluor conjugated  
Goat Anti-Ms IgG specific 
Invitrogen A11001 
R-PE-conjugated  
Goat Anti-Mouse IgM 
specific 
Jackson ImmunoResearch 
Laboratories, Inc 
115-116-075 
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Table A9.5. List of assays or kits. 
PRODUCT COMPANY CAT# NO 
Annexin V-FITC Apoptosis Detection kit Sigma-Aldrich APOAF 
FAST TM p-Nitrophenyl Phosphate Tablets  Sigma-Aldrich N1891 
High capacity cDNA Reverse Transcription 
kit 
Applied 
Biosystems 
4368813 
 
 
Table A9.6. List of reagents or chemicals. 
PRODUCT COMPANY CAT# NO 
-glycerophosphate Calbiochem 35675 
-MEM GIBCO 22571 
Accutase Sigma-Aldrich A6964 
Alamar Blue AbD Serotec BUF012B 
Alizarin Red S Sigma-Aldrich A5533 
Cetylpyridium Chloride Sigma-Aldrich C0732 
Chloroform-isoamyl alcohol mixture, --
DNase, RNase free 
Fluka 25668 
DAPI Sigma-Aldrich D9542 
Dex Sigma-Aldrich D2915 
Direct Red 80 Fluka 43665 
DMEM-high glucose PAA E15-843 
DMEM-low glucose PAA E15-806 
Ethanol  
-DNAse, RNase free 
Sigma-Aldrich 51976 
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Fast Red Violet LB Salt Sigma-Aldrich F3381 
FBS GIBCO/PAA 
10270/ 
A15-151 
Fn, from bovine plasma Sigma-Aldrich F4759 
Gel Sigma-Aldrich G1393 
Glycogen, DNase & RNase free Invitrogen 10814-10 
HCl 
BDH Laboratory 
Supplies 
20252.420 
Indomethacin Sigma-Aldrich I7378 
Insulin-like Growth Factor-1(E3R) Sigma-Aldrich I2656 
Iso-propyl alcohol 
-DNase RNAse free 
Acros Organics 327270010 
L-ascorbic acid 2-phosphate Sigma-Aldrich A8960  
Magnesium Chloride Sigma-Aldrich M-8266 
Methanol 
BDH Laboratory 
Supplies 
10252 
Methyl-Thiazolyl Blue Tetrazolium Bromide Sigma-Aldrich M5655 
N,N-DMF Sigma-Aldrich D4551 
NaCl 
BDH Laboratory 
Supplies 
10241AP 
NaN3 Sigma-Aldrich 71289 
NaOH 
BDH Laboratory 
Supplies 
10252 
Naphtanol Sigma-Aldrich N5000 
Paraformaldehyde  Sigma-Aldrich 158127 
PBS - Ca 2+ & Mg2+ free PAA H15-002 
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PBS tablets Sigma-Aldrich D4551 
Penicillin/Streptomycin PAA P11-010 
SDS solution (20%) Fluka 05030 
Sodium phosphate Sigma-Aldrich 342483 
TaqMan Universal PCR Master Mix 
Applied 
Biosystems 
4364340 
Ti Straumann N/A 
Triton-X Sigma-Aldrich 101586B 
TRIZOL®Reagent Invitrogen 15596-018 
Trypsin PAA L11-004 
Water 
-RNAase/DNAse free 
5 Prime 2900136 
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A9.1.7 APPARTUS AND SOFTWARE 
 
Table A9.7. List of apparatus.  
APPARATUS MODEL COMPANY 
Confocal microscopy Radiance 2100 Bio-Rad 
CoolSnap-Pro camera 
Roper Scientific 
Photometrics 
MediaCybernetic 
Flow cytometry FACScanTM  Becton Dickinson 
Fluoroscan Ascent Labsystems 
Fluorescent microscope Leica FW4000  Leica 
Bright field microscope Olympus BX50  MediaCybernetic 
PCM Olympus CK MediaCybernetic 
pH-meter HI8520 Hanna Instruments  
Plate reader MRX-TC Dynex Technologies 
qPCR 
ABI 7300 Real Time PCR 
machine in 96well format.  
Applied Biosystems 
Spectrophotometer  Ultrospec2000 UV/Visible  
spectrophotometer, 
Pharmacia Biotech 
Thermal cycler  PTC-100 
Genetic Research 
Instrumentation Ltd  
UV Sterilizer 2537å Steristrom Coast-Air 
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Table A9.8. List of software. 
SOFTWARE FUNCTION 
7300 System SDS Software Run qPCR  
Cell Quest Run flow data 
Flouroscan software Measuring fluorescent  
FWLeica 4300 Capture images 
G*Power version 3.1 Sample size estimation 
Image-Pro Plus 4.5, MediaCybernetic Analysing images 
Revelation Measure absorbance 
WinMDI 2.9 Analyse flow data 
 
